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General introduction

General introduction
Ion channels
An estimated 100 trillion cells of different size and function build up the human body. Each cell is 
to some extent self-maintaining and can, therefore, be seen as the smallest entity of life [1]. All cells 
are surrounded by a plasma membrane, which separates the intracellular compartment from its 
environment. The plasma membrane is made from a double layer of hydrophobic lipids and 
hydrophilic phosphorus molecules, therefore also named phospholipid bilayer. It functions as a barrier 
controlling the movement of hydrophilic and charged molecules, mainly ions. By the early 70’s it had 
become clear that integral membrane proteins exist that underlie the electrical signaling in nerve and 
muscle tissue. These integral membrane proteins, known as ion channels, provide a high conducting, 
hydrophilic passageway for the ions to flow down their electrochemical gradient. The 1950s and 
1960s were important decennia for exciting discoveries concerning ion channels, though that term 
came in use later. In 1952, Alan Hodgkin and Andrew Huxley were the first to determine the 
elementary current properties of membranes as part of their research on excitation and inhibition of 
the nerve cell membrane. They received the Nobel Prize in physiology and medicine for their findings 
in 1963 (Table 1). Following, Bernard Katz obtained the Nobel Prize in physiology and medicine in 
1970 for his research on the biochemistry and action of neurotransmitters and synapse properties 
(Table 1). He noticed an interesting noise on the recorded signal with acetylcholine application. 
Together with Ricardo Miledi, he worked on this noise analysis and provided information about how 
single ion channels behave. During this work, Bert Sakmann started working in Katz’s laboratory and 
he did set up an electrical recording technique known as the "patch clamp". This fortuitous discovery 
was recognized by the Nobel Prize in 1991 to Erwin Neher and Bert Sakmann (Table 1). In the last 
decennia, research in the ion channel field led to the discovery of hundreds of different ion channels. 
They are classified according to their gating mechanism into voltage-gated, ligand-gated, pH-gated, or 
mechanically gated. In combination with ion selectivity and sequence similarity, these groups are 
further subdivided into several subtypes:
Voltage-gated potassium channels
The family of voltage-gated potassium (K+) channels covers a functionally heterogeneous group 
of transmembrane channels specific for potassium. They activate in response to depolarization of the 
cell’s membrane potential. This property makes the voltage-gated K+ channels essential in shaping 
action potentials and controlling electric activity in excitable cells [2]. These channels are typically 
formed by four independent alpha-subunits surrounding the pore region. Each subunit has six 
transmembrane spanning a-helices (S1-S6) with both the amino (N) and the carboxyl (C) terminal on 
the intracellular side [3, 4]. The S1-S4 segments form the voltage sensing domain, whereas S5 and S6 
along with the intervening re-entrant P-loop form the pore domain [5-7]. It was not until 1998 that the 
detailed molecular structure of a bacterial K+ channel and the pore selectivity were unravelled by X-
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ray crystallography [8]. Importantly, the X-ray structure of the voltage sensor was resolved in 2003, in 
a bacterial homolog of voltage-gated K+ channels for which Roderick MacKinnon received the Nobel 
Prize in Chemistry in 2003 (Table 1) [9]. These structural discoveries opened a new research field that 
focuses on the mechanism of conformational changes in response to voltage changes. It is generally 
accepted that the positively charged amino acids in the S4 helices are responsible for voltage sensing. 
However, there exist a number of competing models for the orientation and conformation of the 
voltage-sensor domain relative to the pore domain upon membrane depolarization, i.e. the canonical 
or helical screw model, the transporter model, the paddle model, and the twisted S4 model (reviewed 
in [7].
Table 1. Nobel prize winners in the ion channel research field.
Desiphering ion channels: Nobel prize winners
Laureate Year Nobel prize Discovery
"for their discoveries concerning the 
ionic mechanisms involved in excita­
tion and inhibition in the peripheral 
and central portions o f the nerve cell 
membrane”
"for the discoveries concerning the 
humoral transmitters in the nerve 
terminals and the mechanism for their 
storage, release and inactivation"
"for their discoveries concerning the 
function o f single ion channels in cells"
"for structural and mechanistic studies 
o f ion channels"
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Other potassium channels
Other classes of channels selective for K+ are the calcium (Ca2+)-activated K+ channels, inwardly 
rectifying K+ channels, and tandem pore domain K+ channels. Ca2+-activated K+ channels open in 
response to intracellular calcium and voltage changes. They are subdivided in BK, IK, and SK 
channels. The inwardly rectifying potassium channels consist of a voltage-dependent block by 
endogenous polyamines and Mg2+, which is removed upon hyperpolarization. These channels differ 
from the more typical (outwardly rectifying) voltage-gated K+ channels in their ability to pass ions 
more easily into the cell (inwardly rectifying). Tandem pore domain (two-pore domain) K+ channels 
are formed by four subunits that all contain two pore loops. They function as ‘leak channels’ and are 
gated by oxygen, pH, mechanical stretch and G-proteins. The enormous variety of K+ channel 
function arises from the multiplicity of subunits, the formation of heteromultimers within subfamilies 
and from association with intracellular beta-subunit proteins [10, 1 1 ].
Voltage-gated calcium channels
Voltage-gated Ca2+ channels mediate Ca2+ influx upon membrane depolarization that regulates 
gene expression, excitation-contraction coupling in cardiac and skeletal muscle fibers, neuronal 
excitation, hormone secretion, and neurotransmission [12, 13]. Ca2+ channels are composed of four or 
five distinct subunits known as a1, a26, (31-4, and y. The channels arise form multiple a1 subunit, 
while the other associated subunits are involved in modulation of gating. Mammalian a1 subunits are 
encoded by at least ten genes and various names had been given to the corresponding gene products, 
which gave rise to confusing nomenclatures. In 2000, a rational nomenclature was adopted based on 
the well-defined potassium channel nomenclature. Furthermore, these various subunits led to the 
formation of channels with different types of Ca2+ currents. The L-type Ca2+ channels (Cav1.1-Cav1.4) 
are activated by strong depolarization and can be block by the organic L-type channel blockers 
dihydropyridines, phenylalkylamines, and benzothiazepines. These channels play a role in muscle and 
endocrine cells, where they initiate contraction and hormone secretion. The N-type (Cav2.2), R-type 
(Cav2.3), and closely related P/Q-type (Cav2.1) Ca2+ channels, primarily expressed in neurons, also 
activate upon strong depolarization. They are mostly unaffected by L-type channel antagonists, but 
are blocked by specific polypeptide toxins. The T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) already 
activate upon weak depolarization, resistant to the other channel blockers and are expressed more 
ubiquitously.
Voltage-gated sodium channels
Voltage-gated sodium (Na+) channels are mainly expressed in excitable cells where they are 
important for the depolarising phase of action potentials [2]. Voltage-gated Na+ channels have three 
types of states: deactivated (closed), activated (open), and inactivated (closed). The channels are 
likely blocked in the deactivated state. This block is removed upon depolarization that opens the
11
Chapter 1
channel, starting an action potential. Shortly after the channel has been activated, it inactivates via a 
so-called inactivation gate that blocks the pore region of the channel. The inactivation state lasts for a 
few milliseconds and is removed during the repolarization phase of the action potential allowing the 
channel to be activated for the next action potential. The voltage-gated Na+ channels are formed by a 
large a  subunit that might associate with p subunits. The a  subunit consists of four repeated domains 
(I-IV), all containing six transmembrane spanning segments (S1-S6). Similar to voltage-gated K+ 
channels, the S4 segment functions as the voltage sensor and a pore-forming region exists between S5 
and S6 [14]. The p subunits are not essential for channel function, but their association with the a  
subunit complex can alter the channel’s voltage dependence or cellular localization [15]. So, the 
nomenclature is standardized according to the a  subunit expression and the family of voltage-gated 
Na+ channels contains nine members, named Nav1.1-Nav1.9 [16].
Chloride channels
Chloride (Cl-) channels belong to a diverse superfamily of anion channels [17]. They differ 
significantly in structure, gating mechanism, and physiological function. In general, Cl- channels play 
an important role in the maintenance of cell volume and are involved in setting the resting membrane 
potential. So far, three mammalian gene families have been established of which the CLC gene family 
is best known. This family consists of nine CLC channel members, each build up by 10 or 12 
transmembrane domains. The importance of several CLC channels is strikingly illustrated by four 
human inherited diseases linked to mutations in their genes, namely autosomal and recessive 
myotonia (CLC-1), osteopetrosis (CLC-7), inherited kidney stone diseases (CLCN5) and Bartter’s 
syndrome type III (CLCNKB) [18-21]. Interestingly, the known Cl- channel genes do not yet match 
the large variety of biophysically identified Cl- channels, indicating that new families of Cl- channels 
still need to be identified.
Cyclic nucleotide regulated channels
The cylcic nucleotide-regulated channel family consists of two subfamilies, the cyclic nucleotide- 
gated (CNG) and the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. CNG 
channels activation is mediated by direct binding of intracellular cAMP or cGMP [22]. They play 
important roles in sensory transduction and are mainly expressed in cilia of olfactory neurons and in 
photoreceptor neurons. CNG channels form heterotetramers by combining A subunits (CNGA1- 
CNGA4) and B subunits (CNGB1 and CNGB3) [23]. These channels are permeable to monovalent 
cations as K+ and Na+, which are sensitive to voltage-dependent Ca2+ blockage [24]. HCN channels 
are activated upon hyperpolarization and channel activity is enhanced by cAMP and cGMP since they 
shift the activation to more positive potential. The mammalian HCN channel family contains four 
members (HCN1-HCN4) [25]. Homo- or heterotetrameric channels are formed of four HCN subunits,
12
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each containing six transmembrane spanning helices (S1-S6) [26, 27]. HCN channels are widely 
expressed in heart and brain tissue, where they function as ‘pacemaker channels’ to control cardiac 
and neuronal rhythmicity [26, 28].
Ligand-gated channels
The ligand-gated ion channels are regulated by binding of a chemical messenger or ligand. They 
are generally selective to one or more ions like Na+, K+, Ca2+, or Cl-. The channel is a complicated 
pentameric structure, composed of five subunits, each with an extracellular ligand-binding domain 
and a transmembrane domain. The transmembrane domain consists of four transmembrane helices 
[29]. Ligand-gated ion channels can be subdivided into three superfamilies:
• Cys-loop receptors (nicotinic acetylcholine receptors, 5-HT3 receptors, GABAa and GABAc 
receptors, glycine receptors, anionic glutamate receptors, histamine-gated receptors, and 
serotonin-activated anionic channels) are composed of five subunits, each with an 
extracellular ligand-binding domain and a transmembrane domain. The transmembrane 
domain consist of four transmembrane helices [29].
• Ionotropic glutamate receptors (AMPA receptors, NMDA receptors, and kainate receptors) 
are made of four subunits, each containing two transmembrane segments.
• ATP gated channels (ATP2x receptors) consist of three homologous subunits with three 
transmembrane segments.
Figure.1 Phylogenetic tree of the mammalian Transient Receptor Potential Melastatin (TRPM) channel 
subfamily. (adapted from Nilius et al., 2006) .
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The Transient Receptor Potential (TRP) channels are a family of cation channels that are 
permeable to both monovalent and divalent cations. TRP channels were initially discovered in trp 
mutant strain of the fruit fly Drosophila melanogaster [30]. In 1989, the trp gene was cloned [31] and 
it was shown that the encoded TRP protein constitutes a Ca2+-permeable channel [32]. Subsequently, 
28 mammalian TRP channels have been cloned that can be subdivided into six subfamilies: canonical 
(TRPC), vanilloid (TRPV), polycystin (TRPP), mucolipin (TRPML), ankyrin (TRPA), and melastatin 
(TRPM) [33]. The TRPM subfamily contains eight members (Fig. 1), which are expressed in many 
cell types and tissues [33, 34]. They are activated by a wide variety of stimuli including voltage, Ca2+, 
temperature, cell swelling, and several endogenous and exogenous compounds [34, 35]. TRPM 
proteins are composed of six transmembrane spanning helices, a pore-forming region, and large 
intracellular N- and C-termini (Fig. 2A). The six transmembrane units are assembled around a central 
pore in a homo- or heterotetrameric configuration [33] (Fig. 2B).
The magnesiotropic TRP channels
Within the TRPM subfamily, two members, TRPM6 and TRPM7 have been identified as 
important molecular players in Mg2+ homeostasis. These channels share the unique feature of 
combining an atypical protein kinase domain in the C-termini with an ion channel domain, which 
gave them the name ‘chanzyme’ [36-38] (Fig. 2A).
Mg2+ homeostasis
The tight control of blood magnesium (Mg2+) is of central importance for various essential 
physiological processes, since it functions as a cofactor in multiple enzymatic reactions involved in 
energy metabolism, DNA and protein synthesis [39-41]. Clinical manifestations of altered Mg2+ 
homeostasis are multifold. Hypermagnesemia can cause lethargy, confusion, coma and extreme cases 
can result in cardiac arrest [42]. Hypomagnesemia may lead to similar symptoms as tetany, seizures, 
and cardiac arrhythmias [42, 43]. Furthermore, disturbances in the Mg2+ balance have been associated 
with diabetes mellitus, osteoporosis, asthma, and heart and vascular disease [44-48]. Consequently, 
plasma Mg2+ levels are maintained within a narrow range (0.7-1.1 mM) by the joint action of 
intestinal absorption, exchange with bone, and renal excretion. The kidney is the most important 
organ for the regulation of total body Mg2+ homeostasis as fine-tuning of Mg2+ excretion via the urine 
ultimately preserves a constant Mg2+ concentration in the blood. Approximately 80% of total plasma 
Mg2+ is filtered by the glomeruli [49, 50], the majority of which is absorbed along the nephron [41, 
51]. Most of filtered Mg2+ is reabsorbed in the proximal tubule (~20%) and thick ascending limb 
(TAL) of the loop of Henle (~70%) via passive paracellular transport [52, 53]. The remaining 10% of 
filtered Mg2+ is reabsorbed by an active transcellular mechanism in the distal convoluted tubule
Transient Receptor Potential channels
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(DCT). This process defines the amount of Mg2+ excreted in the urine, as no reabsorption occurs 
beyond this segment [41]. Finally, on a normal diet, the fractional Mg2+ excretion is between 3 and 
5% [54] (Fig. 3).
Figure 2. Structural organization of TRPM6. A. Side view: The protein consists of six transmembrane spanning 
segments with large intracellular amino (NH2) and carboxyl (COOH) termini. There is a putative pore-forming 
region between the fifth and sixth transmembrane segments. Uniquely, TRPM6 and its closest homologue 
TRPM7 contain an atypical protein kinase in the carboxyl terminus. B. Top view: Four of these six 
transmembrane subunits will form a functional channel, either in homomeric configuration (red) or by 
heteromeric formation with TRPM7 subunits (red/blue).
Transcellular transport: distal convoluted tubule
Mg2+ reabsorption in the DCT occurs in a transcellular manner. Mg2+ enters the epithelial cell 
through the epithelial Mg2+ channel TRPM6 [55]. This uptake from the pro-urine is driven by a 
favourable transmembrane potential [41]. Then, Mg2+ will diffuse through to cell to be extruded 
actively across the basolateral membrane. This Mg2+ efflux is suggested to occur via a secondarily 
active process, involving Na+-dependent exchange or an ATP-dependent Mg2+ pump [40, 41]. So far, 
intracellular Mg2+ buffering proteins have not been identified. Interestingly, parvalbumin and 
calbindin-D28k have an overlapping expression with TRPM6 and both proteins have a Mg2+ binding 
affinity [55, 56]. In addition to these proteins, the y-subunit of the basolateral Na+,K+-ATPase has 
been implicated in active Mg2+ reabsorption in DCT. Mutations in the FYXD2 gene, encoding the y- 
subunit of the Na+,K+-ATPase, were found in patients with isolated dominant hypomagnesemia with 
hypocalciuria (IDHH) [57, 58]. This protein is primarily expressed in the kidney with highest 
expression levels at the basolateral membrane of DCT and medullary TAL [59]. However, the
15
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molecular mechanism by which the y-subunit affects the Mg2+ reabsorption remains to be ascertained. 
The Na+,Cl- cotransporter (NCC) is another protein exclusively expressed in DCT [60] and indirectly 
involved in transcellular Mg2+ reabsorption. Patients with Gitelman syndrome (GS) suffer from 
hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria, which has been associated 
with mutations in the SLC12A3 gene, encoding NCC [60]. Inhibition of NCC by thiazide treatment 
mostly results in hypomagnesemia as well [61]. Importantly, NCC knockout mice, an animal model 
for GS, and mice treated with thiazide diuretics have decreased expression of TRPM6 [62], which 
could explain the Mg2+ wasting in this disorder. However, at present it is unknown what signals the 
observed TRPM6 down-regulation (Fig. 3).
Mg2+ extrusion?
Figure 3. Mg2+ reabsorption along the nephron. Mg2+ is filtered in the glomerulus, followed by passive 
reabsorption in the proximal tubule (PT) (~20%) and thick ascending limb (TAL) of the loop of Henle (~70%). 
The remaining 10% of filtered Mg2+ is reabsorbed in active manner in the distal convoluted tubule (DCT). This 
segment can be further subdivided into an early (DCT1) and late (DCT2) portion. TRPM6 is located in the 
apical membrane, which facilitates Mg2+ transport from the pro-urine into the cell. TRPM6 expression is shown 
to be regulated by estrogen, cyclosporin, and tacrolimus. Diffusion of Mg2+ in the cytoplasma and extrusion to 
the interstitium occurs through so far unidentified proteins. NCC is exclusively expressed at the apical 
membrane of DCT, where it cotransports Na+ and Cl- from the pro-urine into the cell. The gradient for Na+ 
transport is provided by the basolateral Na+,K+-ATPase. Cl- is extruded at the basolateral membrane via CLC- 
Kb.
TRPM6
The TRPM6 gene contains 39 exons encoding a protein of 2022 amino acids [63, 64]. A variety of 
splice variants have been identified including three alternative first exons [65]. However, the 
biological relevance of these multiple variants remains to be investigated. TRPM6 shows 
approximately 50% homology with its closest homologue TRPM7 [36, 38]. Mutations in TRPM6 
were found to be causative for autosomal recessive hypomagnesemia with secondary hypocalcemia 
(HSH), characterized by a defect in intestinal Mg2+ transport and impaired renal Mg2+ reabsorption 
[63, 64]. In kidney, TRPM6 is expressed along the apical membrane of DCT, the main site of active
16
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Mg2+ reabsorption [55]. Furthermore, TRPM6 is detected in the brush border membrane of absorptive 
epithelial cells of the ilieum and colon [55, 63]. This restricted expression pattern, together with the 
Mg2+ leak in HSH patients, is supportive for an important role of TRPM6 in transcellular Mg2+ 
transport.
TRPM7
The TRPM7 gene is also made up of 39 exons and encodes a protein of 1865 amino acids The 
protein was originally discovered by three independent studies using different techniques: 
identification by screening databases for homologues of human eukaryotic elongation factor 2  kinase 
[66], via a yeast two-hybrid screen using the C2 domain of phospholipase C as a bait [36], and 
through a bioinformatics approach aimed at identifying novel ion channels expressed in immune cells 
[37]. TRPM7 is ubiquitously expressed and represents the only ion channel known that is essential for 
cellular viability [37, 67]. Cellular knockout of TRPM7 has been shown to induce cell death, which 
can be rescued by Mg2+ supplementation [67]. Interestingly, providing these TRPM7-- cells with Ca2+ 
or Mn2+ in the extracellular medium did not lead to cell survival. Furthermore, TRPM7 plays a role in 
anoxic neuronal death [68], actomyosin contractility and cell adhesion [69, 70]. The study of 
zebrafish touchtone/nutria with mutations in TRPM7 showed a requirement for this protein in 
skeletogenesis [71]. Taken together, these data point towards a critical role of TRPM7 in cellular 
Mg2+ homeostasis.
Channel properties
TRPM6, like TRPM7, is defined as a Mg2+-permeable channel and electrophysiological analysis 
of TRPM6-expressing HEK293 cells demonstrated a typical outwardly rectifying current-voltage (I­
V) relationship [55]. The I-V curve is linear in the absence of extracellular divalent cations. So, the 
outwardly rectifying currents are reflected by the outward flux of monovalent cations and the small 
inward flux of divalent cations. The small inward currents are intriguing as they occur within the 
typical range of physiological membrane potentials [55]. The unique permeation rank order of the 
inward current is Ba2+>Ni2+>Mg2+>Ca2+ [55]. So, the pore of TRPM6 has a higher affinity for Mg2+ 
than for Ca2+, in contrast to other members the TRP superfamily, which usually display a 10-1000 
times lower affinity for Mg2+ than for Ca2+. TRPM6 is found to be constitutively open, but strongly 
regulated by intracellular levels of Mg2+ ([Mg2+]i), shown by flash experiments with a photolabile 
Mg2+ chelator, 1-(2-nitro-4,5-dimethoxyphenyl)-N,N,N’,N’-tetrakis[(oxycarbonyl)methyl]-1,2- 
ethanediamine (DM-nitrophen) [55]. Thus, in order to allow current development, TRPM6-expressing 
cells are dialyzed by high concentrations of the chelator ethylenediaminetetraacetate (EDTA) in the 
intracellular solution. Monovalent currents are highly sensitive to ruthenium red in a voltage- 
dependent manner. It causes a strong inhibition of inward monovalent currents without affecting 
outward currents [55]. This inhibition is likely a direct block of the channel pore within the
17
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transmembrane electrical field. The inhibition of ruthenium red on TRPM6 is unspecific since it is a 
potent blocker of other TRPV channels [72, 73] as well as Ca2+-activated K+ channels [74]. The 
channel properties of TRPM6 , such as outward rectifying I-V curve, intracellular Mg2+ regulation, 
and the lack of voltage dependence, were found to be indistinguishable from those of TRPM7 [36, 37, 
55]. This raises the important question whether the TRPM6 currents are mediated by TRPM6 itself or 
represent the combined activity of TRPM6 and TRPM7.
Homo/Heteromultimeration
The TRPM6 and TRPM7 channels can form homo- or heterotetramers. Fluorescence resonance 
energy transfer (FRET) analysis has indicated that TRPM6 can interact with itself and with TRPM7 
[65]. Based on experiments in Xenopus laevis oocytes and HEK293 cells, it has been suggested that 
co-expression of TRPM7 is required for plasma membrane expression of TRPM6 and channel activity 
[65]. This idea was supported by the analysis of the TRPM6 S141L mutant, observed in HSH. 
TRPM6 S141L was found to hamper the interaction between TRPM6 and TRPM7 resulting in 
intracellular retention [65]. Another study also demonstrated that plasma membrane trafficking of 
TRPM6 strongly depends on TRPM7 co-expression [75]. In contrast, Voets et al. was able to express 
TRPM6 in human embryonic kidney (HEK293) cells and measure its channel activity without co­
expressing TRPM7 [55]. In line, another group has detected TRPM6 , TRPM7 and TRPM6/TRPM7 
channels with distinct biophysical characteristics [76]. They demonstrated a greater permeability of 
TRPM6 to Ni2+, a differential response of TRPM7 to the IP3-inhibitor, 2-aminoethoxydiphenyl borate, 
and a larger unitary conductance of TRPM6 relative to TRPM7 [76]. Further studies are needed to 
clarify the exact functional channel composition in native tissues.
Channel regulation
Both TRPM6 and TRPM7 are regulated by intracellular free Mg2+ ions and Mg2+-complexed 
nucleotides. The endogenous correlate of TRPM7, identified in several cell lines, has been named 
MagNuM (Mg2+-nucleotide-inhibited metal) or MIC (Mg2+-inhibited cation) [37, 77-79]. The native 
MIC current was shown to be suppressed by internal free Mg2+ and not by MgATP [80], while other 
studies pointed towards the Mg2+-nucleotide-mediated regulation of TRPM7. Nadler et al. observed 
that increasing intracellular MgATP concentrations, while keeping free Mg2+ levels constant, steadily 
decreased the TRPM7 activation [37]. This regulation is not mediated by the free nucleotide as 
NaATP causes TRPM7 activation, which was suggested to occur via ATP-dependent phosphorylation 
by the kinase domain [36, 37, 81]. However, free Mg2+ was also shown to be an important regulator 
of TRPM7 activity [37] and addition of NaATP reduced the level of free Mg2+ thereby causing strong 
channel activation. Next to the Mg2+-dependent regulation, several studies have shown that 
phosphatidylinositol bisphosphate (PIP2) is essential to maintain TRPM7 activity [82-84]. PIP2 
breakdown by receptor-mediated stimulation of phospholipase C (PLC) results in channel
18
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inactivation, which can be recovered by PIP2 perfusion [83]. Another study suggested that TRPM7 
activity is regulated, in kinase activity-dependent manner, by receptor-mediated changes in cyclic 
AMP (cAMP) and protein kinase A (PKA) levels [85]. Interestingly, Langeslag et al. recently used 
perforated patch clamping to maintain a more physiological internal environment for cellular 
signaling and could not demonstrate TRPM7 activation upon increased cAMP levels [86]. 
Furthermore, it was demonstrated that TRPM7 can be activated by stimulation of endogenous PLC- 
activating receptors in perforated patch configuration [86]. A feedback mechanism was proposed in 
which PIP2 depletion counteracts or limits the PLC-mediated activation of TRPM7 [86]. The 
regulation of TRPM6 by PIP2, PLC, and cAMP remains to be examined.
Systemic control of TRPM6
The Mg2+ excretion and TRPM6 expression in kidney are strongly regulated by Mg2+ intake. It 
has been shown by mice studies that reduction in dietary Mg2+ results in hypomagnesemia and renal 
Mg2+ and Ca2+ conservation, whereas a high dietary Mg2+ content has the opposite effect. The Mg2+ 
restricted diet led to a significant increase in renal TRPM6 abundance, while the enriched diet tended 
to decrease renal TRPM6 mRNA levels [87]. Variation in dietary Mg2+ content did not alter TRPM7 
mRNA expression levels. These data support the idea of TRPM6 being the gatekeeper of 
transepithelial Mg2+ transport. Early knowledge about renal Mg2+ handling is derived from 
micropuncture and microperfusion studies. Several hormones have been implicated in the regulation 
of renal Mg2+ reabsorption, including parathyroid hormone (PTH), calcitonin, and glucagon. 
Importantly, these effects have only been shown in a mouse distal convoluted tubule (mDCT) cell line 
and need further confirmation in a more physiologically relevant model [88, 89]. Further, Groenestege 
et al. demonstrated that 17^-estradiol regulates TRPM6 expression as it could restore the decreased 
renal TRPM6 mRNA levels in ovariectomized rats, in contrast to 1,25-dihydroxyvitamin D3 and PTH 
[87]. However, stimulation with these hormones in the mDCT cell line resulted in increased Mg2+ 
influx and cellular cAMP accumulation (reviewed in [41, 90]). This suggests that their effect on Mg2+ 
reabsorption is not mediated by the TRPM6 transcriptional level, but through altered channel activity. 
Insulin has also been shown to stimulate Mg2+ uptake in mDCT cells [91]. Moreover, a disturbed 
Mg2+ balance has been related to insulin resistance and type 2 diabetes mellitus. Streptozotocin 
(STZ)-induced diabetic rats display an increased renal TRPM6 mRNA expression, which may 
represent a compensatory mechanism for the increased Mg2+ load to the DCT. Insulin administration 
reversed this increased abundance in TRPM6 and corrected the hypermagnesiuria observed in these 
rats [92]. So, diabetes is associated with renal Mg2+ wasting, but the responsible molecular 
mechanism remains elusive so far. Additionally, Mg2+ handling can be affected by changes in acid 
base status via TRPM6 regulation. Mice with chronic metabolic acidosis display increased Mg2+ 
excretion, reduced renal TRPM6 expression, and decreased serum Mg2+ [93]. The reverse effects 
occur during chronic metabolic alkalosis. In line with these findings, Li et al. demonstrated that acidic
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pH increased TRPM6 inward currents, potentially by decreasing the divalent affinity of the channel 
[76]. Finally, hypomagnesemia can be caused by use of the immunosuppressive agents cyclosporin A 
and tacrolimus (FK506) [94, 95] and anticancer drugs like cetuximab and cisplatin [96, 97]. The 
effect of FK506 can be explained by downregulation of renal TRPM6 expression [98], while the 
molecular mechanisms of the other compounds are not known yet.
The a-kinase domain
TRPM6 and TRPM7 are unique since they contain an atypical serine/threonine kinase domain, 
which has similarities with members of the a-kinase family [36, 66, 99]. Apart from containing a 
zinc-finger domain [99, 100], the a-kinases share little sequence homology with conventional 
eukaryotic protein kinases [101]. The role of this a-kinase domain in the activation and regulation of 
these channels is highly debated. On one hand, the TRPM7 kinase has been presented as an essential 
factor for channel gating [36], while other studies support a regulatory role of the kinase in 
modulating Mg2+ and Mg2+-nucleotide sensitivity [67, 81], and it has even been proposed to be 
uncoupled from the channel function [102]. Based on the channel’s dependence on ATP and the 
absence of TRPM7 currents in two putative phosphotranferase-deficient mouse TRPM7 mutants, it 
was suggested that the a-kinase domain is required for channel activation [36]. However, the lack of 
channel activity in the TRPM7 mutants is likely due to impaired protein expression, since other 
studies showed normal TRPM7 activation in mutated human TRPM7 channels without 
phosphotransferase activity (K1648R and G1799D) [67, 102]. The latter group observed a similar 
Mg2+ sensitivity for mutant and wildtype TRPM7 channels, from which they concluded that a-kinase 
domain and channel activity are dissociated [102]. However, this statement was based on two 
relatively high Mg2+ concentrations (4 and 6 mM). A complete dose-response analysis of the mutant 
TRPM7 channels demonstrated a significant right shift in their Mg2+/MgATP sensitivity compared to 
wildtype TRPM7 [67]. Interestingly, The TRPM7-A-kinase mutant showed a markedly increased 
sensitivity to both Mg2+ and MgATP with almost full ablation of channel activity at 1 mM 
Mg2+/MgATP [67]. Further study suggested that the a-kinase domain enclosed a MgATP binding site 
which acts synergistically with a separate Mg2+-binding site extrinsic to the domain that regulates 
TRPM7 channel activity [81]. Another interesting issue is whether the nucleotide binding alone 
regulates channel activity or whether the kinase activity also plays a role, since TRPM6/TRPM7 are 
able to undergo autophosphorylation and phosphorylate other substrates. TRPM6 is capable of cross- 
phosphorylating TRPM7, but not vice versa [75]. Annexin 1 and myosin IIA have been identified as 
endogenous phosphorylation targets of the TRPM7 a-kinase [69, 103]. Recently, it has been 
demonstrated that TRPM7 regulates the myosin IIA filament stability and localization via a kinase- 
dependent mechanism [104]. TRPM6 and TRPM7 share exogenous substrates, as myosin IIA, IIB, 
and IIC, which were not phosphorylated by the functionally distant eEF2-kinase [105]. Furthermore,
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Clark et al. provided a model where substantial autophosphorylation of the cytosolic C-termini of 
both TRPM6 and TRPM7 leads to increased substrate phosphorylation via enhancing the kinase­
substrate interactions [106]. Finally, the a-kinase domain might play a role as modulator of TRPM6 
and TRPM7 via regulation by interaction partners, which have not been discovered so far. Further 
experiments should help to elucidate the role of the a-kinase domain in regulating TRPM6/TRPM7 
channel activity.
Channelomics
Channelomics is a new term for proteomics of ion channels. It includes all aspects of ion channel 
research such as transcriptional and translational regulation, post-translational consequences on the 
protein composition and modulatory effects of hormones, durgs, and toxins on the structure and 
function of ion channels. In this section several biochemical, biophysical and electrophysiological 
technologies, which are frequently employed to study the channelomics, will be highlighted.
Cell surface biotinylation
Biotinylation is a rapid method of covalently attaching a biotin tag to cell surface proteins, while 
intracellularly located proteins are not stained. The technique uses a cell-impermeable, cleavable 
biotinylation reagent (Sulfo-NHS-SS-Biotin) to label exposed amines of proteins on the surface of 
mammalian cells. As long as the cell remains intact, only the amines exposed on the surface will be 
biotinylated by Sulfo-NHS-SS-Biotin. Subsequently, the cells are harvested and lysed, and the labeled 
surface proteins are affinity-purified with avidin containing beads. Avidin is a glycoprotein found in 
egg whites and oviducts of birds, reptiles and amphibians. It contains four identical subunits, each 
able to bind a single biotin molecule [107]. Avidin is highly useful for protein purification and 
detection as most chemical modifications have barely any effect on the avidin activity. Subsequently, 
antibody labelling or a fluorescent dye can detect the biotin-avidin protein complex, which is used in 
ELISA (enzyme-linked immunosorbent assay) assays, western blots, and other immunoanalytical 
methods. In the light of ion channel research, the cell surface biotinylation assay is valuable for 
differentiation of plasma membrane proteins from those localized to organelle membranes, 
distribution of membrane proteins in polarized epithelial cells, and internalization and recycling of 
cell surface proteins.
Tags
Protein tags are peptide sequences genetically attached to a recombinant protein. The various tags 
can be grouped according to their purposes: i) Affinity tags, such as glutathione-S-transferase (GST), 
are used for purification of proteins from their biological source; ii) solubilization tags assist proper 
protein folding and prevent precipitating, when the recombinant protein is expressed in chaperone-
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deficient species such as E. coli; iii) chromatography tags, like a FLAG-tag, can alter 
chromatographic properties of the protein to provide different resolution using a particular separation 
technique; iv) epitope tags are short peptide sequences, usually derived from viral genes, that are 
predominantly used for western blotting and immunoprecipitation studies. Epitope tags involve V5- 
tag, c-myc-tag, and HA-tag; v) fluorescence tags are used to visualize a protein, mostly during live 
cell imaging. The green fluorescent protein (GFP) and its derivatives (i.e. BFP, YFP) are the most 
frequently used fluorescence tags. Combinations of protein tags are even used to achieve 
multifunctional control of the protein. However, an important risk with addition of tags is the 
alteration or ablation of the native function of the protein.
Fluorescence microscopy
Ion channels are dynamic in nature: they are continuously formed, trafficked to the plasma 
membrane, inserted in the plasma membrane, and removed to be degraded or recycled. So, ion 
channel function is not just dependent on electrophysiological channel properties, but on channel 
trafficking as well. The development of molecular techniques to tag channels with fluorescent 
proteins, and of advanced microscopic imaging techniques such as fluorescence resonance energy 
transfer (FRET), fluorescence recovery after photobleaching (FRAP), and total internal reflection 
fluorescence (TIRF) microscopy, generated new opportunities to study the intracellular movement of 
channels to and from the plasma membrane.
FRET (fluorescent resonance energy transfer)
FRET, also known as Förster resonance energy transfer, is a mechanism of energy transfer 
between two chromophores. This mechanism is named after the German scientist Theodor Förster. 
The term ‘fluorescence resonance energy transfer’ is often used instead, since the chromophores are 
fluorescent (fluorophores). The non-radiative transfer of photon energy from an electronic excited 
fluorophore (the donor) to another fluorophore (the acceptor) occurs when both are located within 
close proximity (1-10 nm). The donor and acceptor fluorophores for FRET analysis come from a 
class of green fluorescent proteins (GFPs). Importantly, the GFPs should be selected on the basis of 
sufficient separation in excitation spectra to stimulate only the donor GFP, an overlap (>30%) 
between the donor emission spectrum and the acceptor excitation spectrum for efficient energy 
transfer, and adequate separation in emission spectra between donor and acceptor GFPs to 
independently measure the fluorescence of each fluorophore [108]. If FRET occurs, the donor 
fluorophore signal will be quenched and the acceptor fluorophore signal will be sensitized or 
increased. Current advances in fluorescence microscopy, together with the development of new 
fluorescent probes, make FRET a great technique for studying molecular interactions within living 
cells. It can be used to examine protein-protein interactions, such as heteromeric assembly of ion 
channels [109]. The binding of intracellular signalling molecules to ion channel domains, as well as
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the downstream pathway of receptor or channel activation like the cAMP signaling, can be studied by 
this technique [110, 111]. Furthermore, FRET is used to monitor conformational rearrangements 
associated with channel gating [1 1 2 ].
FRAP (fluorescence recovery after photobleaching)
FRAP microscopy is introduced in the 1970s for imaging intracellular molecular dynamics. 
Similar as to FRET, fluorophores as GFP will be tagged to the protein of interest, which results in an 
intracellular fluorescence signal upon protein expression. A special illumination step is used to 
perturb the steady-state fluorescence distribution within single cells. After this high intensity 
illumination had permanently photobleached the fluorescent dye in a small selected region, 
surrounding molecules that are still fluorescent migrate into this blackened area recovering the 
fluorescence distribution. In this way, the trafficking of proteins to the plasma membrane can be 
measured by the time and amount of fluorescent recovery. More recently, the technique is now used 
to study channel subunits, isoforms, or accessory proteins that modulate trafficking and membrane 
localization [113, 114].
Total internal reflection fluorescence (TIRF)
TIRF microscopy was developed by Daniel Axelrod in the early 1980s [115]. With this type of 
microscopy a thin region of cells can be visualized. It employs the phenomenon of total internal 
reflection, which occurs at the glass-water interface of the glass coverslip containing a bath solution 
with cells that lies under the microscope. At large angle of incidence, the excitation light reflects back 
into glass and generates at the interface with water a so-called evanescent wave. The evanescent wave 
selectively illuminates and excites fluorophores in small region of approximately 100-200 nm from 
the interface. Thus, TIRF allows high resolution imaging of features and events occurring close to the 
plasma membrane of living cells. In contrast to conventional fluorescence microscopy, TIRF can be 
used to examine the fluorescence of single molecules. Similar to FRAP, TIRF is only recently used to 
study channel trafficking and function [116, 117]. In addition, TIRF is used together with FRET to 
detect channel assembly, the effect of small molecule binding, and conformational channel 
rearrangement at the plasma membrane level [118-120].
Patch clamp technique
Studies in artificial lipid membranes showed that certain proteins isolated from bacteria and other 
antibiotic polypeptides were able to induce discrete changes in membrane conductance [1 2 1 , 122]. 
These conductance changes were of the same order of magnitude as single channel conductances 
measured in current fluctuations by voltage clamp of neuromuscular junction and in nodes of Ranvier 
[123, 124]. The voltage clamp allows the membrane voltage to be controlled independent of ionic 
currents across a lipid membrane [125]. However, background noise in these voltage clamp setups
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was mostly higher that the single channel signals to be measured. Therefore, a small area of the 
membrane (“patch”) should be isolated for localized electrical measurements by placing a glass 
micropipette on the surface of the voltage-clamped cell. Erwin Neher and Bert Sakmann developed 
the patch clamp technique and could measure single channel currents from the acetylcholine-activated 
receptor [126]. Subsequently, the technique was improved significantly with the phenomenon now 
called gigaseal formation [127, 128].
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Figure 4. Schematic representation of the patch clamp configurations. Applying slight suction to the back of the 
pipette results in a tight seal between pipette and membrane, which is called the cell-attached patch recording 
method. Rupture of the membrane patch within the pipette, through short strong suction, gives access to the 
cytoplasm of the cell, whole-cell recording method. From the cell-attached configuration, the pipette can be 
retracting and a small vesicle of membrane remains attached to the pipette. By exposing the tip of the pipette to 
air, this vesicle opens, leading to the inside-out patch recording configuration. The intracellular surface of the 
membrane is exposed to the extracellular medium). On the other hand, retracting the pipette in the whole-cell 
configuration, a membrane patch will form a vesicle that is exposed to the extracellular medium. This is called 
the outside-out recording configuration.
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Following formation of the gigaseal, a variety of recording configurations can be established (Fig. 4): 
i) Cell-attached patch recording. In this recording configuration, the cell remains intact. Following 
gigaseal formation, single channel currents through ion channels trapped within the patch of 
membrane can be recorded. ii) Inside-out patch. A patch of the membrane can be pulled off the cell by 
withdrawing the pipette after gigaseal formation. The cytoplasmic membrane is then facing the bath 
solution, allowing manipulation of the intracellular environment of ion channels during single channel 
measurements. iii) Whole-cell recording. Following a gigaseal, the patch of membrane under the 
pipette can be ruptured by application of strong suction. Patch rupture is detected as a sudden increase 
in capacitative current in response to a test potential step. This configuration results in electrical 
contact and diffusional exchange between the pipette electrode and the cytoplasm, which allows 
optimal control of the intracellular compartment. iv) Outside-out patch. This configuration can be 
achieved by pulling away the pipette during a whole-cell recording. The patch of membrane 
withdrawn from the cell will reseal on the pipette such that the extracellular membrane surface can be 
exposed to different solutions during a single channel measurement. v) Perforated-patch recording. A 
disadvantage of whole-cell recording is the loss of cytoplasmic ions, nucleotides and other signaling 
molecules. Therefore a gigaseal can be formed with a pipette filled with pore-forming antibiotic 
molecules. These antibiotics form small perforations in the membrane, providing electrical access to 
the cell, without dialyzing the interior of the cell. The variety of patch clamp configurations, 
combined with the single channel resolution, offers a powerful experimental tool, from the molecular 
level of altered channel gene expression, to the cellular level, where signaling mechanism are 
unravelled, to the tissue level, in which cellular interactions in slice preparations are revealed.
Outline of this thesis
As illustrated in the aforementioned paragraphs, ion channels are essential proteins for all living 
organisms. They regulate the flow of ions across the plasma membrane of each cell in the body and 
are involved in a wide variety of biological processes. The epithelial Mg2+ channel TRPM6 is the 
gatekeeper of transcellular Mg2+ (re)absorption, and thus an important component for the control of 
body Mg2+ homeostasis. However, the molecular mechanism for active Mg2+ reabsorption is largely 
unknown. The aim of this thesis was, therefore, to provide more insight in the physiological and 
molecular regulation of renal ion channels in general and in particular of the epithelial Mg2+ channel 
TRPM6 and the voltage-operated K+ channel Kv1.1. Chapter 2 describes the identification of the 
first TRPM6-associated protein, named receptor for activated c-kinase 1 (RACK1). RACK1 was 
found as an interaction partner of the TRPM6 a-kinase by yeast two-hybrid screening and via a 
combination of GST pull-down and Fourier transform ion cyclotron resonance mass spectrometry 
(FTMS). The function of RACK1 was further studied using biochemical and electrophysiological 
analysis. The identification of a new a-kinase interaction partner, repressor of estrogen receptor
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activity (REA), and its role on TRPM6 regulation are outlined in chapter 3. The chapter also points 
out a rapid stimulatory effect of 17^-estradiol on TRPM6. Next, chapter 4 portrays the identification 
of a third protein interacting with the TRPM6 a-kinase domain, called Methionine Sulfoxide 
Reductase B1 (MsrB1). It highlights the effect of oxidative stress on TRPM6 channel activity and 
partial recovery via MsrB1, involving a methionine residue in the peripheral region of the TRPM6 a- 
kinase domain. The study presented in chapter 5 illustrates the effect of the widely used anti-cancer 
drug Erlotinib on Mg2+ handling. By combining mice studies with biochemical and 
electrophysiological data, the effect on TRPM6 expression and channel activity was examined. 
Chapter 6 reports the identification of a mutation in the KCNA1 gene as cause for autosomal 
dominant hypomagnesemia in a Brazilian family. The mutation results in the amino acid change 
N255D in the encoded K+ channel Kv1.1. This study provides a new coupling between renal K+ 
handling and active Mg2+ reabsorption as Kv1.1 co-localizes with TRPM6 along the apical membrane 
of DCT. Furthermore, hypomagnesemia is presented as a new phenotypic characteristic associated 
with a mutation in KCNA1. Functional analysis demonstrated that this mutation in Kv1.1 results in a 
non-functional channel. The effect of the mutation on Kv1.1 channel function was further examined 
in the study described in chapter 7. Combining structural modelling with patch clamp recordings was
used to investigate the result of substituting N255 by other amino acids (N255E, N255Q, N255A, N255V,
N255T, N255H).). Finally, the studies of this thesis and the physiological implications of the finding are 
discussed and summarized in chapter 8.
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RACK1 inhibits TRPM6 through its a-kinase domain
Background: The maintenance of the body’s Mg2+ balance is of great importance because of its 
involvement in numerous enzymatic systems and its intervention in neuromuscular excitability, 
protein synthesis, and nucleic acid stability. Recently, the transient receptor potential melastatin 6 
(TRPM6) was identified as the gatekeeper of active Mg2+ transport and therefore plays a crucial role 
in the regulation of Mg2+ homeostasis. Remarkably, TRPM6 combines a Mg2+ channel with an a- 
kinase domain whose function remains elusive.
Results: Here, we identify the receptor for activated C-kinase 1 (RACK1) as the first regulatory 
protein of TRPM6 that associates with the a-kinase domain. RACK1 and TRPM6 are both present in 
renal Mg2+-transporting distal convoluted tubules. We demonstrate that RACK1 inhibits channel 
activity in an a-kinase activity-dependent manner, whereas small interference (si) RNA-mediated 
knockdown of RACK1 increases the current. Moreover, threonine1851 in the a-kinase domain was 
identified as an autophosphorylation site of which the phosphorylation state is essential for the 
inhibitory effect of RACK1. Importantly, threonine1851 was crucial for the Mg2+ sensitivity of TRPM6 
autophosphorylation and channel activity. TRPM6 channel activity was less sensitive to Mg2+ when 
RACK1 was knocked down by siRNA. Finally, activation of protein kinase C by phorbol 12- 
myristate 13-acetate-PMA prohibited the inhibitory effect of RACK1 on TRPM6 channel activity.
Conclusions: We propose a unique mode of TRPM6 regulation in which the Mg2+ influx is 
controlled by RACK1 through its interaction with the a-kinase and the phosphorylation state of the
threonine1851 residue.
Introduction
The maintenance of the body’s Mg2+ balance is of crucial importance for various vital cellular 
processes [1, 2]. Mg2+ homeostasis in mammals depends on the equilibrium between intestinal 
absorption and renal excretion. The renal distal convoluted tubule (DCT) reabsorbs ~10% of the 
filtered Mg2+, and the reabsorption rate in this segment defines the final urinary Mg2+ concentration 
[3]. Mg2+ reabsorption in DCT is active and transcellular in nature, but the molecular details and 
regulation of this pathway remain largely unknown. Recently, transient receptor potential melastatin 6 
(TRPM6) was identified as a pivotal component in active Mg2+ (re)absorption, mutations of which 
cause hypomagnesemia with secondary hypocalcemia (HSH) [4, 5]. TRPM6 is localized along the 
apical membrane of DCT and intestinal cells. It confines a Mg2+-permeable channel, the activity of 
which is strongly regulated by the intracellular Mg2+ concentration ([Mg2+]i) [2]. Expression of 
TRPM6 is regulated by dietary Mg2+, whereas TRPM7 is unaffected, supporting the idea of an 
important role of TRPM6 in transepithelial Mg2+ transport [6].
Remarkably, TRPM6 and TRPM7 contain a unique carboxyl (C)-terminal serine/threonine 
protein kinase domain belonging to the a-kinase family [7-9]. This distinctive combination of a
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channel and an enzyme domain within a single molecule raises still unsolved questions concerning the 
regulatory role of this catalytic domain on channel activity. While it has been demonstrated that the 
TRPM7 a-kinase is able to autophosphorylate the channel and downstream substrates such as myosin 
IIA heavy chain and annexin I [10-13], the role of this a-kinase activity in modulating channel 
function is far from clear. Previous studies indicated that the a-kinase activity is not essential for 
TRPM7 activation [11, 13] and that regulation of TRPM7 activity by intracellular Mg2+ is dissociated 
from autophosphorylation or a-kinase activity [13]. Other groups demonstrated regulation of TRPM7 
activity by intracellular Mg2+ and nucleotides as well as the cAMP/protein kinase A pathway, which 
required the a-kinase [14, 15]. It was reported that deletion of the TRPM7 a-kinase domain or 
phosphotransferase-deficient kinase mutants results in nonfunctional channels [9]. Compared to 
TRPM7, little is known about the a-kinase function of TRPM6. So far, only one study reported that 
the a-kinase of TRPM6 is capable of crossphosphorylation of TRPM7, but not vice versa, underlying 
the functional nonredundancy of these two “ chanzymes” [12].
The aim of the present study was, therefore, to investigate the role of the a-kinase domain in 
TRPM6 channel activity through the identification of regulatory proteins specifically interacting with 
the a-kinase domain.
Results
RACKl associates with TRPM6
To identify potential TRPM6-interacting proteins, two independent approaches were used, i.e., 
the yeast two-hybrid screening of a mouse kidney cDNA library with the complete C-tail of TRPM6 
and the combination of a GST pull-down with the a-kinase domain of TRPM6 in mouse kidney lysate 
followed by Fourier transform ion cyclotron resonance mass spectrometry (FTMS). RACK1, a 
scaffold protein originally discovered as an adaptor for protein kinase C (PKC) [16], was identified as 
a TRPM6 interacting protein in both approaches. Figure 1A shows that RACK1 interacted with 
TRPM6, whereas no interaction was observed in the absence of either RACK1 or the TRPM6 C-tail. 
To further establish this interaction, GST pull-down binding assays were performed, which 
demonstrated that RACK1 interacts specifically with the a-kinase domain, but not with GST alone 
(Fig. 1B). Next, the association between TRPM6 and RACK1 was substantiated in mammalian 
HEK293 cells. RACK1 coprecipitated with the GST-kinase and GST-TRPM6-C-tail, but not with 
GSTTRPM6-C-tail-A-kinase and GST alone (Fig. 1C). Furthermore, coprecipitation experiments also 
demonstrated that the endogenously expressed RACK1 in HEK293 cells is associated with the 
TRPM6 a-kinase domain (Fig. 1D). Finally, coimmunoprecipitation studies of RACK1 with full- 
length TRPM6 or TRPM6 A-kinase in HEK293 cells showed that wild-type TRPM6 but not TRPM6 
A-kinase co-precipitates with RACK1 (Fig. 1E).
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Figure 1. RACK1 interacts with a-kinase domain in TRPM6. A. The C-terminus of TRPM6 and the empty 
pAS1 vector were co-expressed with full-length RACK1 into the Y153 yeast strain and grown on media without 
tryptophan, leucine and histidine. B. GST-pull down assay between [35S]-methionine-labeled RACK1 protein 
and GST or GST fused to the a-kinase domain. C. Co-precipitation studies of GST-kinase, GST-TRPM6-C-tail- 
A-kinase and GST-TRPM6-C-tail in RACK 1-expressing HEK293 cells (top panel). RACK1 input (1%) 
expression was analyzed by immunoblotting (bottom panel). D. Co-precipitation studies of GST and GST-a- 
kinase with endogenous RACK1 in HEK293 cells (top panel). RACK1 input (0.5%) expression was analyzed 
by immunoblotting (bottom panel). E. Co-immunoprecipitation studies of RACK1 with GFP-TRPM6 or GFP- 
TRPM6 A-kinase in HEK293 cells (top panel). Input (0.5%) expression was analyzed by immunoblotting 
(bottom panel). F. Mapping of the RACK1 binding site within the a-kinase domain. Schematic diagram of the 
GST-fusion proteins containing different truncations of the a-kinase. G. Coomassie staining of the SDS/PAGE 
gel. H. RACK1 binding site in the predicted 3D-structure model of the a-kinase domain.
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Figure 2. A. [ S]-methionine-labeled RACK1 
protein was incubated with GST or GST-fused to 
the TRPM7 a-kinase domain immobilized on 
glutathione-sepharose 4B beads. Bound RACK1 
was separated by SDS/PAGE and visualized by 
autoradiography. B. Time course of the current 
density (pA/pF) at +80 mV of TRPM6 (o); 
TRPM6 and RACK1 (0.5 |ig, •)  transfected 
HEK293 cells. C. Corresponding time course at - 
80 mV. D. Time course of the current density at 
+80 mV of TRPM6 (• , n = 9) and mock (o, n = 
4) TRPM6-transfected HEK293 cells (selected 
from the MIC-developing HEK293 cells).
Mapping o f the R A C K  binding site in TRPM6
To determine the RACK1 binding site within 
TRPM6, a series of deletion mutants in the a-kinase 
domain of the channel was constructed and
35evaluated for their interaction with [35S]-methionine- 
labeled RACK1 protein using pull-down 
experiments (Fig. 1F). The interaction between the 
two proteins was abolished when TRPM6 was 
truncated at position 1857, whereas truncation at 
position 1885 had no effect on the interaction with 
RACK1. Moreover, a GST-fusion protein containing 
only the short stretch between the amino acids 1857 
and 1885 of the TRPM6-kinase domain bound to 
RACK1 (Fig. 1F). Therefore, the RACK1 binding 
site within TRPM6 is restricted to the region 
between the positions 1857 and 1885. The integrity 
and quantity of the GST-fusion proteins was 
analyzed and confirmed by Coomassie staining (Fig. 
1G). To explore the RACK1 binding site in the 
TRPM6 a-kinase domain, the tertiary structure of 
TRPM6 a-kinase domain was modeled by SWISS- 
MODEL (http://swissmodel.expasy.org//SWISS- 
MODEL.html) (Fig. 1H), based on the homology 
between the TRPM6 a-kinase and the crystallized 
TRPM7 a-kinase domain [17]. Due to the high 
homology between the TRPM7 and TRPM6 a- 
kinase domains (84%), these two a-kinase s share a 
highly conserved secondary structure. Indeed, the 
GST pull-down assay showed that RACK1 also 
interacts with the TRPM7 a-kinase domain (Fig. 2A). 
The surface and accessibility analysis of the RACK1 
binding site (6th, 7th, and 8th p sheets) suggested that, 
among the 28 amino acids of the RACK1 binding 
site, 18 are localized at the surface of the TRPM6 a- 
kinase domain (see
http://www.cmbi.ru.nl/whvensela/trpm6/).
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RACK1 and TRPM6 co-express in kidney
To study the localization of RACK1 in kidney, immunohistochemistry was performed on kidney 
sections using the thiazide-sensitive Na+/Cl- cotransporter (NCC) as a DCT marker These analyses 
indicated immunopositive staining for RACK1 in the NCC-expressing DCT cells (Fig. 3A, top panel). 
TRPM6 completely colocalized with NCC [2] along the apical membrane in DCT, indicating the 
presence of RACK1 in the TRPM6-expressing DCT segment (Fig. 3 A, bottom panel). Subsequent 
immunohistochemical stainings confirmed the colocalization of RACK1 and TRPM6 in the DCT 
(Fig. 3B).
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Figure 3. Localization of RACK1 in kidney. A. Immunohistochemical analysis of RACK1 and NCC in kidney 
sections (top panel). Kidney sections were co-stained with antibodies against TRPM6 and NCC. B. 
Immunohistochemical analysis of TRPM6 and RACK1 in rat kidney sections.
RACK1 inhibits TRPM6 channel activity
The functional role of RACK1 on TRPM6 current was investigated in HEK293 cells by whole­
cell recordings. In mock-transfected HEK293 cells, dialyzed with a Mg2+-free pipette solution, around 
40% of the cells developed small albeit significan currents, generally referred to as the Mg2+-inhibited 
cation current (MIC current) [18, 19]. This endogenous current was approximately ten times smaller
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and developed over a longer time period compared to the TRPM6 current (Fig. 2D). We demonstrated 
that co-expression of RACK1 with TRPM6 significantly inhibited the TRPM6-mediated current 
amplitude in a dose-dependent manner.
Figure 4. Functional effect of RACK1 on TRPM6 activity. A. Time course of the current density (pA/pF) at +80 
mV of TRPM6 (o),TRPM6 and RACK1 (0.5 ^g, ♦), TRPM6 and RACK1 (0.1 ^g, A), and mock TRPM6 (*) 
transfected HEK293 cells. B. Corresponding time course at -80 mV. C. Averaged values of the current density 
at +80 and -80 mV after 200 s of mock TRPM6 (n=10), TRPM6 (n=22), mock TRPM6 and RACK1 (0.1 ^g, 
n=11), TRPM6 and RACK1 (0.1 ^g, n=18), mock TRPM6 and RACK1 (0.5 ^g, n=13), and TRPM6 and 
RACK1 (0.5 |ig, n=24). Open bars correspond to cells transfected with mock transfected DNA and closed bars 
to cells transfected with TRPM6 in the absence and presence of RACK1. * indicates P = 0.001 compared to 
TRPM6 current. D. Time course of the current density at +80 mV of TRPM6 A-kinase (□); and TRPM6 A- 
kinase and RACK1 (0.5 |ig, ■) transfected HEK293 cells. E. Averaged values of the current density at +80 and - 
80 mV after 200 s of mock TRPM6 A-kinase (n=9); TRPM6 A-kinase (n=22); mock TRPM6 A-kinase and 
RACK1 (0.5 |ig, n=10) and TRPM6 A-kinase and RACK1 (0.5 |ig, n=19) transfected HEK293 cells. Open and 
closed bars correspond to cells transfected with mock TRPM6 A-kinase and TRPM6 A-kinase, respectively, in 
the absence and presence of RACK1. F,G. Immunoblot analysis of RACK1 and p-actin expression in mock, 
siRNA-RACK1(1) and siRNA-RACK1(2) transfected HEK293 cells. H. Averaged values of the current density 
at +80 and -80 mV after 200 s of mock TRPM6 (n=9), TRPM6 (n=19), mock TRPM6 and siRNA-RACK 1(1) 
(0.5 ^g, n=17), TRPM6 and siRNA-RACK1(1) (0.5 ^g, n=21, P = 0.029) , mock TRPM6 and siRNA- 
RACK1(2) (0.1 ^g, n=18), TRPM6 and siRNA-RACK1(2) (0.1 ^g, n=23, P = 0.001), mock TRPM6 and 
siRNA(luc) (0.5 |ig, n=13), and TRPM6 and siRNA(luc) (0.5 |ig, n=17, P = 1.000). * indicates P <0.05 
compared to the TRPM6 current. Open bars correspond to cells are transfected with mock DNA whereas closed 
bars to cells transfected with TRPM6 in the absence and presence of siRNA-RACK1 or luciferase. I. Similarly 
to Figure 3H, averaged values of mock TRPM6 A-kinase (n=10), TRPM6 A-kinase (n=23), mock TRPM6 A- 
kinase and siRNA-RACK 1(1) (0.5 ^g, n=12), TRPM6 A-kinase and siRNA-RACK1(1) (0.5 ^g, n=19, P = 
1.000), mock TRPM6 A-kinase and siRNA-RACK 1(2) (0.1 |ig, n=17), TRPM6 A-kinase and siRNA- 
RACK1(2) (0.1 ^g, n=22, P = 1.000), mock TRPM6 A-kinase and siRNA(luc) (0.5 ^g, n=18), and TRPM6 A- 
kinase and siRNA(luc) (0.5 |ig, n=25, P = 1.000) current densities. P values are relative to the TRPM6 A-kinase 
current.
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Figure 5. A. Current recorded after 200 sec stimulation by a voltage ramp between -100 and +100 mV of 
TRPM6 (1), TRPM6 and RACK1 (0.1 ^g, 2), TRPM6 and RACK1 (0.5 ^g, 3), and mock TRPM6 (4) 
transfected HEK293 cells. B. Current recorded after 200 sec stimulation by a voltage ramp between -100 and 
+100 mV of TRPM6 A-kinase (1), and TRPM6 A-kinase and RACK1 (0.5 |ig, 2) transfected HEK293 cells C. 
Current recorded after 200 sec stimulation by a voltage ramp between -100 and +100 mV of TRPM6 (3), 
TRPM6 and siRNA-RACK 1(1) (0.5 ^g, 2), TRPM6 and siRNA-RACK 1 (2) (0.1 ^g, 1), and TRPM6 and 
siRNA(luc) (0.5 |ig, 4) transfected HEK293 cells. D. Time course of the current density at +80 mV of TRPM6 
(o), TRPM6 and siRNA-RACK 1(1) (0.5 ^g, ♦), TRPM6 and siRNA-RACK 1 (2) (0.1 ^g, ▲), and TRPM6 and 
siRNA(luc) (0.5 |ig, •)  transfected HEK293 cells. E. Current of TRPM6 A-kinase (1), TRPM6 A-kinase and 
siRNA-RACK 1(1) (0.5 ^g, 2), TRPM6 A-kinase and siRNA-RACK 1 (2) (0.1 ^g, 3), and TRPM6 A-kinase and 
siRNA-luc (0.5 |ig, 4) transfected HEK293 cells. F. Time course of the current density at +80 mV of TRPM6 A- 
kinase (□), TRPM6 A-kinase and siRNA-RACK 1(1) (0.5 ^g, ♦), TRPM6 A-kinase and siRNA-RACK 1 (2) (0.1 
fig, A), and TRPM6 A-kinase and siRNA-luc (0.5 |ig, ■) transfected HEK293 cells.
TRPM6 current was reduced by 56% ± 4% and 88% ± 3% compared to TRPM6 alone when 0.1 
[Ag or 0.5 ¡Ag RACK1 cDNA, respectively, was co-transfected (Fig. 4A-4C and Fig. 5A). 
Furthermore, RACK1 also inhibited the TRPM7 channel activity (Fig. 2B and 2C). However, the 
inhibitory effect of RACK1 on TRPM6/7 current was specific, since RACK1 did not significantly
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affect the current in TRPV5-expressing HEK293 cells (-11% ± 3%, -16% ± 3%, and -9% ± 2% at -80 
mV in divalent-free, EDTA, and 10 mM Ca2+ solutions, respectively, n = 10-12 cells as described 
previously [20]). Importantly, RACK1 co-expression with an a-kinase -deleted TRPM6 mutant 
(TRPM6 A-kinase) failed to suppress the TRPM6 A-kinase-mediated current at both +80 and -80 mV 
(Fig. 4D and 4E and Fig. 5B).
Figure 6. Inhibition of TRPM6 by 
RACK1 depends on phosphorylation 
of the a-kinase A. In vitro protein 
kinase assay of TRPM6 and the 
TRPM6 A-kinase mutant (32P, top 
panel). Addition of alkaline 
phosphatase (AP) was used as a 
negative control. Immunoblotting 
(IB, bottom panel) and densitometry 
quantification (right panel) of 
TRPM6 and TRPM6 A-kinase 
expression. * indicates P = 0.001, 
n=3. B. In vitro protein kinase assay 
of TRPM6 and the K1804R mutant 
(32P, top panel). Immunoblotting (IB, 
bottom panel) and densitometry 
quantification (right panel) of 
TRPM6 and K1804R expression. * 
indicates P = 0.001, n=3. C. 
Summary of the current density at 
+80 and -80 mV of K1804R (n=22), 
K1804R and RACK1 (0.5 ^g, n=24; P 
= 1.000 compared to the K1804R 
current), mock K1804R (n=15) and 
mock K1804R and RACK1 (n=16). 
Open bars correspond to mock 
conditions whereas closed bars to 
cells transfected with K1804R in the 
absence and presence of RACK1.
Small interference RNA-mediated RACK1 silencing stimulates TRPM6 activity
To further elucidate the molecular mechanism of the RACK1 inhibitory effect, siRNA technology 
was applied. Immunoblot analysis revealed a significant downregulation of RACK1 protein 
abundance in HEK293 cells expressing RACKl-targeted siRNA(1) and siRNA(2) in comparison to 
mock-transfected cells (Fig. 4F and 4G). siRNA(l) and siRNA(2) for RACK1 induced a significant 
increase of the TRPM6 current amplitude [356 ± 31 pA/pF, -18 ± 1 pA/pF and 397 ± 25 pA/pF, -33 ± 
6 pA/pF for RACK1 siRNA(1) and siRNA(2) at +80 and -80 mV, respectively, in comparison to 275 
± 26 pA/pF, -13 ± 2 pA/pF for TRPM6 and empty vector, respectively] (Fig. 4H and Fig. 5C and 5D). 
The siRNA for luciferase, siRNA(luc), did not significantly affect TRPM6 current amplitudes.
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Importantly, RACK1 siRNA(1), RACK1 siRNA(2), and siRNA(luc) did not alter the current 
amplitude of the TRPM6 A-kinase mutant (Fig. 4I and Fig. 5E and 5F).
RACKl-mediated inhibition o f  TRPM6 is kinase activity-dependent
Next, the role of the kinase-mediated autophosphorylation was investigated. TRPM6 a-kinase 
autophosphorylation activity was first assessed by an in vitro protein kinase assay. Figure 6A 
indicates that TRPM6 is autophosphorylated, whereas deletion of its a-kinase or the addition of 
alkaline phosphatase prevents channel autophosphorylation. Next, we constructed a 
phosphotransferase-deficient mutant (K1804R) according to the homologous TRPM7 
phosphotransferase-deficient mutant (K1648R) [13]. The in vitro phosphorylation assay showed that the 
kinase activity of the K1804R mutant was abolished, while the mutant was equally expressed compared 
to wild-type TRPM6 (Fig. 6B). K1804R mutant was still able to bind RACK1, as demonstrated by GST 
pulldown assay (Fig. 7A).
Figure 7. A. GST-pull down 
binding assay between 
RACK1 protein and GST, 
GST-fused to the kinase 
domain of TRPM6 or the 
K1804R mutant (top panel). 
Coomassie staining of the 
corresponding gel (bottom 
panel). B. Current recorded 
after stimulation by a voltage 
ramp between -100  and 
+100 mV of K1804R (1), and 
K1804R and RACK1 (0.5 ^g, 
2) transfected HEK293 cells. 
C. Time course of the current 
density at +80 mV of K1804R
(o), and K1804R and RACK1 
(0.5 |ig, •)  transfected 
HEK293 cells.
Autophosphorylation o f  threonine1851 in the kinase domain is essential fo r  the inhibitory effect o f  
RACK1
To address the autophosphorylation site(s) in TRPM6 that are essential for the regulatory effect of 
RACK1, the purified GST-TRPM6 a-kinase protein was subjected to an in vitro phosphorylation
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assay and subsequently analyzed by FTMS. Figure 8A revealed a single autophosphorylation site 
within the a-kinase domain corresponding to the threonine residue at position 1851 (T1851). 
Interestingly, in the tertiary structure model of the TRPM6 a-kinase domain, T1851 is located at the end 
of the fourth a helix adjacent to the RACK1 binding site (Fig. 8B). Subsequently, T1851 was either 
point mutated into an alanine, resulting in a nonphosphorylated residue (T1851A), or into an aspartate, 
mimicking the constitutive autophosphorylated threonine residue (T1851D). Both T1851A and t 1851D 
mutations significantly decreased TRPM6 autophosphorylation in comparison to the wild-type 
channel (Fig. 8C and Fig. 9A), while GST pull-down assays demonstrated that RACK1 binding to 
T1851A and t 1851D mutants was not altered (Fig. 9B). Importantly, the expression of the (mutated) 
TRPM6 proteins was equal (Fig. 8C, lower panel). Furthermore, both mutants (T1851A and T1851D) 
displayed currents similar to the wild-type channel (Fig. 8D and 8E and Fig. 9C-9F). However, the 
T1851A mutation prevented the inhibitory effect of RACK1 (Fig. 8D and Fig. 9C and 9D), whereas the 
RACK1-induced inhibition remained unaltered when coexpressed with the t 1851D mutant (Fig. 8E 
and Fig. 9E and 9F).
Threonine1851 andRACK1 play an important role in M g2+-dependent channel activity
To explore whether RACK1 and the T1851 residue in the a-kinase domain are important for the 
inhibitory effect of Mg2+ on TRPM6 current, the influence of [Mg2+] on TRPM6 and T1851A mutant 
autophosphorylation was investigated. TRPM6 autophosphorylation activity was strongly dependent 
on the Mg2+ concentration and steadily increased in the physiological range of 0.1—1.0 mM Mg2+ (Fig. 
8F). In contrast, the autophosphorylation activity of the T1851A mutant was not affected by the Mg2+ 
concentration (Fig. 8G). Both TRPM6 and T1851A mutant channel activities were significantly 
inhibited by Mg2+ in the patch-pipette. However, the T1851A mutant channel was less sensitive to the 
intracellular Mg2+ concentration compared to wild-type TRPM6 (IC50 0.72 ± 0.07 mM versus IC50
0.51 ± 0.06 mM, respectively) (Fig. 8H). Figure 8I showed that knockdown of endogenous RACK1 
by siRNA significantly reduces the Mg2+-dependent inhibition of the TRPM6 current. Together, these 
data suggest that the T1851 phosphorylation-dependent inhibitory effect of RACK1 may play an 
important role in the suppression of the TRPM6 current by intracellular free Mg2+.
Coexpression o f  RACK1 does not affect expression o f  TRPM6 at the plasma membrane
The influence of RACK1 on the amount of TRPM6 channels expressed at the plasma membrane 
was investigated by cell surface biotinylation experiments. As shown in Figure 10 (upper panel), 
coexpression of RACK1 did not affect the amount of TRPM6 channels expressed at the plasma 
membrane. Of note, TRPM6 was equally expressed in all tested conditions, as determined in the total 
cell lysates (Fig. 10, bottom panel).
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Next, the effect of PKC activation by phorbol 12-myristate 13-acetate-PMA (PMA) [21] on the 
regulatory effect of RACK1 was studied. PKC activation by preincubation with 100 nM PMA for 5 
min prevented the inhibitory effect of RACK1 on the TRPM6 current (Fig. 11B and Fig. 12C and 
12D). The current amplitude in the presence of PMA was, however, not modified in cells expressing 
TRPM6 only (Fig. 11A and Fig. 12A and 12B).
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Figure 8. Mapping and function of the auto-phosphorylation site in TRPM6 a-kinase domain. A. Analysis of 
phosphorylated tryptic peptide by LTQ-FT ICR mass spectrometer. For detailed information see materials and 
methods. B. Auto-phosphorylated threonine at position 1851 in the putative 3-D structure of the TRPM6 a- 
kinase domain, in which the RACK1 binding site is highlighted. C. In vitro protein kinase assay (32P, top panel)
1851 1851and immunoblotting analysis (IB, bottom panel) of TRPM6, T1851A and T1851D mutants. D, E. Averaged values 
of the current density at +80 and -80 mV of T1851A with (n=23; P = 1.000 compared to T1851A) or without 
RACK1 (n=25) (D) and T1851D with (n=27; P = 0.001 compared to T1851D) or without RACK1 (n=23) (E). 
Open and closed bars correspond to cells transfected with mock DNA and TRPM6 mutants, respectively, in the 
absence or presence of RACK1. F,G. In vitro phosphorylation of TRPM6 (F) and TRPM6 T1851A (G) at 
different Mg2+ concentrations (32P, top panels). Autoradiograms were exposed 4 days for TRPM6 and 8 days for 
TRPM6 T1851A. TRPM6 and TRPM6 T1851A expression was determined by immunoblotting (IB, bottom 
panels). The phosphorylated proteins were quantified and plotted against 0.1 mM [Mg2+] (n=3 for each; P 0 2 mM 
[Mg2+] = 0 120' P °'5 mM [Mg2+] = 0 042' P 1,0 mM [Mg2+] = 0 049 for TRPM6 and P °'2 mM [Mg2+] = 0 442' P °'5 mM [Mg2+] = 
0.370; P 10 mM [Mg2+] = 0.973 for TRPM6 T1851A). H. Effect of the pipette Mg2+ concentration on the inhibition of 
the inward Na+ current at -80 mV of TRPM6 (• , n=8-11) and the T1851A transfected HEK293 cells (o, n=9-13). 
* indicates P < 0.05, compared to TRPM6 current in 0 mM [Mg2+]. I. Effect of the pipette Mg2+ concentration 
on the inhibition of the inward Na+ current at -80 mV of TRPM6 (n=10) and TRPM6 and siRNA-RACK1(1) 
(0.5 ^g, n=10, P = 0.03) transfected HEK293 cells.
To confirm the specificity of PMA, HEK293 cells coexpressing TRPM6 and RACK1 were 
incubated with 5 ¡aM chelerythrine chloride, a specific PKC inhibitor [22], for 20 min prior to PMA
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treatment. As shown in Figure 11B and Figures 12C and 12D, the stimulatory action of PMA was 
counteracted by chelerythrine chloride, suggesting that the PMA effect is indeed due to PKC 
activation. To further elucidate the PKC effect, the TRPM6 C-tail was coexpressed with RACK1 in 
HEK293 cells, subjected to PKC activation by PMA or vehicle, and subsequently precipitated using 
glutathione Sepharose 4B beads. The interaction of RACK1 with the TRPM6 C-tail was significantly 
reduced when PKC was activated (Fig. 11C, upper panel). Importantly, RACK1 was equally 
expressed in all situations (Fig. 11C, lower panel).
Figure 9. A. Densitometry 
quantification (right panel) of 
TRPM6, T1851A and T1851D 
expression. * indicates p T1851A 
= 0.001 and p T1851D = 0.002 
compared to wild-type 
TRPM6, n=3 samples). B. 
GST-pull down binding assay 
between RACK1 protein and 
GST or GST-fused to the 
kinase domain of TRPM6, 
T1851A and T1851D mutants (top 
panel). Coomassie staining of 
the corresponding gel (bottom 
panel). C. Current recorded 
after stimulation by a voltage 
ramp between -100  and 
+100 mV of T1851A (1), and 
T1851A and RACK1 (0.5 ^g, 2) 
transfected HEK293 cells. D. 
Time course of the current 
density at +80 mV of T1851A
(A), and T1851A and RACK1 
(0.5 |ig, A) transfected 
HEK293 cells. E. Current 
recorded after stimulation by a 
voltage ramp between -100 
and +100 mV of t 1851D (1), 
and T1851D and RACK1 (0.5 
fig, 2) transfected HEK293 
cells. F. Time course of the 
current density at +80 mV of 
T1851D (open ▼), and T1851D 
and RACK1 (0.5 ^g, ▼) 
transfected HEK293 cells.
Discussion
In the present study, we identified RACK1 as the first TRPM6-associated protein and 
demonstrated that RACK1 inhibits TRPM6 channel activity depending on the phosphorylation state 
T1851 in the a-kinase domain. First, RACK1 binds to the TRPM6 a-kinase domain and shares a similar 
expression pattern with TRPM6 in the kidney. Second, overexpression of RACK1 inhibits TRPM6
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activity, and conversely, silencing of RACK1 by siRNA increases the TRPM6 current. Third, the
RACK1-mediated inhibition of TRPM6 is prevented by deletion of the a-kinase domain. Fourth,
inactivation of the a-kinase abrogates the inhibitory effect of RACK1. Fifth, T1851 is identified as an
important autophosphorylation site in TRPM6-modulating channel activity by RACK1. Sixth, T1851 
2+was crucial for the Mg sensitivity of TRPM6 autophosphorylation and channel activity. Finally, 
knockdown of endogenous RACK1 by siRNA significantly reduces the Mg2+-dependent inhibition of 
the TRPM6 current.
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Figure 10. Co-expression of RACK1 does not affect the 
plasma membrane expression of TRPM6. TRPM6 and 
RACK1 transfected HEK293 cells were subjected to cell 
surface biotinylation analysis. TRPM6 expression was 
analyzed by immunoblotting for the plasma membrane 
fraction (top panel) and in total cell lysates (bottom 
panel). As negative control, mock cells were used.
Total cell lysates
2+ 2+TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ (re)absorption and is
so far the only known molecular identity in the process of active transepithelial Mg2+ transport.
However, TRPM6 regulation remains poorly understood. In this respect, the identification of RACK1
as a TRPM6 regulator provides the first molecular insight into the control o f renal Mg2+ entry and,
therefore, into the maintenance of Mg2+ balance. The interaction between RACK1 and TRPM6 was
confirmed by GST pull-down assay and coimmunoprecipitation. Unfortunately, similar studies
investigating an interaction between endogenous TRPM6 and RACK1 in kidney DCT cells were
unsuccessful, possibly due to the low protein abundance of the channel. In addition, we demonstrated
that endogenously expressed RACK1 in HEK293 cells interacts with the TRPM6 a-kinase domain. At
the molecular level, our results suggest that RACK1 specifically binds to the 6th, 7th, and 8th p sheets
of the a-kinase domain. Eighteen amino acids o f the RACK1 binding site are located on the peripheral
region of the tertiary structure o f the TRPM6 a-kinase domain, which may facilitate the association
between RACK1 and TRPM6. Importantly, we showed that RACK1 is abundantly present in
TRPM6-expressing tubules, which further suggests the physiological relevance of the interaction
between these proteins in the kidney.
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Figure 11. Inhibitory effect of RACK1 is PKC-dependent. A. Effect of PKC activation by PMA (100 nM, 5 
minutes pre-treatment) on the current density at +80 and -80 mV of mock TRPM6 (n=14) and TRPM6 (n=22). 
Open bars correspond to cells transfected with mock DNA whereas closed bars to cells transfected with 
TRPM6 . B. Effect of PKC activation by PMA and PKC inhibition by chelerythrine chloride (CC, 5 ^M, 20 
minutes pre-treatment prior to PMA treatment) on the current density at +80 and -80 mV of TRPM6 and 
RACK1 (0.5 |ig, n=7-12) transfected HEK293 cells. * indicates P = 0.01 compared to TRPM6 and RACK1 
without pre-treatment and # indicates P = 0.02 compared to TRPM6 and RACK1 pretreated with PMA. C. 
Effect of PKC activation on RACK1 binding. After PMA or vehicle pre-incubation, RACK1 was co­
precipitated with GST-fused C-tail, separated by SDS/PAGE and visualized using the anti-RACK1 antibody 
(top panel). Immunoblotting (bottom panel) and densitometry quantification (right panel) of TRPM6-C-tail and 
RACK1 binding. * indicates P = 0.001 compared to TRPM6-C-tail.
RACK1, a member of the WD-40 family of proteins, is regarded as a scaffolding protein in 
multiple intracellular signal transduction pathways, including ion channel proteins such as the IP3 
receptor, NMDA receptor, and GABAA receptor channels [23-25]. RACK1-mediated decline of the 
TRPM6 current was dose-dependent, and depletion of endogenously expressed RACK1 in HEK293 
cells resulted in increased TRPM6 currents. The inhibitory effect of RACK1 requires the a-kinase 
domain with functional phosphotransferase activity. This was supported by the analysis of the 
TRPM6 A-kinase and the phosphotransferase-deficient (K1804R) mutants, which were both insensitive 
to RACK1. While the autophosphorylation activity of the a-kinase domain has been well documented 
[10-13], the regulatory role of this catalytic domain on channel activity remains elusive. Previously, it 
has been demonstrated that the balance between phosphorylation and dephosphorylation operates as a 
key mechanism to regulate ion channel activity [26, 27]. However, the phosphotransferase-deficient 
K1804R mutant displayed currents indistinguishable from wild-type TRPM6. Interestingly, the mutants
1851 1851T A and T D displayed currents similar to the wild-type channel but exhibited a significant albeit 
reduced autophosphorylation, while the autophosphorylation of mutant K1804R was fully abolished. 
These data suggest that, besides T1851, additional autophosphorylation sites are present in TRPM6. 
Our findings support the conclusion that TRPM6 a-kinase autophosphorylation events are not vital for 
TRPM6 channel activation. Consistently, previous studies showed that TRPM7 phosphotransferase 
activity is not essential for channel activation [11, 12]. In contrast, the inhibitory action of RACK1
50
RACK1 inhibits TRPM6 through its a-kinase domain
requires functional phosphotransferase activity. This notion is supported by the fact that the current of 
the phosphorylation-impaired mutants (K1804R and T1851A) is insensitive to RACK1. Furthermore, the 
constitutive phosphorylated mutant T1851D was still inhibited by RACK1. Based on these 
observations, an increased channel activity for the phosphorylation-impaired mutants (K1804R and 
T1851A) and the TRPM6 A-kinase mutant was expected. However, functional analysis of these 
mutated channel proteins did not indicate elevated channel activity. It has been demonstrated that the 
a-kinase domain can regulate TRPM7 channel activity via other signaling pathways besides RACK1. 
For instance, previous studies [13-15] indicated that the TRPM7 activity controlled by intracellular 
Mg2+, nucleotides, and the cAMP/protein kinase A pathway requires the a-kinase domain or kinase 
activity. Therefore, it is conceivable that removing the a-kinase domain or suppressing its 
phosphotransferase activity may abolish associated regulation(s) of TRPM6 channel activity. This 
could compensate a potential upregulation of TRPM6 activity caused by removal of the inhibitory 
RACK1 action. In reminiscence o f the adjacent location of the autophosphorylation site in the a- 
kinase and the RACK1 binding site, we hypothesize that the phosphorylation state of T1851 plays a key 
role in controlling channel activity via RACK1.
Together, our results convincingly demonstrate a novel indirect model of regulation in which 
RACK1 functions as a mediator linking autophosphorylation of the a-kinase domain to channel 
activity. In this way, TRPM6 channel activity is controlled efficiently to manage constitutively active 
epithelial Mg2+ channels. Furthermore, cell-surface biotinylation experiments demonstrated that 
coexpression of RACK1 does not affect the amount of TRPM6 channels expressed at the plasma 
membrane. These data suggest that the inhibitory effect of RACK1 on TRPM6 is likely due to 
channel gating. Association of RACK1 and TRPM6 seems a dynamic process that can be abolished 
by PKC activation, thereby preventing the inhibitory effect of RACK1. An increased TRPM6 current 
upon PMA treatment in TRPM6-overexpressed HEK293 cells was anticipated, since PKC activation 
prevents the RACK1 inhibitory effect in TRPM6 and RACK 1-overexpressing HEK293 cells. 
However, this inhibitory effect was not observed, which might be due to the fact that the amount of 
endogenous RACK1 is insufficient to inhibit the overexpressed TRPM6.
TRPM6 and TRPM7 confine a Mg2+-permeable channel of which the activity is strongly 
regulated by [Mg2+]i [2, 9, 11, 14, 28]. Channel inactivation by elevated [Mg2+]i may function as 
negative-feedback machinery to balance the Mg2+ homeostasis. Matsushita and coworkers postulated 
that regulation of TRPM7 channel activity by [Mg2+]i is disassociated from its a-kinase activity [11], 
whereas other studies suggested the involvement of the a-kinase domain [13, 14]. In our study, the 
T1851A mutant is less sensitive to [Mg2+]i, which is in agreement with previous studies showing that 
TRPM7 phosphotransferase activity influences the Mg2+-dependent inhibition of channel activity [13, 
14].
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Figure 12. A. Current recorded 
after stimulation by a voltage 
ramp between -100  and 
+100 mV of TRPM6 transfected 
HEK293 cells in non-treated 
conditions (1) or pre-treated 
with PMA (2). B. Time course 
of the current density at +80 mV 
of TRPM6 transfected HEK293 
cells in none-treated conditions
(0) or pre-treated with PMA (•). 
C. Current recorded after 
stimulation by a voltage ramp 
between -100 and +100 mV of 
TRPM6 transfected HEK293 
cells in non-treated conditions
(1), pre-treated with PMA alone
(2) or with chelerythrine 
chloride (CC) and PMA (3). D. 
Time course of the current 
density at +80 mV of TRPM6 
transfected HEK293 cells in 
none-treated conditions (o) and 
pre-treated with PMA alone (•) 
or with CC and PMA (♦).
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This shift in Mg2+ sensitivity could have significant impact on TRPM6 activity during
2+ 2+ 1851transepithelial Mg transport because the channel is tightly controlled by [Mg ] i  [2]. The T A 
mutant is still inhibited by high [Mg2+]b suggesting that additional Mg2+-sensing site(s) are present 
within TRPM6. Our data indicated that wild-type TRPM6 autophosphorylation activity is gradually 
enhanced by increasing the Mg2+ concentration, in contrast to autophosphorylation of the T1851A
2+ 1851 2+mutant for which the Mg2+ sensitivity is abolished. Thus, residue T1851 seems crucial in the Mg2+ 
sensitivity of TRPM6 autophosphorylation. In line with our study, Minagawa and coworkers 
demonstrated that the Mg2+ sensitivity o f PhoQ phosphorylation, vital for Escherichia coli Mg2+
homeostasis, relies on a single residue, D179 [29]. Over the last decade, the idea was that the free
2+  2+ [Mg ] i  is more or less constant. However, more recent studies provided evidence that the free [Mg ] i
concentration varies significantly [30, 31]. Enzymes like adenylate kinases and TRPM7 kinase are
dependent on the [Mg2+] [13, 32, 33]. Moreover, we showed that siRNA-mediated downregulation of
endogenous RACK1 significantly reduced the inhibition of the TRPM6 current by Mg2+. These
findings suggest that RACK1 is involved in the Mg2+ sensitivity of TRPM6 channel activity.
Together, we suggest that TRPM6-mediated Mg2+ influx induces phosphorylation of T1851 located
1851in the a-kinase domain. Subsequently, the phosphorylation of T will activate the inhibitory effect 
of RACK1. This latter step may act as an intracellular feedback regulation to control TRPM6- 
mediated Mg2+ influx and avoid Mg2+ overload during renal epithelial Mg2+ transport. Our data
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contribute to a further understanding of molecular mechanisms involved in renal Mg2+ handling and 
to the a-kinase-dependent regulation of TRPM6 channel activity.
Material and methods
DNA Constructs and cRNA Synthesis- The C-tail of human TRPM6 (1075-2022) was cloned in 
the pAS-1 yeast expression vector. The kinase domain of mouse TRPM6 (1759-2028) and human 
(1750-2022) was cloned into pGEX6p-2 (Amersham Pharmacia Biotech, Uppsala, Sweden) by PCR 
using mouse kidney cDNA or human TRPM6 in pCINeo/IRES-GFP [2] as template. The C terminus 
(1075- 2022) and the a-kinase domain (1750-2022) of human TRPM6 were subcloned into the pEBG 
vector [34]. TRPM6-C-tail-A-kinase (1075-1749) was subcloned from TRPM6 D-kinase- 
pCINeo/IRES-GFP construct into the pEBG vector by PCR. Full-length mouse RACK1 cDNA was 
subcloned into pT7Ts, pCB7, and pGEX6p-2 from RACK1-pACT2. Wild-type TRPM6 in the 
pCINeo/IRES-GFP vector was HA-tagged at the N-terminal tail as described previously [2]. TRPM6 
A-kinase (L1749X), TRPM6 phosphotransferase-deficient (K1804R), TRPM6-autophosphorylation 
(T1851A and T1851D), and GST-a-kinase truncant (TRPM6 1759-1993, 1759-1885, 1759-1857, 1857­
1885, and 1759-1813) mutants were created using the QuickChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s protocol. GFP-fused-TRPM6 in 
pCINeo vector was constructed by site-directed mutagenesis and PCR based on the TRPM6 cDNA in 
pCINeo/IRES-GFP. Human RACK1 siRNA plasmids were constructed as described previously [35]. 
The target sequences of siRNA are positioned at bp 195-215 (human RACK1 sequence accession 
number NM_006098). pSUPER-luciferase construct was used as a control as described previously 
[36]. All constructs were verified by sequence analysis. Chemically synthesized double-stranded 
RACK1 siRNA was purchased from Santa Cruz Biotechnology (Delaware, CA, USA). RACK1 
cRNA was synthesized in vitro using T7 RNA polymerase as described previously [37].
GST-Fusion Proteins and Pull-Down Assay- TRPM6 a-kinase GST fusion protein was purified as 
previously described [38]. RACK1 protein was labeled with [35S]-methionine using a reticulocyte 
lysate system (Promega, Madison, WI, USA) and added to purified GSTfusion proteins, immobilized 
on glutathione Sepharose 4B beads. After 2 hr of incubation at room temperature (RT), beads were 
washed extensively with pull-down buffer (10 mM Tris pH 7.4-HCl), 150 mM NaCl, 0.2% (v/v) 
Triton X-100). The bound proteins were eluted with SDS-PAGE loading buffer, separated on SDS- 
polyacrylamide gel, and visualized by autoradiography.
Sequence Analysis and Structure Modeling- The structural model of TRPM6 a-kinase domain 
was built based on the crystal structure of TRPM7 a-kinase domain [17] [Protein DataBank ID codes: 
1IAJ (apo), 1IAH (ADP complex), and 1IA9 (AMP^PNP complex)] using SWISS-MODEL
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(http://swissmodelexpasy.org//SWISS-MODEL.html) and analyzed by DeepView Swiss-PdbViewer 
(Version 3.7; http://swissmodel.expasy.org/spdbv/) and Yasara (http://www.yasara.org).
Mapping o f  Autophosphorylation in the a-kinase Domain by Nano Liquid Chromatography 
Tandem Mass Spectrometry- Proteins were treated with dithiothreitol (DTT) and iodoacetamide and 
digested in-gel by trypsin as previously described [39]. Peptide identification experiments by liquid 
chromatography tandem mass spectrometry were performed using a nano-HPLC Agillent 1100 
nanoflow system connected on-line to a 7 Tesla linear quadrupole ion trap-Fourier transform ion 
cyclotron resonance (LTQ-FT) mass spectrometer (Thermo Electron, Bremen, Germany) as 
previously described [39]. Peptides and proteins were identified using the Mascot 2.1 (Matrix 
Science, Boston, MA, USA) algorithm to search a local version of the Uniprot database and an 
inhouse-created database containing the GST-TRPM6 kinase sequence. First-ranked peptides were 
parsed from Mascot database search html files with MSQuant to generate unique first-ranked peptide 
lists and internal calibration of measured ion masses. Assignment o f phosphorylated peptides and 
modification sites were verified manually. The parent ion mass was determined with a mass accuracy 
of 0.39 ppm and sequenced using CID fragmentation. The assignment of the fragmentation spectrum, 
mostly as a doubly charged Y ion series, is depicted. The Mascot search engine identified the 
phosphorylated peptide with a score of 48.
Electrophysiology- Electrophysiological recordings with standard pipette and extracellular 
solutions were performed as already described [40]. The pipette solutions used for the intracellular 
Mg2+ experiments contained 150 mM NaCl, 10 mM HEPES, pH 7.2-NaOH, 0.1 mM EGTA, and
0.25, 0.5, 0.6, 0.7, 0.8, 1.2, or 1.5 mM MgCl2 as indicated. The extracellular solutions contained (in 
mM) 150 NaCl and 10 HEPES (titrated to pH 7.4 with NaOH), supplemented or not with 1 mM 
CaCl2 . The standard pipette solution contained (in mM) 150 NaCl, 10 Na-EDTA, and 10 HEPES 
(titrated to pH 7.2 with NaOH). In all figures, except Figures 5H and 5I, the extracellular solution was 
supplemented with 1 mM CaCl2 . In Figures 5H and 5I, the recordings were conducted in divalent-free 
solution (150 mM NaCl and 10 mM HEPES) to observe the effect of Mg2+ in the patch pipette on the 
inward current. Transfected cells were identified by their green appearance, and GFP-negative cells 
from the same batch of cells were used as controls. The current density values presented in the 
histograms correspond to the current density after full development of the current, i.e., 200 s. In 
Figure 2D, only mock and TRPM6-transfected HEK293 cells that developed the MIC current (about 
40%) were included.
Coimmunoprecipitation- HEK293 cells transfected with RACK1 and pEBG-TRPM6 kinase or 
pEBGTRPM6-C-tail or pEBG-TRPM6-C-tail-A-kinase were lysed for 1 hr on ice in lysis buffer [150 
mM NaCl, 5 mM EDTA, 50 mM Tris pH 7.5-NaOH, 10 mM NaF, 0.5 mM Na3VO4 , 2.5 mM
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Na4P2O7 , 0.5% (v/v) Triton including the protease inhibitors leupeptin (0.01 mg/ml), pepstatin (0.05 
mg/ml), and phenylmethylsulfonyl fluoride (1 mM)]. The supernatants of the lysates were incubated 
overnight with glutathione Sepharose 4B beads at 4°C for coprecipitations. In the 
coimmunoprecipitation experiments, HEK293 cells transfected with RACK1 and GFP-TRPM6, GFP- 
TRPM6 D-kinase, or mock were lysed as indicated above. The anti-RACK1 antibody (IgM) was 
labeled with biotin and precipitated by neutravidin-agarose beads (Pierce) and subsequently incubated 
overnight with the supernatants of the lysates. After extensive washing, the bound proteins were 
eluted with SDS-PAGE loading buffer. The coprecipitation was analyzed using the anti-RACK1 
antibody or anti-GFP (Transduction Laboratories, Lexington, KY, USA).
Immunoblotting- Protein samples were denatured by incubation for 30 min at 37°C in Laemmli 
buffer and then subjected to SDS-PAGE. Immunoblots were incubated with either mouse anti-HA 
(Sigma), anti-RACK1, anti-GFP (Transduction Laboratories), or anti-^-actin (Sigma) antibodies. 
Subsequently, blots were incubated with sheep horseradish peroxidase-conjugated anti-mouse IgG 
(Sigma) or anti-rabbit IgG (Sigma) and then visualized using enhanced chemiluminescence system.
Immunohistochemistry- Immunohistochemistry was performed as described previously [41]. 
Briefly, rat kidney sections were incubated for 16 hr at 4°C with rabbit anti-thiazide-sensitive Na+/Cl- 
cotransporter (NCC), mouse anti-RACK1, and guinea pig anti-TRPM6 [2]. To visualize RACK1, 
tyramide signal amplification kit (NEN Life Science Products, Zaventem, Belgium) was used after 
incubation with biotin-coated goat anti-mouse secondary antibody. Images were taken with a Bio-Rad 
MRC 100 confocal laser scanning microscope.
Cell-Surface Labeling with Biotin- HEK293 cells were transiently cotransfected with 12 ^g HA- 
TRPM6 and 3 ^g RACK1 or PCB7, in poly-L-lysine (Sigma) coated 10 cm dishes. Cell- 
surfacelabeling with biotin was performed as described previously [20]. At 72 hr after transfection, 
the biotinylation assay was performed. Cells were homogenized in 1 ml lysis buffer as described 
previously [20], using the NHS-LC-LC-biotin (Pierce, Etten-Leur, The Netherlands). Finally, 
biotinylated proteins were precipitated using neutravidin-agarose beads (Pierce). TRPM6 expression 
was analyzed by immunoblot for the precipitates (plasma membrane fraction) and for the total cell 
lysates using the anti-HA antibody.
In Vitro Phosphorylation and Phosphatase Assays- HA-TRPM6 was precipitated by using the 
anti-HA antibody. The precipitates were incubated in a total volume of 30 ml kinase reaction buffer A 
(50 mM HEPES pH 7.4-KOH, 4 mM MnCl2, 0.5 mM CaCl2, 100 ^M ATP) or kinase reaction buffer 
B (50 mM HEPES pH 7.4-KOH, 1 mM MnCh, 0.5 mM CaCh, 100 ^M ATP containing different
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MgCl2 concentrations) and 2 ^Ci of [y32P]ATP for 30 min at 30°C. For in vitro phosphatase assay, 15 
units alkaline phosphatase (Roche, Mannheim, Germany) was added to TRPM6 immunoprecipitates 
before in vitro phosphorylation assays. The reaction was terminated by three washing steps with 
phosphorylation washing buffer (50 mM HEPES pH 7.4-KOH, 4 mM MnCl2, 0.5 mM CaCl2). 
Phosphorylation was analyzed after gel electrophoresis by autoradiography.
Statistical Analysis- Values are expressed as mean ± SE. Statistical significance between groups 
was determined by analysis of variance (ANOVA) followed by pair-wise comparison using the 
method of Scheffe' for patch-clamp recordings and unpaired Student’s t test for immunoblot and 
phosphorylation quantifications. Differences in means with p < 0.05 were considered statistically 
significant. The statistical analysis was performed using the SPSS software (SPSS Inc, Chicago, 
Illinois, USA).
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TRPM6 regulation by REA and estrogen
The maintenance of the body's Mg2+ balance is essential for neuromuscular excitability, protein 
synthesis, nucleic acid stability and numerous enzymatic systems. The Transient Receptor Potential 
Melastatin 6 (TRPM6) functions as the gatekeeper o f transepithelial Mg2+ transport. However, the 
molecular regulation of TRPM6 channel activity remains elusive. Here, we identified the Repressor of 
Estrogen receptor Activity (REA) as an interacting protein of TRPM6 that binds to the 6th, 7th and 8th 
P-sheets in its a-kinase domain. Importantly, REA and TRPM6 are coexpressed in renal Mg2+- 
transporting distal convoluted tubules (DCT). We demonstrated that REA significantly inhibits 
TRPM6, but not its closest homologue TRPM7, channel activity. This inhibition occurs in a 
phosphorylation-dependent manner, since REA has no effect on the TRPM6 phosphotransferase- 
deficient mutant (K1804R), while it still binds to this mutant. Moreover, activation of protein kinase C 
by phorbol 12-myristate 13-acetate-PMA potentiated the inhibitory effect of REA on TRPM6 channel 
activity. Finally, we showed that the interaction between REA and TRPM6 is a dynamic process, as 
short-term 17p-estradiol treatment disassociates the binding between these proteins. In agreement 
with this, 17P-estradiol treatment significantly stimulates the TRPM6-mediated current in HEK293 
cells. These results suggest a rapid pathway for the effect of estrogen on Mg2+ homeostasis in addition 
to its transcriptional effect. Together, these data indicate that REA operates as a negative feedback 
modulator of TRPM6 in the regulation of active Mg2+ (re)absorption and provides new insight into the 
molecular mechanism of renal transepithelial Mg2+ transport.
Introduction
Mg2+ is a central electrolyte important for many biological functions by its intervention in gene 
transcription, protein synthesis, nucleic acid stability, channel regulation, cell cycle and numerous 
enzymatic systems [1-4]. In most species, serum Mg2+ levels are kept within a narrow range between
0.8—1.1 mM, while the free intracellular Mg2+ concentration [Mg2+]i has been estimated around 0.5­
1.0 mM [5]. Regulation of the Mg2+ balance principally resides within the kidney where Mg2+ 
excretion tightly matches the intestinal absorption of Mg2+ [5]. The majority of Mg2+ in the renal 
ultrafiltrate is reabsorbed passively in the proximal tubule and the thick ascending limb of the loop of 
Henle, while the final Mg2+ excretion is determined in the distal convoluted tubule (DCT) via an 
active reabsorption process [5].
The Transient Receptor Potential Melastatin 6 (TRPM6) localizes along the apical membranes of 
DCT and intestinal cells where it plays a crucial role in active Mg2+ (re)absorption. Mutations in 
TRPM6 lead to hypomagnesemia with secondary hypocalcemia (HSH) indicating that this channel is 
important for the maintenance of the Mg2+ balance [6-8]. Previous studies demonstrated that 
expression of TRPM6 is regulated by dietary Mg2+ and its channel activity is strongly inhibited by the 
intracellular Mg2+ concentration ([Mg2+]i) [8, 9]. Generally, Mg2+-free solutions are used to measure
Summary
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the characteristic outwardly rectifying TRPM6 currents [8, 10, 11]. Remarkably, TRPM6 contains a 
carboxyl-terminal a-kinase domain, of which the regulatory role on channel activity remains elusive 
[12-14]. It has been shown that RACK1 can interact with this domain and inhibit channel activity in a 
phosphorylation-dependent manner [15]. A recent study demonstrated that the ATP binding motif in 
the a-kinase domain is required for modulation of TRPM6 channel activity by intracellular ATP [16]. 
Previous studies suggested that Mg2+ uptake in DCT is stimulated by hormones, such as parathyroid 
hormone, calcitonin, arginine vasopressin, insulin and prostaglandins [17]. A recent study reported 
that Epidermal Growth Factor (EGF) acts as an autocrine/paracrine magnesiotropic hormone via 
stimulating its receptor on the basolateral membrane of DCT cells, thereby specifically increasing 
TRPM6 current [18]. Further, Groenestege et al. demonstrated that the renal TRPM6 mRNA level in 
ovariectomized rats was significantly reduced, whereas 17p-estradiol treatment normalized TRPM6 
mRNA levels [9]. Next to this classical transcriptional pathway, accumulating evidence suggests also 
rapid estrogen effects that occur within minutes via a non-transcriptional route [19-22]. Estrogen has 
the ability to facilitate rapid membrane-initiated signaling cascades through activation of plasma 
membrane-associated receptors, such as the recently discovered G protein-coupled receptor 30 
(GPCR30) [23]. In addition, it has been demonstrated that the classical estrogen receptor alpha (ERa) 
can be localized to the plasma membrane in response to estrogen or by interaction with adaptor 
proteins like Shc and p130Cas [24, 25].
The aim of the present study was to investigate the regulation of the a-kinase domain on TRPM6 
channel activity by identification of proteins specifically interacting with the a-kinase domain. Using 
a combined approach including biochemical, immunohistochemical, mass spectrometrical and 
electrophysiological analyses, we demonstrated a novel operation mode for rapid estrogen regulation 
on TRPM6 channel activity via attenuating the inhibitory effect of the TRPM6 associated protein, 
Repressor of Estrogen receptor Activity (REA).
Results
REA associates with TRPM6
To identify proteins potentially interacting with the TRPM6 a-kinase domain, the combination of 
a GST-pull down with the a-kinase domain of TRPM6 in mouse kidney lysate, followed by Fourier 
Transform Mass Spectrometry (FTMS), was performed. REA, the Repressor o f Estrogen receptor 
Activity [26], was identified as an interacting protein of the TRPM6 a-kinase domain. Next, GST-pull 
down binding assays were used to confirm the interaction between REA and TRPM6 a-kinase 
domain. [35S]-methionine-labeled REA protein was incubated with GST and GST-a-kinase 
immobilized on glutathione-sepharose 4B beads. REA interacted specifically with the GST-a-kinase, 
but not with GST alone (Fig. 1A). Next, the association between TRPM6 and REA was further 
substantiated in mammalian cells by co-precipitation studies of GST and GST-a-kinase in REA-
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expressing HEK293 cells. REA co-precipitated with the GST-a-kinase, but not with GST alone (Fig.
1B).
I
37 25 kD
Figure 1. REA interacts with the a-kinase domain in TRPM6. A. GST-pull down assay between [35S]- 
methionine-labeled REA protein and GST or GST fused to the a-kinase domain. B. Co-precipitation studies of 
GST and GST-a-kinase in REA-expressing HEK293 cells (top panel). REA input (1%) expression was 
analyzed by immunoblotting (bottom panel). C. Mapping of the REA binding site within the a-kinase domain. 
Predicted 3D structure model of the a-kinase domain with different truncations of the a-kinase. D. Coomassie 
staining of the SDS-PAGE gel. E. Co-precipitation studies of GST and GST-a-kinase in REA-expressing 
HEK293 cells in the presence of different amounts of RACK1 (dilution 1:10 (0.1), 1:2 (0.5), and non-diluted 
(1.0)) (top panel). REA and RACK1 input (1%) expression was analyzed by immunoblotting (bottom panels).
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Figure 2. Tissue distribution and localization of REA. A. Distribution of REA (top panel) mRNA expression 
analyzed by RT-PCR on various tissues. p-actin was used as a positive control (bottom panel). B. 
Immunohistochemical analysis of REA (left panel) and TRPM6 (right panel) in mouse kidney serial sections. * 
indicates overlapping immunopositive tubules for TRPM6 and REA.
REA binds to the 6th, 7th and 8th P-sheets in the TRPM6 a-kinase domain
To determine the REA binding site within TRPM6, a series of deletion mutants in the a-kinase 
domain was constructed. Truncated TRPM6 a-kinase mutants were expressed as GST-fused proteins 
and evaluated for their interaction with [35S]-methionine-labeled REA protein (Fig. 1C). Truncation at 
position 1857 abolished the interaction between the two proteins, whereas truncation at position 1885 
had no effect on the interaction with REA. Moreover, a GST-fusion protein containing only the short 
peptide between the amino acids 1857 and 1885 of the TRPM6 a-kinase domain bound to REA (Fig.
1C). Therefore, the REA binding site within TRPM6 is restricted to the region between the positions 
1857 and 1885. The integrity and quantity of the GST-fusion proteins was analyzed and confirmed by 
Coomassie staining of SDS-PAGE gel (Fig. 1D). The lower abundant product bands of different sizes 
might be due to binding of so far unknown proteins to the bigger truncation mutants or degradation 
products. To explore the REA binding site in the TRPM6 a-kinase domain, the tertiary structure of 
this domain was modeled by SWISS-MODEL (http://swissmodel.expasy.org//SWISS-MODEL.html) 
(Fig. 1D) based on the homology between TRPM6 and TRPM7 a-kinase domains [15, 27]. Due to the 
significant homology between the TRPM6 and TRPM7 a-kinase domains (84%), these two domains 
share a well-conserved secondary structure. The surface and accessibility analysis of the REA binding
66
TRPM6 regulation by REA and estrogen
site (6th, 7th and 8th P-sheets) using Yasara software (http://www.yasara.org) suggested that, among the 
28 amino acids of the REA binding site, 18 are localized at the surface of the TRPM6 a-kinase 
domain (see http://www.cmbi.ru.nl/~hvensela/trpm6/). Since RACK1 also binds to this region, we 
investigated whether RACK1 can affect the interaction between TRPM6 and REA. As shown in Fig 
1E, REA co-precipitated in similar amounts with GST-a-kinase in the presence and absence of 
RACK1.
REA co-expresses with TRPM6 in kidney
To address the tissue distribution o f REA, reverse transcriptase polymerase chain reaction (RT- 
PCR) analysis was performed on mouse tissues. The expected DNA fragment of 916 bp for REA was 
detected in most tested tissues as indicated in Fig. 2A. The P-actin fragment was present in all the 
tissues evaluated. Of note, REA is present in kidney where TRPM6 is predominantly expressed [8]. 
To further study the co-expression between REA and TRPM6 in kidney, immunohistochemistry was 
performed on serial kidney sections. This analysis indicated immunopositive staining for REA in the 
TRPM6-expressing DCT cells that have been implicated in active Mg2+ reabsorption [8] (Fig. 2B).
Figure 3. Functional effect of REA on TRPM6 activity. A. Time course of the current density (pA/pF) at +80 
mV of TRPM6 and mock (■), and TRPM6 and REA (• )  transfected HEK293 cells. B. Averaged values of the 
current density at +80 mV after 200 s of TRPM6 and mock (n = 17), and TRPM6 and REA (n = 17). * indicates 
P < 0.05 compared to TRPM6 and mock. C. Time course of the current density (pA/pF) at +80 mV of TRPM7 
and mock (□), and TRPM7 and REA (o) transfected HEK293 cells. D. Averaged values of the current density at 
+80 mV after 200 s of TRPM7 and mock (n = 18), and TRPM7 and REA (n = 17).
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Figure 4. REA inhibits TRPM6 channel activity in a rapid and phosphorylation-dependent manner. A. 
Coomassie staining of purified GST and GST-REA. B. Current-voltage (I/V) relation of TRPM6 transfected 
cells infused with GST (solid trace) or GST-REA (dashed trace). C. Averaged values of the current density at 
+100 mV after 600 s of GST infused (n = 16) and GST-REA infused (n = 18) cells. * indicates P < 0.05 D. 
Current-voltage (I/V) relations of TRPM6 K1804R transfected cells infused with GST (solid trace) or GST-REA 
(dashed trace). E. Averaged values of the current density at +100 mV after 600 s of GST infused (n = 26) and 
GST-REA infused (n = 21) cells. F. Co-precipitation studies of GST, GST-a-kinase and GST- a-kinase K1804R 
in REA-expressing HEK293 cells (top panel). REA input (1%) expression was analyzed by immunoblotting 
(bottom panel). G. In vitro protein kinase assay of TRPM6 and TRPM6 and REA (left panel), analyzed for total 
expression by immunoblotting (right panels). H. Effect of PKC activation by PMA (100 nM, 5 min 
pretreatment) on the current density at +80 after 200 s of TRPM6 and mock (n = 17-44), and TRPM6 and REA 
(n=17-36). * indicates P < 0.05 compared to TRPM6 and mock without pretreatment, and # indicates P < 0.05 
compared to TRPM6 and REA without pretreatment.
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Figure 5. Effect of 17p-estradiol on the binding between REA on TRPM6 and on TRPM6 channel activity. A. 
GST-fused TRPM6 a-kinase domain, GST (control) and REA were co- expres sed in HEK293 cells. After 
treatment with 50 nM 17p-estradiol (17p-E2) or vehicle, REA was co-precipitated with GST-fused a-kinase 
domain and visualized using the anti-REA antibody (top panel). Immunoblotting (bottom panel) and 
densitometry quantification (right panel) of binding between TRPM6 a-kinase domain and REA. * indicates P 
< 0.05 compared to vehicle treatment. B. Time course of the current density (pA/pF) at + 80 mV of TRPM6 
transfected HEK293 cells in control condition (■) and treated with 50 nM 17p-estradiol (E2) for 10 min at 37°C 
(A). C. Averaged values of the current density at + 80 mV after 200 s of TRPM6 (n = 37) and TRPM6 pre­
treated with 50 nM of 17p-estradiol (E2) (n = 37). * indicates P < 0.05 compared to control condition. D. 
TRPM6 expressing HEK293 cells were treated with 50 nM 17p-estradiol (E2) or vehicle and subsequently 
subjected to cell surface biotinylation assay. TRPM6 expression was analyzed by immunoblot for the plasma 
membrane fraction (top panel) and for the total cell lysates (bottom panel). Surface expression of TRPM6 was 
quantified by densitometry (right panel). As negative controls, mock cells were used.
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REA inhibits TRPM6 channel activity in a phosphorylation-dependent manner
The functional role of REA on TRPM6 channel activity was investigated by whole-cell patch 
clamp recordings in HEK293 cells. Steeply outward rectifying currents carried by Na+ were measured 
in HEK293 cells co-expressing TRPM6 and empty vector (mock) (Fig. 3A,B). These currents were 
significantly inhibited in cells co-expressing TRPM6 and REA (Fig. 3A,B). Of note, the inhibitory 
effect of REA was specific for TRPM6, since REA did not affect the current in TRPM7-expressing 
HEK293 cells (Fig. 3C,D). To further analyze the inhibitory effect of REA on TRPM6, GST and 
GST-REA were expressed in HEK293 cells and purified using glutathione-sepharose 4B beads (Fig. 
4A). These purified GST and GST-REA proteins were subsequently perfused into TRPM6-expressing 
HEK293 cells via the patch pipette before whole-cell recording. As shown in Figure 4B,C, REA 
significantly inhibited the TRPM6-mediated current, but the associated protein did not change the 
electrophysiological characteristics of the recorded currents. GST alone did not affect the TRPM6- 
mediated current. Next, the phosphotransferase-deficient mutant (K1804R) was used to investigate the 
role of TRPM6 phosphorylation activity in this process. REA was unable to inhibit the K1804R mutant­
mediated current, similar as GST alone (Fig. 4D,E). Importantly, the co-precipitation assay showed 
that the K1804R mutation did not influence the binding between TRPM6 and REA (Fig. 4F). 
Importantly, our in vitro phosphorylation assay demonstrated equal autophosphorylation of TRPM6 
with or without REA co-expression (Fig. 4G). Next, we investigated the effect of PKC activation by 
phorbol 12-myristate 13-acetate-PMA (PMA) on the regulatory effect of REA, since it has been 
shown that RACK1 inhibition can be prevented by 5 min preincubation of 100 nM PMA [15]. Pre­
treatment of cells co-expressing TRPM6 and REA significantly decreased TRPM6 channel activity. 
Of note, the current amplitude in the presence o f PMA was not altered in cells expressing TRPM6 
alone (Fig. 4H). Finally, we investigated whether REA is a phosphorylation target of TRPM6. The in 
vitro phosphorylation assay showed that REA is not phosphorylated by TRPM6 (Fig. 4G).
17ft-estradiol dissociates the REA-TRPM6 interaction and stimulates channel activity
Given the role of REA in the estrogen signaling pathway [26, 28, 29], the influence of estrogen on 
the TRPM6 and REA interaction was investigated by co-precipitation experiments. To this end, GST- 
a-kinase and GST were co-expressed with REA in HEK293 cells, subjected to 17p-estradiol (50 nM) 
or vehicle for 10 min at 37 °C, and then precipitated using glutathione-sepharose 4B beads. The 
interaction between REA and TRPM6 a-kinase domain was significantly reduced by 17P-estradiol 
treatment (Fig. 5A, upper panel), whereas REA was equally expressed in all situations (Fig. 5A, lower 
panel). Next, the influence of estrogen on TRPM6 channel activity was investigated. To this end, 
HEK293 cells expressing TRPM6 were pre-incubated for 10 min with 17^-estradiol (50 nM) at 37°C 
and analyzed by whole-cell patch clamp recordings. As shown in Figure 5B,C, the TRPM6 current 
was significantly increased when treated with 17p-estradiol compared to control. Subsequently, the
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influence of 17p-estradiol treatment on the amount of TRPM6 channels expressed at the plasma 
membrane was investigated by cell surface biotinylation experiments using HEK293 cells. As shown 
in figure 5D (upper panel), treatment with 17p-estradiol does not affect the amount of TRPM6 
channels expressed at the plasma membrane. Of note, TRPM6 was equally expressed in all tested 
conditions as determined in the total cell lysates (Fig. 5D, bottom panel).
Discussion
In the present study, we identified REA as a TRPM6-associated protein and demonstrated that 
this estrogen-responsive protein inhibits the channel activity in a phosphorylation activity-dependent 
manner. First, REA binds to the TRPM6 a-kinase domain and co-expresses with the Mg2+ channel in 
the renal distal convoluted tubule (DCT). Second, REA specifically inhibits channel activity of 
TRPM6, but not TRPM7. Third, this inhibition depends on TRPM6 phosphorylation activity, since 
REA has no effect on the TRPM6 phosphotransferase-deficient K1804R mutant. Fourth, the association 
between REA and TRPM6 is a dynamic process, which is regulated by 17p-estradiol treatment. 
Finally, 17P-estradiol treatment stimulates TRPM6 activity via a rapid non-transcriptional pathway. 
TRPM6 functions as the gatekeeper o f active transepithelial Mg2+ transport [6-8].
Here, REA was identified as a dynamic regulator of TRPM6 channel activity and, therefore, a 
molecular component in Mg2+ homeostasis. REA binds to the a-kinase domain of TRPM6, which was 
initially identified by the combination of a GST-pull down with the a-kinase domain of TRPM6 in 
mouse kidney lysate followed by FTMS analysis. This interaction was confirmed by co-precipitation 
between REA and TRPM6 a-kinase domain in HEK293 cells. Interestingly, our GST-pull down 
experiment and structure modeling analysis suggest that REA specifically binds to the 6th, 7th and 8th 
P-sheets in the a-kinase domain, which has been demonstrated as the binding region for RACK1 as 
well [15]. This might be due to the fact that most amino acids in this area are located on the peripheral 
region of the tertiary structure of the TRPM6 a-kinase domain, thereby facilitating the interaction 
with its regulatory proteins. Importantly, we demonstrated that RACK1 has no effect on the binding 
between REA and the a-kinase domain. This could be explained either by different binding sites 
within this region or by a higher binding affinity for REA than RACK1. Moreover, we showed that 
REA is abundantly present in TRPM6-expressing tubules in kidney. The co-expression of REA and 
TRPM6 in DCT further substantiates the physiological relevance of the interaction between both 
proteins.
REA was first identified as an interacting protein of the estrogen receptor (ER), where it functions 
as a selective co-regulator repressing the transcriptional activity of ERs [26]. Genetic deletion of REA 
significantly enhances estrogen responsiveness in vivo [28]. Recently, He et al. showed that REA 
forms a heteromer with prohibitin and acts as a transcriptional co-repressor for ERa [29]. Our study 
demonstrated a novel role of REA in TRPM6 regulation by showing that the inhibitory effect of REA
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on TRPM6 channel activity is not via the long-term transcriptional pathway. This notion is supported 
by the fact that rapid perfusion of purified GST-REA through the patch pipette into TRPM6 
expressing cells induced a significant inhibition of channel activity. Moreover, this inhibitory effect is 
dependent on the kinase activity of the TRPM6 a-kinase domain since the TRPM6 
phosphotransferase-deficient K1804R mutant is insensitive to REA. Of note, REA can still bind to the 
TRPM6 K1804R mutant. Next, we demonstrated that PKC activation by PMA potentiated the 
inhibitory effect of REA. Taken together, these data suggest that the phosphorylation activity of 
TRPM6 a-kinase domain plays a role in the REA effect. Although the phosphorylation activity of the 
TRPM6 and TRPM7 a-kinase domains has been well established [15, 30-35], the regulatory role of 
this catalytic domain on channel activity remains elusive. While it has previously been shown that 
these domains are not essential for TRPM6/7 channel activation [15, 32, 35], several studies have 
demonstrated an indirect regulatory role in modulation of channel activity[15, 36]. In this line, we 
previously demonstrated that ATP can regulate TRPM6 channel activity through the ATP binding 
motif within the a-kinase domain, independent of the TRPM6 a-kinase activity [36]. Moreover, we 
showed earlier that the inhibitory effect of RACK1 on TRPM6 is dependent on the TRPM6 
phosphorylation activity [15]. It has also been illustrated that the phosphorylation-impaired T1851A 
mutant is less sensitive to [Mg2+]i, in agreement with previous studies demonstrating that TRPM7 a- 
kinase activity influences the Mg2+-dependent inhibition of channel activity [35, 37]. Remarkably, 
while REA inhibits TRPM6 channel activity, it has no effect on TRPM7, the closest homologue of 
TRPM6. Based on the structural analysis, the REA binding site in TRPM6 a-kinase domain is highly 
conserved in TRPM7, therefore REA most likely binds to TRPM7 a-kinase domain as well. 
However, it has been reported that the a-kinase of TRPM6 is capable of cross-phosphorylation of 
TRPM7, but not vice versa, suggesting the functional non-redundancy of these two a-kinase domains 
[33]. One hypothesis is that REA is a specific phosphorylation target of TRPM6, but not TRPM7, and 
this phosphorylation may function as a switch of the REA regulatory activity on TRPM6. However, 
we demonstrated that REA could not be phosphorylated by TRPM6. Furthermore, TRPM6 
autophosphorylation is not affected in the presence of REA. So, the present study revealed another 
indirect regulation of TRPM6 channel activity, free from TRPM6 autophosphorylation, but dependent 
on its a-kinase activity.
REA has been well documented as a regulator in the estrogen signaling pathway [26, 28, 29]. 
Interestingly, our data showed that the interaction between REA and TRPM6 is a dynamic process 
that is regulated by estrogen. Treatment with 17p-estradiol disassociated the interaction between 
TRPM6 and REA, and attenuated its inhibitory effect on TRPM6 channel activity. According, our 
electrophysiological data demonstrated that pre-incubation of 17p-estradiol indeed induced a 
significant increase of TRPM6-mediated current. It is well known that estrogen can enhance Mg2+ 
utilization and uptake [38-41]. In this line, Groenestege et al. demonstrated that the renal TRPM6
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mRNA level in ovariectomized rats was significantly reduced, whereas 17p-estradiol treatment 
normalized TRPM6 mRNA level, suggesting that estrogen can regulate Mg2+ homeostasis via a 
transcriptional pathway [9]. Accumulating evidence showed that, in addition to the classical 
transcriptional pathway, estrogen has the ability to facilitate rapid, membrane-initiated, fast signaling 
cascades via plasma membrane-associated receptors [19-22]. Our current data pointed out a rapid 
regulatory pathway for estrogen, since the TRPM6-expressing cells were only treated with 17P- 
estradiol for 10 min prior to path clamp analysis. Interestingly, we demonstrated that 17P-estradiol 
significantly disassociated the interaction between TRPM6 a-kinase domain and REA. In 
reminiscence of REA inhibition on TRPM6 channel activity, the molecular mechanism o f estrogen 
stimulation might be due to disassociation of the TRPM6 and REA interaction and subsequent 
diminishment of the REA inhibition. It would, therefore, be of interest to further elucidate the detailed 
signaling pathway involved in estrogen stimulation leading to attenuation of the TRPM6 and REA 
interaction. It is conceivable that estrogen activates an estrogen receptor and its downstream signaling 
pathway, which might couple to TRPM6 or REA and influence their structure.
Taken together, we presented REA as a novel negative modulator involved in active 
transepithelial Mg2+ transport via regulating TRPM6 channel activity. Furthermore, estrogen 
disassociated the interaction between TRPM6 and REA and thereby increases TRPM6-mediated Mg2+ 
influx, which may function as a rapid pathway for estrogen to regulate the Mg2+ balance. These 
findings shed new light on the molecular regulation of TRPM6 and contribute to a further 
understanding of the molecular basis of transepithelial Mg2+ (re)absorption.
Material and methods
Cell culture and transfection- HEK293 cells were grown and transfected as previously described 
[42], and electrophysiological recordings were performed 48 hours post-transfection.
DNA constructs and cRNA synthesis- The kinase domain of mouse (1759-2028) and human 
(1750-2022) TRPM6 was cloned into pGEX6p-2 (Amersham Pharmacia Biotech, Uppsala, Sweden) 
by PCR using mouse kidney cDNA or human TRPM6 in pCINeo/IRES-GFP [8] as template. The a- 
kinase domain (1750-2022) of human TRPM6 was subcloned into the pEBG vector [43]. Full-length 
mouse REA cDNA was cloned into pT7Ts, pCB7 and pEBG by PCR using mouse kidney cDNA. 
Wild-type TRPM6 in the pCINeo/IRES-GFP vector was HA-tagged at the N-terminal tail as 
described previously [8]. GST-a-kinase truncants (TRPM6 1759-1993, 1759-1885, 1759-1857, 1857­
1885 and 1759-1813) mutants, TRPM6 phosphotransferase-deficient mutant (K1804R) and GST-a- 
kinase K1804R mutant were created using the QuickChange site-directed mutagenesis kit (Stratagene, 
La Jolla, CA, USA) according to the manufacturer’s protocol. All constructs were verified by
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sequence analysis. REA cRNA was synthesized in vitro using T7 RNA polymerase as described 
previously [44].
Identification o f  proteins by nano liquid chromatography tandem mass spectrometry- After SDS- 
PAGE, GST and GST-TRPM6 a-kinase interacting proteins were treated with dithiothreitol (DTT) 
and iodoacetamide, and digested in-gel by trypsin as previously described [45]. Peptide identification 
experiments by liquid chromatography tandem mass spectrometry were performed using a nano- 
HPLC Agillent 1100 nanoflow system connected online to a 7-Tesla linear quadrupole ion trap­
Fourier Transform Ion Cyclotron Resonance (LTQ-FT) mass spectrometer (Thermo Electron, 
Bremen, Germany) as described previously [45]. Peptides and proteins were identified using the 
Mascot 2.1 (Matrix Science, Boston, MA, USA) algorithm to search a local version o f the Uniprot 
database. First ranked peptides were parsed from Mascot database search html files with MSQuant to 
generate unique first ranked peptide lists and internal calibration of measured ion masses.
GST-fusion proteins and pull-down assay- TRPM6 a-kinase GST fusion protein was purified as 
previously described [46]. REA protein was labeled with [35S]-methionine using a reticulocyte lysate 
system (Promega, Madison, WI, USA) and added to purified GST-fusion proteins, immobilized on 
glutathione-sepharose 4B beads. After 2 h incubation at room temperature (RT), beads were washed 
extensively with pull-down buffer (10 mM Tris pH 7.4-HCl), 150 mM NaCl, 0.33% (v/v) Triton X- 
100). The bound proteins were eluted with SDS-PAGE loading buffer, separated on SDS-PAGE gel 
and visualized by autoradiography.
Sequence analysis and structure modelling- The structural model of TRPM6 a-kinase domain 
was built based on the crystal structure of TRPM7 a-kinase domain [27] (Protein DataBank under ID 
codes: 1IAJ (apo), 1IAH (ADP complex), and 1IA9 (AMP^PNP complex)) using SWISS-MODEL 
(http://swissmodel.expasy.org//SWISS-MODEL.html) and analyzed by DeepView Swiss-PdbViewer 
(Version 3.7; http://swissmodel. expasy.org/spdbv/) and Yasara (www.yasara.org).
RT-PCR- Total RNA isolation from mouse tissue and reverse transcription were performed as 
described previously [46]. REA and P-actin were amplified by PCR and subsequently analyzed by 
agarose gel electrophoresis.
Electrophysiology- Patch clamp experiments were performed in the tight seal whole-cell 
configuration at room temperature using an EPC-10 patch clamp amplifier computer controlled by the 
Patchmaster software (HEKA Elektronik, Lambrecht, Germany). Electrode resistances were 2-5 MQ, 
and capacitance and access resistance were monitored continuously. A ramp protocol, consisting of 
linear voltage ramps from -100 to +100 mV (within 450 ms), was applied every 2 s from a holding
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potential of 0 mV. Current densities were obtained by normalizing the current amplitude to the cell 
membrane capacitance. The time course of current development was determined by measuring the 
current at +80 and -80 mV. I/V relations were established from the ramp protocols. The analysis and 
display of patch clamp data were performed using Igor Pro software (WaveMetrics, Lake Oswego, 
USA). The standard pipette solution contained 150 mM NaCl, 10mM EDTA, and 10 mM HEPES pH 
7.2-NaOH. The extracellular solutions contained 150 mM NaCl, 10 mM HEPES, and 1 mM Ca2+ pH
7.4-NaOH. To investigate the effect of purified GST-REA or GST on TRPM6-mediated currents, 
proteins were added to the standard pipette solution and thereby infused via the patch pipette for 7 
min before starting the recordings.
Co-precipitation- HEK293 cells were transiently co-transfected with REA and pEBG-TRPM6 a- 
kinase or pEBG empty vector. Cells were treated with 50 nM 17p-estradiol or vehicle for 10 min at 
37°C and were lysed for 1 hour on ice in lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris pH
7.5-NaOH, 0.33% (v/v) triton including the protease inhibitors leupeptin (0.01 mg/ml), pepstatin (0.05 
mg/ml) and phenylmethylsulfonyl fluoride (1 mM)). After centrifugation, supernatants of the lysates 
were incubated overnight with glutathione-sepharose 4B beads at 4°C. After extensive washing in 
lysis buffer, the bound proteins were eluted and separated by SDS-PAGE. The co-precipitation was 
analyzed using the anti-REA antibody (Abcam, Cambridge, UK).
Cell surface labeling with biotin- HEK293 cells were transiently transfected with 15 ^g HA- 
TRPM6 in poly-L-lysine (Sigma, MO, USA) coated 10 cm dishes. 72 hours after transfection, cells 
were treated with 50 nM 17p-estradiol or vehicle for 10 min at 37°C. Cell surface labeling with NHS- 
LC-LC-biotin (Pierce, Etten-Leur, The Netherlands) was performed as previously described [47]. 1 
hour after homogenizing, biotinylated proteins were precipitated using neutravidin-agarose beads 
(Pierce, Etten-Leur, The Netherlands). TRPM6 expression was analyzed by immunoblot for the 
precipitates (plasma membrane fraction) and for the total cell lysates using the anti-HA antibody 
(Sigma, MO, USA).
Immunoblotting- Protein samples were denatured by incubation for 30 min at 37°C in Laemmli 
buffer, and then subjected to SDS-PAGE. Immunoblots were incubated with either mouse anti-HA 
(Sigma, MO, USA) or rabbit anti-REA (Abcam, Cambridge, UK) antibody. Subsequently, blots were 
incubated with sheep horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (Sigma, MO, 
USA) and then visualized using the enhanced chemiluminescence system.
Immunohistochemistry- Immunohistochemistry was performed as previously described [48]. 
Briefly, mouse kidney serial sections were incubated for 16 hours at 4°C with rabbit anti-REA 
(Abcam, Cambridge, UK) and guinea pig anti-TRPM6 [8]. To visualize TRPM6, tyramide signal
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amplification kit (NEN Life Science Products, Zaventem, Belgium) was used after incubation with 
biotin-coated goat anti-mouse secondary antibody. Images were taken with a Bio-Rad MRC 100 
confocal laser scanning microscope.
In vitro phosphorylation assays- HA-TRPM6 was precipitated by using the anti-HA antibody. 
The precipitates were incubated in a total volume of 30 ^l kinase reaction buffer (50 mM HEPES pH
7.4-KOH, 4 mM MnCfe, 0.5 mM CaCfe, 100 ^M ATP) and 2 ^Ci o f [y32P]ATP for 30 min at 30°C. 
The reaction was terminated by three washing steps with phosphorylation washing buffer (50 mM 
HEPES pH 7.4-KOH, 4 mM MnCl2, 0.5 mM CaCl2). Phosphorylation was analyzed after gel 
electrophoresis by autoradiography.
Statistical analysis- Values are expressed as mean ± SE. Statistical significance between groups 
was determined by analysis of variance (ANOVA). In case of significance, differences between the 
means of two groups were analyzed by unpaired t test. P < 0.05 was considered statistically 
significant.
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TRPM6, MsrBl, and oxidative stress
Mg2+ is an essential ion for many cellular processes, including protein synthesis, nucleic acid 
stability and numerous enzymatic reactions. Mg2+ homeostasis in mammals depends on the 
equilibrium between intestinal absorption, renal excretion, and exchange with bone. The Transient 
Receptor Potential Melastatin type 6 (TRPM6) is an epithelial Mg2+ channel, which is abundantly 
expressed in the luminal membrane of the renal and intestinal cells. It functions as the gatekeeper of 
transepithelial Mg2+ transport. Remarkably, TRPM6 combines a Mg2+-permeable channel with an a- 
kinase domain. Here, by the Ras recruitment system (RRS), we identified methionine sulfoxide 
reductase B1 (M srBl) as an interacting protein of the TRPM6 a-kinase domain. Importantly, MsrBl 
and TRPM6 are both present in the renal Mg2+-transporting distal convoluted tubules (DCT). MsrBl 
has no effect on TRPM6 channel activity in the normoxic conditions. However, hydrogen peroxidase 
(H2O2) decreased TRPM6 channel activity. Co-expression of MsrBl with TRPM6 attenuated the 
inhibitory effect of H2O2 (TRPM6: 67 ± 5% of control; TRPM6 + M srBl: 81 ± 5% of control). Cell 
surface biotinylation assays showed that H2O2 treatment does not affect the expression of TRPM6 at 
the plasma membrane. Next, mutation of Ml755 to A in TRPM6 reduced the inhibitory effect of H2O2 
on TRPM6 channel activity (TRPM6 Ml755A: 84 ± l0% of control), thereby mimicking the action of 
M srBl. Thus, these data suggest that MsrBl recovers TRPM6 channel activity by reducing the 
oxidation of Ml755 and could, thereby, function as a modulator of TRPM6 during oxidative stress.
Introduction
To maintain a physiological extra- and intracellular Mg2+ concentration is of great importance to 
keep the accurate function of more than 300 enzymatic systems and the subsequent various biological 
and physiological processes [ l -4]. The kidney is the principal organ responsible for the regulation of 
the body Mg2+ balance. Around 80 % of the total plasma Mg2+ is ultrafiltered through the glomeruli 
and subsequently reabsorbed passively in the proximal tubule and the thick ascending limb of Henle’s 
loop [5]. The final urinary Mg2+ concentration is defined by active Mg2+ reabsorption in the distal 
convoluted tubule (DCT) [6].
The Transient Receptor Potential Melastatin type 6 (TRPM6) is a cation channel playing a crucial 
role in Mg2+ homeostasis. Mutations in TRPM6 cause hypomagnesemia with secondary hypocalcemia 
(HSH) [7, 8]. Interestingly, mice deficient o f TRPM6 (TRPM6-- mice) were essentially 
embryonically lethal and the incidental TRPM6-- mice that survived had neural tube defects [9]. 
TRPM6 and its closest homologue TRPM7, uniquely combine an ion channel pore-forming region 
with a serine/threonine protein kinase domain. It is located at the carboxyl terminus and has 
similarities with members o f the a-kinase family [l0 , l l] .  Previous studies demonstrated that 
Receptor for Activated C-Kinase l (RACKl) and Repressor of Estrogen Receptor Activity (REA) 
interact with this domain and inhibit channel activity in an (auto)phosphorylation-dependent manner
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[12, 13]. Moreover, modulation of TRPM6 channel activity by intracellular ATP requires the ATP- 
binding motif in the a-kinase domain [14]. While the phosphorylation acitvity of the TRPM6/7 a- 
kinase domains has been well determined, the role of these domains in regulating channel activity 
remains elusive [12, 15-18].
Over the last years, several studies have implicated TRPM channels in ischemia [19, 20]. Sun et 
al. showed that decreased TRPM7 channel expression significantly reduced neuronal cell death after 
global ischemia [21]. Furthermore, TRPM4 channel activation in vascular smooth muscle has been 
shown to contribute to cell death of vascular cells during ischemic injury and TRPM2 has been well 
studied in relation to oxidative stress [22-25]. Accumulating evidence suggests that reactive oxygen 
species (ROS) are not only harmful side products of cellular metabolism, but also central players in 
cell signaling and regulation [26-29]. Interestingly, renal DCT cells contain the largest number of 
mitochondria. However, the effect of oxidative stress on the epithelial Mg2+ channel TRPM6, 
expressed at the apical membrane of the DCT, has not been studied.
The aim of the present study was to investigate the role of the a-kinase domain in TRPM6 
channel activity by the identification of associated proteins. To this end, the Ras recruitment system 
(RRS), a novel yeast two hybrid screening system, which is designed to screen for partners of plasma 
membrane proteins, was applied [30]. Here, we identified methionine sulfoxide reductase B1 (MsrB1) 
as a TRPM6- associated protein, binding to the TRPM6 a-kinase domain. Using biochemical, 
immunohistochemical and electrophysiological analyses, we demonstrated a novel operation mode for 
MsrB1 in the regulation of TRPM6 channel activity in oxidative stress through modulating 
methionine oxidation in TRPM6.
Results
M srBl interacts with TRPM6 a-kinase domain
To identify proteins interacting with the a-kinase domain of TRPM6, we applied the RRS. 
Compared with the conventional yeast two-hybrid, RRS is more appropriate to detect interaction 
partners of plasma membrane proteins [30]. In this approach, MsrB1, a methionine sulfoxide 
reductase [31], was identified as an interacting protein of the TRPM6 a-kinase domain. Subsequently, 
MsrB1 cDNA was co-transformed with the a-kinase domain of TRPM6 into cdc25-2 yeast strain to 
confirm the interaction. As shown in Fig 1A, while the cdc25-2 strains co-transformed with MsrB1 
and TRPM6 a-kinase domain grow at 37 °C, yeast co-transformed with the control vector and 
TRPM6 a-kinase domain only survived at 24 °C. The association between TRPM6 and MsrB1 was 
further substantiated by co-precipitation studies of glutathion S-transferase (GST) and GST-TRPM6- 
kinase in MsrB1-expressing HEK293 cells. MsrB1 co-precipitated with the GST-a-kinase, but not 
with GST alone (Fig. 1B, upper panel).
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Figure 1. Interaction and co-expression between TRPM6 and MsrBl. A. Complementation of the cdc25-2 
mutation through the interaction of TRPM6 a-kinase domain with MsrBl. The temperature-sensitive cdc25-2 
yeast strain was co-transformed with TRPM6 a-kinase domain and MsrBl or control plasmid (mock), and 
incubated on galactose-containing plates either at 25 °C or 37 °C. B. Co-precipitation studies of GST and GST- 
a-kinase in MsrBl-expressing HEK293 cells (top panel). MsrBl input (1%) expression was analyzed by 
immunoblotting (bottom panel). C. Co-precipitation of GST-MsrBl in TRPM6-expressing HEK293 cells (top 
panel). TRPM6 input (5%) and MsrBl precipitation expression were analyzed by immunoblotting (middle panel 
and bottom panel). D. Distribution of MsrBl (top panel) mRNA expression analyzed by RT-PCR on various 
tissues. P-actin was used as a positive control (bottom panel). E. Immunohistochemical analysis of TRPM6 
(upper panel) and MsrBl (lower panel) in serial mouse kidney sections. * indicates overlapping immunopositive 
tubules for TRPM6 and MsrBl.
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M srBl was equally expressed in the tested conditions (Fig. 1B, lower panel). Furthermore, co ­
precipitation studies o f  full-length TRPM6 with M srB l in HEK293 cells showed that full-length  
TRPM6 associates with G ST-M srBl but not with GST alone (Fig. 1C, upper panel). TRPM6 and 
M srBl were expressed in all conditions tested (Fig. 1C, middle and bottom panel).
Figure 2. H2O2 effect on TRPM6 channel activity and plasma membrane expression. A. Time course of the 
current density (pA/pF) at +80 mV of TRPM6-transfected HEK293 cells, where 1 mM H2O2 was added to the 
bath solution after 200 s (arrow). B. Current-voltage (I/V) relation of TRPM6- transfected cells perfused with 
standard extracellular solution (solid) and 1 mM H2O2 (dashed). C. Percentage inhibition of the TRPM6 current 
at +80 mV after 1000 s in response to different H2O2 concentrations, normalized to 1 mM H2O2. D. TRPM6- 
expressing HEK293 cells were treated with 1 mM H2O2 and subsequently subjected to cell surface biotinylation 
assays. TRPM6 expression was analyzed by immunoblotting for the plasma membrane fraction (top panel) and 
for the total cell lysates (bottom panel). Representative immunoblot of 3 independent experiments is shown. As 
negative controls, mock-transfected cells were used. E. Densitometry quantification of TRPM6 surface 
expression with/without H2O2 treatment.
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M srBl co-expresses with TRPM6 in kidney
To address the tissue distribution of M srBl, reverse transcriptase polymerase chain reaction (RT- 
PCR) analysis was performed on a panel of mouse tissues. The expected DNA fragment of MsrBl 
was detected in all tissues as indicated in Fig. 1D. The integrity of the cDNA was confirmed by the 
detection of P-actin. To further study the co-expression of MsrBl and TRPM6 in kidney, 
immunohistochemistry was performed on serial mouse kidney sections. This analysis indicated 70% 
immunopositive staining for MsrBl in the TRPM6-expressing DCT segment, that has been implicated 
in active Mg2+ reabsorption [32] (Fig. 1E).
H 2 O2 inhibits TRPM6 channel activity
Considering that MsrBl is a stress protein which mainly exerts its function during oxidative stress 
[31], we hypothesized that MsrBl regulates TRPM6 channel activity during oxidative stress. 
Therefore, we examined the effect of H2O2 on TRPM6 channel activity. To this end, HEK293 cells 
expressing TRPM6 were treated with l mM H2O2 during whole-cell patch clamp recordings. As 
shown in Fig. 2A-B, H2 O2 caused a significant inhibition of the TRPM6-mediated current (67 ± 5% of 
control, n=l3, P<0.05) compared to the non-treated cells (n= ll). Furthermore, we demonstrate that 
H2 O2 inhibits TRPM6 channel activity in a dose-dependent effect with an IC50 of l48 ¡aM (Fig 2C).
A B
T im e (sec)
Figure 3. MsrBl reduces the inhibitory effect of H2O2 on TRPM6. A. Time course of the current density 
(pA/pF) at +80 mV of TRPM6 and TRPM6+MsrBl-transfected HEK293 cells, where l mM H2O2 was added to 
the bath solution after 200 s (arrow). B. Normalized values of the current at +80 mV after 800 s of TRPM6 and 
TRPM6+MsrBl, treated with (open bars) or without (closed bars) H2O2. * indicates P<0.05.
H 2 O2 treatment does not affect TRPM6 cell surface expression
Next, the influence o f H2 O2 on the amount of TRPM6 channels at the plasma membrane was 
investigated by cell surface biotinylation experiments. As shown in Fig. 2D (upper panel), treatment 
with H2O2 did not affect the plasma membrane abundance of TRPM6. Of note, the protein levels of 
TRPM6 were equal in all tested conditions as verified by the total cell lysates (Fig. 2D, bottom panel).
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M srBl prevents the inhibitory effect o f  H 2 O2
Next, the effect o f  M srBl on TRPM6 channel activity was investigated. Patch clamp analysis 
demonstrated that M srB l has no effect on TRPM6 channel activity (TRPM 6+empty vector: 250 ± 42  
pA/pF and TRPM6+MsrB1: 224 ± 37 pA/pF, P>0.2). To investigate the role o f  M srB l on TRPM6
channel activity during oxidative 
stress, TRPM6 and M srB l were co ­
expressed in HEK293 cells and 
treated with H2O2 during w hole-cell 
patch clamp recordings. Treatment 
with H2O2 significantly decreased 
TRPM6 current (67 ± 5% o f  control, 
n=13, P<0.05), while co-expression  
o f  M srBl significantly attenuated 
this inhibition (8 l ± 5% o f  control, 
n = l3 , P<0.05) (Fig. 3A -B).
A755 H 2 O2 -
Figure 4. TRPM6 M A is not significantly inhibited by H2O2. 
A. Normalized values of the current at +80 mV after 800 s of 
TRPM6 and all TRPM6 M-A mutants, treated with (open bars) 
or without (closed bars) 1 mM H2O2. * indicates P<0.05. B. 
Time course of the current density (pA/pF) at +80 mV of 
TRPM6 and TRPM6 M1755A-transfected HEK293 cells, where 1 
mM H2O2 was added to the bath solution after 200 s (arrow).
Involvement o f  M 7”  in 
inhibited TRPM6 activity
Since MsrB 1 binds to the 
TRPM6 a-kinase domain and 
recovers the inhibitory effect o f  H2O2 
on TRPM6 channel activity, we 
hypothesized that M srBl could  
reduce methionine oxidation o f  the 
a-kinase domain. Therefore, the 
methionine residues located on the 
peripheral o f  the TRPM6 a-kinase 
domain 3D structure (see 
http://www.cmbi.ru.nl/~hvensela/trp  
m 6/) that might be more vulnerable 
to H2O2, were mutated into alanines 
(namely M 1755A, M 1775A, M 1947A, and 
M 1904A  as analyzed by Yasara 
software, http://www.yasara.org). 
Subsequent patch clamp analysis 
showed that only the TRPM6 M1755A
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mutant was not significant inhibited by H2 O2 (83 ± 6% of control, n=12, P>0.05) (Fig. 4A-B). Of 
note, the other mutants were significantly inhibited by H2O2 (M1775A: 63 ± 10%, n=8; M1904A: 64 ± 
9%, n=8; M1947A: 64 ± 7%, n=10) (Fig. 4A).
Discussion
In the present study, we identified MsrBl as a new TRPM6-associated protein and showed that 
MsrBl recovers TRPM6 channel activity via reducing the oxidation state of M1755 during oxidative 
stress. First, MsrB1 directly binds to the TRPM6 a-kinase domain and co-precipitates full-length 
TRPM6. Second, MsrB1 is co-expressed with TRPM6 in the renal DCT. Third, H2O2 inhibits TRPM6 
channel activity without affecting the plasma membrane expression. Fourth, MsrB1 prevents the 
inhibitory effect of H2O2 on TRPM6 channel activity. Finally, H2O2 has no significant effect on the 
TRPM6 M1755A mutant.
TRPM6 belongs to the TRPM subfamily of the TRP channels and is so far the only known 
channel directly mediating active transepithelial Mg2+ transport [4, 7, 8, 32]. However, the molecular 
regulation of this channel remains elusive. Here, we used a novel yeast two-hybrid procedure, RRS, to 
screen proteins interacting with TRPM6 a-kinase domain. Our data showed that MsrB1 binds to the 
a-kinase domain of TRPM6 resulting in the recruitment of Ras to the membrane and subsequent 
complementation of the temperature-sensitive cdc25-2 mutation. So, we identified MsrB1 as a new 
interacting protein of the TRPM6 a-kinase domain. This interaction has been confirmed by a 
subsequent GST co-precipitation assay in HEK293 cells with full-length TRPM6. Importantly, MsrB1 
and TRPM6 are co-expressed in the renal DCT, which further substantiates the physiological 
relevance of the interaction between both proteins.
MsrB1 is an oxidoreductase which catalyzes the thiol-dependent reduction of methionine 
sulfoxide [31]. MsrB1 belongs to the Msr family composed of MsrA and MsrB. Mammals contain 
one MsrA and three MsrBs that are highly abundant in kidney, liver, heart and nervous tissue [33-37]. 
These enzymes protect cells from oxidative stress via the repair of oxidative damage to proteins and 
thereby restore biological activity. They can be involved in ROS-mediated signal transduction 
through modulation of the function of target proteins [31, 38-40]. Accumulating data showed that 
reversible methionine oxidation and reduction plays a dynamic role in a variety of cellular signaling 
pathways [41, 42]. For example, the methionine residues of Helix-3, CamKII, shaker voltage- 
dependent K+ channel and Slo1 K+ channels can be oxidized and hereby regulate their function [42­
45]. It has been shown that oxidation of a methionine residue in the shaker voltage-dependent K+ 
channel disrupts its inactivation. This effect can be reversed by co-expression with MsrA1 [43].
In the present study, we showed that MsrB 1 interacts with the TRPM6 a-kinase domain, but does 
not affect the channel activity in normoxic conditions. However, hydrogen peroxide (H2 O2) is a 
product during oxidative stress and has been studied in relation to potassium channel function and the
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TRPM2 channel (reviewed [46, 47]). Here, we demonstrated that H2O2 significantly decreases the 
TRPM6-mediated current in HEK293 cells in a dose-dependent manner. As H2O2 did not change the 
surface expression of TRPM6, it possibly regulates TRPM6 channel activity directly through 
modulation of the channel conductance. Importantly, the decreased TRPM6 channel activity can be 
partly recovered by co-expression with MsrB1. This partial recovery could be explained by the fact 
that Msrs function optimal at 37 °C [48], while our experiments were performed at room temperature. 
Another possible explanation is the time lapse of MsrB 1 functioning, which is likely slower than the 
oxidation by H2O2.
Free and protein-bound methionine residues are among the most susceptible to oxidation by ROS 
[49]. It is proposed that surface exposed methionine residues in a protein constitute an antioxidant 
defense mechanism since various oxidants can easily react with these residues to form methionine 
sulfoxide. Reduction back to methionine by methionine sulfoxide reductases could catalytically drive 
this antioxidant system as has been suggested by several studies [50-52]. Therefore, the methionine 
residues located on the peripheral of the TRPM6 a-kinase domain 3D structure (see
1755 1775http://www.cmbi.ru.nl/~hvensela/trpm6/) were examined. Four methionine residues (M , M , 
M1904, and M1947 were mutated into alanines and their channel activity was studied upon H2O2 
treatment. Mutation of M1755 to A significantly attenuates the effect of H2O2 on TRPM6 channel 
activity, mimicking the MsrB1 effect (co-expression of MsrB1, 81 ± 5% of control; M1755A, 83 ± 6% 
of control). These data suggest that M1755 is a crucial target of H2O2. Notably, renal DCT cells 
contain the largest number of mitochondria, the major source of endogenous H2O2, per unit length of 
any cell along the nephron, underlying a vast source of intracellular H2 O2 [53]. TRPM6 is 
predominantly expressed in DCT and is inhibited by H2O2. Therefore, it is conceivable that the 
metabolic state of DCT cells, which influences the abundance of ROS generated from mitochondria, 
modulates the Mg2+ reabsorption via TRPM6.
Taken together, our study demonstrated that H2 O2 inhibits TRPM6 channel activity and pointed 
out M1775 as an important target for channel oxidation. Moreover, its interacting protein MsrB1 
dynamically regulates this oxidative effect on TRPM6. These data provide insight into the molecular 
basis of TRPM6 channel regulation and transepithelial Mg2+ (re)absorption. Our findings present the 
first example of modulating TRP channel activity by methionine oxidation and contribute to a further 
understanding of the regulation of TRP channels by novel post-translational modifications.
Material and methods
Cell culture and transfection- Human Embryonic Kidney (HEK) 293 cells were grown and 
transfected as previously described [54] and electrophysiological recordings were performed 48 h 
post-transfection.
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DNA constructs- The a-kinase domain of mouse (1759-2028) TRPM6 was cloned into the 
pMet425-Myc-Ras (kind gift from Dr. A. Aronheim, Haifa, Israel) by PCR using mouse kidney 
cDNA as template. The a-kinase domain of human (1759-2022) TRPM6 was cloned into the pEBG 
vector using human TRPM6 in pCINeo/IRES-GFP [32] as template. Full-length mouse M srBl cDNA 
was cloned into pCB7 by PCR using mouse kidney cDNA, and Flag-tagged at the N-terminal tail. 
Wild-type human TRPM6 in the pCINeo/IRES-GFP vector was HA-tagged at the N-terminal tail as 
described previously [32]. TRPM6 M1755A, TRPM6 M1775A, TRPM6 M1904A and TRPM6 M1947A 
mutants were created using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, 
USA) according to the manufacturer’s protocol. All constructs were verified by sequence analysis.
RRS Screening- RRS screening was performed as previously described [30]. Briefly, cdc25-2 
strains (kind gift from Dr. A. Aronheim) were co-transformed with the pMet425-Myc-Ras-TRPM6 a- 
kinase domain and mouse kidney cDNA library. Transformants were grown on selectable minimal 
glucose plates for 5 days at 25 °C, and subsequently replica plating onto minimal galactose plates, 
incubating for 5-7 days at 37 °C. Library plasmids of positive colonies growing on galactose plates at 
37 °C were isolated and further analyzed by DNA sequencing. The positive colonies were co­
transformed with the pMet425-Myc-Ras-TRPM6 a-kinase domain into cdc25-2 cells to confirm 
specificity of interaction.
RT-PCR- Total RNA isolation from mouse tissue and reverse transcription were performed as 
described previously [55]. MsrBl and P-actin were amplified by PCR and subsequently analyzed by 
agarose gel electrophoresis.
Electrophysiology- Patch clamp experiments were performed in the tight seal whole-cell 
configuration at room temperature using an EPC-10 patch clamp amplifier computer controlled by the 
Pulse software (HEKA Elektronik, Lambrecht, Germany). Electrode resistances were 2-5 MQ, and 
capacitance and access resistance were monitored continuously. A ramp protocol, consisting of linear 
voltage ramp from -100 to +100 mV (within 450 ms) was applied every 2 s from a holding potential 
of 0 mV. Current densities were obtained by normalizing the current amplitude to the cell membrane 
capacitance. The time course of current development was determined by measuring the current at +80 
and -80 mV. I/V relations were established from the ramp protocols. The analysis and display of 
patch clamp data were performed using Igor Pro software (WaveMetrics, Lake Oswego, USA). The 
standard pipette solution contained 150 mM NaCl, 10 mM EDTA, and 10 mM HEPES pH 7.2-NaOH. 
The extracellular solution contained 150 mM NaCl, 10 mM HEPES pH 7.4-NaOH supplemented with 
1 mM CaCl2. To avoid breakdown, H2O2 was stored at 4 °C prior to use and added to the perfusate 
immediately (<1 min) prior to making recordings.
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Co-precipitation assay- HEK293 cells were transiently co-transfected with MsrBl and pEBG- 
TRPM6-a-kinase or pEBG empty vector. 24 h after transfection, cells were lysed for 1 h on ice in 
lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris pH 7.5-NaOH, 0.33% (v/v) Triton X-100 
including the protease inhibitors leupeptin (0.01 mg/ml), pepstatin (0.05 mg/ml) and 
phenylmethylsulfonyl fluoride (1 mM)). After centrifugation, supernatants of the lysates were 
incubated overnight with glutathione-sepharose 4B beads at 4 °C. In the co-precipitation experiment 
with full length TRPM6, HEK293 cells were co-transfected with pEBG-MsrB1 and TRPM6 
pCIneo/IRES-GFP or pCIneo/IRES-GFP empty vector, and subsequently lysed and incubated on 
glutathione-sepharose 4B beads as described above. After extensive washing, the bound proteins were 
eluted with SDS-PAGE loading buffer. The co-precipitation was analyzed using the anti-MsrB1 
antibody (kind gift from Dr. J Moskovitz, Lawrence, Kansas, USA), mouse anti-HA (Sigma, MO, 
USA) antibody, or anti-GST antibody (Sigma, MO, USA).
Cell surface labeling with biotin- HEK293 cells, in poly-L-lysine (Sigma, MO, USA) coated 10 
cm dishes, were transiently transfected with 15 ^g HA-TRPM6. 72 h after transfection, cells were 
treated with 1 mM H2O2 for 10 min at 37 °C. Cell surface labeling with NHS-LC-LC-biotin (Pierce, 
Etten-Leur, The Netherlands) was performed as previously described [56]. 1 h after homogenizing, 
biotinylated proteins were precipitated using neutravidin-agarose beads (Pierce, Etten-Leur, The 
Netherlands). TRPM6 expression was analyzed by immunoblot for the precipitates (plasma 
membrane fraction) and for the total cell lysates using the mouse anti-HA antibody.
Immunoblotting- Protein samples were denatured by incubation for 30 min at 37°C in Laemmli 
buffer, and then subjected to SDS-PAGE. Immunoblots were incubated with either mouse anti-HA or 
rabbit anti-MsrB1 antibody. Subsequently, blots were incubated with sheep horseradish peroxidase- 
conjugated anti-mouse or anti-rabbit IgG (Sigma, MO, USA) and then visualized using the enhanced 
chemiluminescence system.
Immunohistochemistry- Immunohistochemistry was performed as previously described [57]. 
Briefly, mouse kidney sections were incubated for 16 h at 4°C with rabbit anti-MsrB1 and guinea pig 
anti-TRPM6. To visualize TRPM6, tyramide signal amplification kit (NEN Life Science Products, 
Zaventem, Belgium) was used after incubation with biotin-coated goat anti-mouse secondary 
antibody. Images were taken with a Bio-Rad MRC 100 confocal laser scanning microscope.
Statistical analysis- Values are expressed as mean ± SE. Statistical significance between groups 
was determined by analysis of variance (ANOVA) followed by Bonferroni’s Multiple Comparsion 
Test. Differences between the means of two groups were analyzed by an unpaired Student’s t test. 
P<0.05 were considered statistically significant.
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Erlotinib modulates TRPM6
A mutation in pro-EGF causes isolated hypomagnesemia. Further, monoclonal antibodies 
targeting the extracellular EGFR domain have been implicated in the regulation of epithelial Mg2+ 
transport. However, the effect of the widely used EGFR tyrosine kinase inhibitor, Erlotinib, on Mg2+ 
homeostasis remains unknown. To investigate the potential role of Erlotinib on Mg2+ handling, 
C57BL/6 mice were given intraperitoneal injections for 23 days. In Erlotinib-injected mice, a small 
but significant decrease in serum Mg2+ concentrations was observed at day 16 and 23, while the 
fractional excretion of Mg2+ remained unchanged after 23 days. Semi-quantitative 
immunohistochemical evaluation did not reveal detectable changes in renal Transient Receptor 
Potential Melastatin 6 (TRPM6) protein expression. The effect of Erlotinib on TRPM6 was 
investigated in HEK293 cells. Patch clamp analysis in TRPM6 expressing cells demonstrated that 
Erlotinib inhibited EGF-induced changes in TRPM6 current density at a concentration of 30 ^M. At 
lower concentrations (0.3 ^M), Erlotinib failed to inhibit EGF-mediated TRPM6 stimulation. 
Likewise, EGF-induced tyrosine phosphorylation of its receptor was only blocked by 30 ^M of 
Erlotinib. In addition, 30 ^M Erlotinib inhibited EGF-stimulated increases in the mobile fraction of 
endomembrane TRPM6 channels. In this mouse model, Erlotinib does influence Mg2+ handling. 
However, the effect on the systemic Mg2+ concentration seems less potent than that observed with 
antibody-based EGFR inhibitors in vivo. Currently, clinical data detailing the effect of Erlotinib on 
Mg2+ handling is lacking. Based on the doses given to cancer patients it is unlikely that Erlotinib 
severely affects serum Mg2+ concentrations in these individuals.
Introduction
Overall maintenance of serum Mg2+ concentration is essential for many cellular processes, 
including adequate function of neurological and cardiovascular systems. The Transient Receptor 
Potential Melastatin subtype 6 (TRPM6) was originally identified as the causative gene for the rare 
autosomal recessive disorder; hypomagnesemia with secondary hypocalcemia [1, 2]. TRPM6, which 
is expressed in kidney and colon[1, 3, 4], constitutes the gatekeeper and postulated rate-limiting entry 
step for active Mg2+ (re-) absorption.
The effect of EGF on TRPM6 has been firmly established. Application of EGF readily increases 
TRPM6 current density [5, 6]. Additional evidence suggests that EGF provokes trafficking of the 
channel to the plasma membrane, via activation of the Rho GTPase, Rac1 [5]. These discoveries were 
prompted by the observations that anti-cancer treatments with monoclonal antibodies (Cetuximab), 
targeting an extracellular epitope on the epidermal growth factor receptor (EGFR), causes 
hypomagnesemia in patients with colorectal cancer. In addition, genetic linkage and sequence 
analysis implicated the pro-EGF gene in isolated recessive renal hypomagnesemia [6-8]. The
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observed decline in serum Mg2+ is accompanied by renal Mg2+ wasting, as these patients maintain an 
inappropriately high fractional Mg2+ excretion [6].
While mostly patients with colorectal cancer are treated with monoclonal EGFR inhibitors, 
numerous patient groups suffering from cancer receive tyrosine kinase inhibitors, such as Erlotinib or 
Gefitinib. These include individuals being treated for non-small cell lung cancer as well as pancreatic 
cancer [9]. Erlotinib has been grouped with platinum compounds in most trials, a combination that 
may potentiate the effects on serum Mg2+ concentrations [10]. At present, there are no published 
clinical reports detailing the potential effect of tyrosine kinase inhibitors on systemic and renal Mg2+ 
handling. Given the pronounced effect of Cetuximab on Mg2+ homeostasis, we sought to ascertain 
whether Erlotinib alters Mg2+ handling. Thus Mg2+ homeostasis and TRPM6 expression levels were 
investigated in wild-type mice receiving Erlotinib for 23 days, and the effect of Erlotinib on current 
density and mobility of TRPM6 was studied in HEK293 cells transiently overexpressing the channel.
Results
Erlotinib reduces serum M g2+ concentration in C57Bl/6 mice
C57BL/6 mice were injected intraperitoneally with a high dose of Erlotinib or vehicle for 23 day 
(2 mg/mouse/day) (n=9 per group). Blood samples were obtained at day 16, by puncturing a vascular 
bundle in the sub-mandibular area. Serum Mg2+ concentration showed a significant decline in the 
Erlotinib-injected group (p<0.05) (Figure 1A), while no difference was detected in serum Ca2+ 
concentration between groups (p>0.5) (Figure 1B). Upon sacrifice after 23 days o f Erlotinib 
injections, similar results were found, namely a slight but significant decline in the serum Mg2+ 
concentration in the Erlotinib-injected group (p<0.05) (Figure 1C). Erlotinib did not affect the 
systemic Ca2+ concentration at day 23 (p>0.2) (Figure 1D). No difference was observed in the urinary 
excretion of Mg2+ (p>0.5), (Figure 2A) and the urinary Ca2+ excretion (p>0.2) (Figure 2B) after 23 
days of Erlotinib administration. The glomerular filtration rate remained within normal limits (p>0.2) 
(Figure 2C). Importantly, no change in the fractional excretion of Mg2+ was observed in mice 
receiving Erlotinib (p>0.2) (Figure 2D). The fractional excretion of Ca2+ (p>0.5) remained unchanged 
after chronic administration of Erlotinib (Figure 2E). These results suggest that Erlotinib-treated mice 
waste Mg2+, as serum Mg2+ is decreased while a compensatory reduction in the fractional Mg2+ 
excretion is absent.
Renal TRPM6 protein expression is unchanged in erlotinib-injected mice
As mice injected with Erlotinib develop a modest reduction in serum Mg2+, without appropriate 
compensation by the kidney, a possible effect could be on the expression level of TRPM6. Therefore, 
TRPM6 mRNA abundance was determined in the Erlotinib-and vehicle-injected mice. Chronic 
administration of Erlotinib caused a significant 0.67 fold decrease in the mRNA expression of
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TRPM6 (p<0.02, n=9) (Figure 3A). TRPM6 protein abundance was determined by semi­
quantification of fluorescence, from anti-TRPM6 immunolabeled kidney sections. However, using 
this method no change in TRPM6 fluorescence was found (p>0.5, n=9) (Figure 3B). As TRPM6 is 
abundantly expressed in colon, the main site for active Mg2+ absorption in the intestine, the effect of 
Erlotinib on colonic TRPM6 mRNA expression was investigated. No change in the abundance of 
colonic TRPM6 was observed between Erlotinib- and vehicle- injected mice (p>0.2, n=9) (Figure 
3C).
Figure 1. Effect of Erlotinib on serum Mg2+ and Ca2+ concentrations. A-B. Changes in serum Mg2+ and Ca2+
concentrations after 16 days, in mice receiving daily injections with Erlotinib or vehicle. C-D. Effect of 
Erlotinib or vehicle on serum Mg2+ and Ca2+ concentrations after 23 days. Values are presented as means ± 
SEM (n = 9). * p<0.05 is considered statistically significant.
Renal EGFR expression is increased in mice injected with erlotinib
To investigate whether changes in the renal EGF system were apparent after chronic 
administration of Erlotinib, renal mRNA expression of EGF and the EGFR was determined. A 1.6 
fold increase in the mRNA abundance o f the EGFR receptor was observed in Erlotinib-injected mice 
(p<0.05, n=9) (Figure 4A). Additionally, no change in renal mRNA expression of EGF was observed 
after injection of Erlotinib (p>0.05, n=9) (Figure 4B). To evaluate changes in the secretion of EGF 
after administration o f Erlotinib, the urinary excretion of EGF was measured in the experimental 
groups. No differences were observed in the total urinary excretion of EGF between vehicle- and 
Erlotinib-injected animals (Figure 4C). In addition, no changes were detected when the values were
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corrected for the urinary creatinine excretion (Figure 4D). As the colonic EGF system may be 
affected in a similar way, as observed in the kidney, the abundance of the EGFR and the EGF mRNA 
was investigated in samples extracted from colon. However, no differences in the colonic expression 
of the EGFR (p>0.5, n=9) (Figure 4E) and EGF (p>0.2, n=9) (Figure 4F) were detectable between 
vehicle- and Erlotinib-injected animals.
Figure 2. Functional data after 23 days of Erlotinib injections. A-B. Daily urinary excretion of Mg2+ and Ca2+ in 
mice injected with Erlotinib for 23 days. C. Creatinine clearance (estimated glomerular filtration rate) in 
Erlotinib- and vehicle- injected mice as well as D-E. the corresponding fractional excretions of Mg2+ (FEMg) 
and Ca2+ (FECa). Values are presented as means ± SEM (n = 9). *p<0.05 is considered statistically significant.
Supraphysio logica l concentra tions o f  erlo tin ib  are necessary to inh ib it TR P M ó channel ac tiv ity
HEK293 cells expressing TRPM6 were subjected to whole cell patch-clamp analysis. Using this 
technique a TRPM6 specific outward current was detectable. Pretreatment with Erlotinib alone did 
not significantly affect channel currents from controls (p>0.05). Application of EGF (10 nM) 
significantly increased channel activity compared to control (p<0.001) (Figure 5A-C). Pretreatment 
with Erlotinib (30 ^M) completely prevented the EGF-induced increase in TRPM6 current density 
(p<0.01). However, at lower Erlotinib concentrations (0.3 ¡aM), Erlotinib did not significantly inhibit 
EGF-stimulated TRPM6 channel currents (Figure 5A-C). Tyrosine phosphorylation of the 
immunoprecipitated EGFR was evaluated under the same experimental conditions as aforementioned 
(Figure 5D). In the presence of EGF, tyrosine phosphorylation of the immunoprecipitated receptor 
was markedly increased. Preincubation of HEK293 cells with Erlotinib at 30 ¡aM blunted the EGF- 
induced EGFR tyrosine phosphorylation. However, incubation with 0.3 ¡aM of Erlotinib was not 
sufficient to effectively block EGFR phosphorylation. Cells incubated in the absence of EGF showed 
no detectable tyrosine phosphorylation of the EGFR.
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Erlotinib inhibits EGF-stimulated mobility o f  endomembrane TRPM6
Fluorescence recovery after photobleaching (FRAP) was used to estimate the mobility and mobile 
fraction of GFP-tagged TRPM6 channels in HEK293 cells. The electrophysiological properties of 
GFP-TRPM6 have previously been shown be display comparable currents to that of wild-type 
TRPM6 in the presence or absence of EGF.[5] In line with this, an increase in the maximal recovery 
was found after EGF application (p<0.05) (Figure 6 D-E). Pretreatment with Erlotinib (at 30 ^M) 
prevented the EGF-stimulated increase in the mobile fraction of TRPM6 channels (p<0.05) (Figure 6 
D-E).
A Kidney C Colon
1 - 2 n
Control Erlotinib
Figure 3. Effect of Erlotinib on mRNA and protein abundance of TRPM6. A. Semi-quantitative real-time PCR 
was used to determine the abundance of TRPM6 mRNA extracted from kidney. B. Histogram depicting TRPM6 
protein abundance determined by computerized analysis of immunohistochemical images. Representative 
immunohistochemical pictures of TRPM6 in vehicle- and Erlotinib- injected mice. C. Semi-quantitative real­
time PCR determination of TRPM6 mRNA expression in colon. Data is presented as means ± SEM. *p < 0.05 
is considered statistically significant.
Discussion
The current study shows that Erlotinib is capable of affecting TRPM6 regulation and thereby 
altering Mg2+ handling. This conclusion is based on: i) mice receiving supraphysiological doses of 
Erlotinib for 23 days develop a decrease in their serum Mg2+ concentration; ii) Erlotinib-injected mice 
fail to reduce the fractional renal excretion of Mg2+ in response to a decreased serum Mg2+ 
concentration; iii) whole-cell patch clamp analysis in HEK293 cells shows that Erlotinib significantly 
inhibited EGF-stimulated TRPM6 channel activity.
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Figure 4. Erlotinib modulates EGFR mRNA expression. A-B. Semi-quantitative determination of the mRNA 
abundance of EGFR and EGF in kidney of vehicle and Erlotinib-injected mice. C-D. Measurements of urinary 
EGF excretion as well as the urinary EGF/creatinine ratio. E-F. Colonic mRNA abundance of EGFR and EGF. 
Data is presented as means ± SEM. *p < 0.05 is considered statistically significant.
Administration of 92 mg/kg Erlotinib (~2.3 mg/ 25 g mouse) intraperitoneally yielded a plasma 
concentration of approximately 40 ¡aM after 1 hr in mice [11]. A virtually identical dose was 
employed in our mice study (2 mg/mouse/day), thus we can expect similar plasma concentrations of 
Erlotinib. HEK293 cells received dosages in the same range (30 ¡aM of Erlotinib). Given the moderate 
effects o f Erlotinib in vivo, application of the compound could still block EGF-stimulated TRPM6 
currents and routing in HEK293 cells. This can possibly be explained by the bioavailability o f the 
compound. It has been estimated that 92-95% of the administered Erlotinib is bound to plasma
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proteins [12], thus the estimated free concentration in our mouse model would approximate 2-3 ^M, a 
dose that likely would impose less inhibition on EGF-stimulated TRPM6 activity in vitro.
Figure 5. EGFR blockade by Erlotinib can prevent EGF-induced changes in TRPM6 current density. A. Time 
course of the current development (pA/pF) at +80 mV of TRPM6 (■) transfected HEK293 cells, pretreated with 
EGF ( • )  and Erlotinib 30 pM (A ) or 0.3 pM (▼) B. Current recorded after 200 sec stimulation by a voltage 
ramp between -1CC and +1CC mV of TRPM6 transfected HEK293 cells (1), pretreated with EGF (2) or Erlotinib 
(3) alone, or pretreated with EGF and Erlotinib 30 pM (4) / 0.3 pM (5) C. Histogram summarizing the current 
density (pA/pF) at +80 of TRPM6 transfected HEK293 cells pretreated with EGF and/or Erlotinib as indicated. 
* indicates p < 0.01 compared to TRPM6 current (n=12-26 cells). # indicates P < 0.05 compared to TRPM6 
pretreated with EGF (n=12-26 cells). D. The immunoprecipitated EGFR was placed on Western blots for the 
detection of tyrosine phosphorylation (pTyr) as well as the EGFR itself. In addition, alpha-tubulin was detected 
in whole cell lysates as a control for total expression.
Individuals receiving a single standard dose o f Erlotinib (150 mg) show a maximal plasma 
concentration amounting to 2.65 ± 2.02 ¡aM (1.14 ¡Ag/ml) of the compound [12, 13], representing a 
~10 times lower circulating concentration than the mouse model. Given that the free circulating 
concentration o f Erlotinib is likely to be around 0.3 ¡aM in human patients, we tested whether this 
concentration would be able to block the effect of EGF on TRPM6 currents. However, we could not 
detect any significant differences from EGF-stimulated cells. Evaluating EGF-induced tyrosine 
phosphorylation of its receptor substantiated these data. At Erlotinib concentrations of 30 ¡aM, we 
were unable to detect any phosphorylation of the EGFR. At lower concentrations (0.3 ¡aM), 
resembling the free concentration found in humans receiving standard doses o f Erlotinib, EGFR 
phosphorylation was still present after application o f EGF. Previous studies show that Erlotinib 
inhibits ligand-stimulated tyrosine autophosphorylation of the EGFR, with a IC50 of approximately 20
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nM in cells. However, concentrations of at least a few hundred nM of Erlotinib are necessary to 
block more than 90% of the ligand-induced autophosphorylation [14, 15].
Figure 6. Erlotinib inhibits EGF-stimulated changes in the mobile fraction of TRPM6. A. Fluorescence 
recovery kinetics as a function of time, measured in HEK293 cells transiently transfected with GFP-TRPM6. 
Cells were pre-incubated with Erlotinib (30 |iM, 30 min) alone (A ) or prior to EGF application (10 nM, 30-60 
min, A), and compared to control (■) or EGF-treated cells (□). B. Histogram representing the maximal 
recovery of fluorescence (estimated mobile fraction) in HEK293 cells expressing GFP-TRPM6 with or without 
application of Erlotinib, EGF, or both. Data is presented as means ± SEM (n = 9). *p < 0.05 is considered 
statistically significant from control. #p<0.05 statistically significant from EGF-treated.
The results obtained in this study fits well with the previous observations. Taken together, these data 
indicate that Erlotinib treatment in human patients is unlikely to induce severe hypomagnesemia as 
observed with EGFR-directed antibodies. However, it remains unclear whether the cellular 
concentration of Erlotinib, namely that obtained in the DCT, is similar to what is observed in plasma.
Similarly, the bioavailability of monoclonal antibodies may explain why colorectal cancer patients
2+receiving Cetuximab show a pronounced decrease in serum Mg2+ concentrations; to such a degree that 
hypomagnesemia develops.
We also found that inhibition of Mg2+ transport by Erlotinib is likely to occur via inhibition of 
TRPM6 routing, by preventing EGF-mediated changes in the mobile fraction of TRPM6 proteins. 
After application of Erlotinib, the EGF-stimulated fraction of TRPM6 channels becomes 
unresponsive. As previously shown, EGF does not only increase the mobile fraction, but also 
increases the plasma membrane expression of the channel, suggesting that EGF exerts its effect by 
redistributing TRPM6 from storage vesicles to the membrane [5]. In the experimental animal, where 
physiological levels of EGF are present, blockade of the EGFR would be expected to retain a bigger 
fraction of TRPM6 channels in endomembrane compartments, thereby preventing plasma membrane 
trafficking and hence reduce Mg2+ influx. This hypothesis would also explain renal Mg2+ wasting, 
without concomitant changes in renal TRPM6 protein expression.
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EGFR inhibition by Erlotinib influences Mg2+ handling, by decreasing serum Mg2+ content, 
without providing a compensatory decrease in the fractional renal Mg2+ excretion. These data are in 
good agreement with those obtained from patients receiving Cetuximab, although less pronounced [6, 
7]. Thus, the kidney is not able to effectively compensate for the reduction in serum Mg2+ 
concentration. Accordingly, the data insofar support tubular Mg2+ wasting, as a potential source of 
reducing serum Mg2+ concentration or at least in keeping serum Mg2+ lowered. Systemic and renal 
Ca2+ homeostasis remained unaffected during administration of Erlotinib, suggesting that EGF does 
not directly affect Ca2+ handling. Thus the changes in renal Mg2+ handling correlate well with 
impaired distal tubular transport, where Mg2+ transport is mechanistically separated from that of Ca2+. 
Also, the lack of secondary changes in Ca2+, which often accompany perturbations in Mg2+ 
homeostasis, may be explained by the modest decline in serum Mg2+ concentration observed in 
Erlotinib-injected animals. This is confirmed in patients treated with Cetuximab, as the appearance of 
hypocalcaemia was limited to individuals presenting with at least grade 2 hypomagnesemia (serum 
Mg2+ between 0.5 to 0.4 mM).[7] The underlying cause of the secondary hypocalcemia during severe 
hypomagnesemia remains incompletely understood, although impaired release of PTH from the 
parathyroid gland and desensitization of bone to PTH is likely implicated [16, 17].
Despite a significant decrease in renal TRPM6 mRNA abundance, semi-quantitative comparison 
of TRPM6 immunofluorescence could not detect a difference in protein expression. These findings 
may be explained by the observation that TRPM6 is retained in endomembrane vesicles, leading to a 
decreased degradation of the protein. In such an event, mRNA expression would be expected reduced, 
as the protein is retained in the cell. In fact, in vitro findings in this study support this observation, i.e. 
impaired mobility of TRPM6 after EGF-stimulation in the presence of Erlotinib.
No change was observed in colonic TRPM6 mRNA abundance. Due to difficulties detecting 
TRPM6 immunohistochemically in the colon, it is not possible to confirm whether TRPM6 protein 
abundance remains unchanged. Moreover, it cannot be excluded whether Erlotinib inhibits EGF- 
stimulated TRPM6 trafficking in the colon, as we observe in HEK293 cells. However, it is currently 
not possible to effectively estimate Mg2+ uptake in the intact animal using tracers, due to the very 
short half-life of the radioactive 28Mg2+ isotope. In addition, one would expect an increased TRPM6 
expression in the colon during conditions of lowered serum Mg2+, an effect that is not observed here 
and elsewhere [3]. It is currently unclear how colonic Mg2+ absorption is regulated. An increase was 
found in the renal EGFR mRNA expression, while in the colon no such change could be detected. 
This response may indicate that particularly in kidney, the EGF axis is affected after Erlotinib 
treatment. Additionally, the EGF mRNA abundance remained unchanged in both organs. 
Measurements of EGF in the urine supported these findings, suggesting that EGF secretion is not 
altered in response to Erlotinib.
The current study is to our knowledge the first to delineate the effects o f Erlotinib on Mg2+ 
handling in vivo. Taken together, these findings suggest that Erlotinib can inhibit EGF-stimulated
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TRPM6 activity and consequently impair Mg2+ reabsorption in the kidney. Additionally, it provides 
an explanation about why hypomagnesemia has not been correlated with Erlotinib treatment in 
patients undergoing chemotherapy, as has been observed with Cetuximab. However, it should be 
noted that Erlotinib has the potential to modulate renal and systemic Mg2+ handling in vivo. Therefore, 
caution should be given when treating individuals prone to developing hypomagnesemia, and patients 
receiving combinational treatment with Mg2+ lowering compounds.
Material and methods
Experimental protocol- C57BL/6 mice (10 weeks old, n=18) received intraperitoneal injections 
with Erlotinib or vehicle for 23 days. The animals were kept in a light- and temperature-controlled 
room with ad libitum access to food and water. Erlotinib (Tarceva®, generously provided by Roche 
Diagnostics GmbH, Penzberg, Germany) was dissolved in 10% dimethyl sulfoxide in saline with
0.1% Pluronic P105 v/v as previously described [11]. The compound was delivered once daily at a 
dose of 2 mg/mouse/day. Controls received an identical vehicle solution. At day 16, blood was 
obtained by puncturing the vascular bundle located rear of the jawbone. During the last 24 hrs of the 
experimental period, mice were placed in metabolic cages and subsequently killed under 1.5% (v/v) 
isofluorane anesthesia (Nicholas Piramal Limited, London, United Kingdom). Blood was withdrawn 
by perforating the orbital vessels and serum was extracted afterwards. Additionally, organs were 
dissected out and immediately frozen in liquid nitrogen. One half kidney was processed for 
immunohistochemistry by immersion fixation in 2% w/v periodate-lysine-paraformaldehyde (PLP), 
followed by overnight incubation in 15% w/v sucrose. The animal ethics board of Radboud 
University Nijmegen approved all experimental procedures.
Analytical Procedures- Serum and urinary Mg2+ and Ca2+ concentrations were measured using a 
colorimetric assay kit according to the manufacturer’s protocol (Roche Diagnostics, Almere, the 
Netherlands). Urinary mouse EGF was measured by an enzyme-linked immunosorbent assay (R&D 
DuoSet® ELISA, DY2028, R&D systems Europe Ltd., United Kingdom). The wells were coated 
with anti-mouse EGF overnight, blocked with BSA (1 hour, room temperature) and washed with 
phosphate-buffered saline with 0.05% (v/v) Tween 20 (PBS-T). Urine samples and recombinant 
mouse EGF, used as standard (diluted in 0.5% (w/v) BSA), were added (2 hours, room temperature). 
After washing in PBS-T, biotinylated goat anti-mouse EGF was added, followed by horseradish 
peroxidase-conjugated streptavidin. Color was developed with OPD (o-Phenylenediamine) and 
stopped with H2SO4 (end concentration 0.33 M). Absorbance was measured at 492 nm (Varioskan, 
Thermo electron corporation, Waltham, USA); data were analyzed using SkanIt Software for 
Varioskan (Thermo electron corporation, Waltham, USA). Detection range of the ELISA was 
between 2-577 pg/ml.
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Semi quantitative Real-Time PCR Analysis- Tissue RNA was extracted using TriZol Total RNA 
Isolation Reagent (Life Technologies BRL, Breda, The Netherlands). After DNase treatment 
(Promega, Madison, WI), 1.5 ^g of RNA was reverse transcribed by Molony-Murine Leukemia 
Virus-Reverse Transcriptase (Invitrogen) as described previously [18]. The cDNA was mixed with 
Power SYBR® green PCR mastermix (Applied Biosystems, Foster City, CA, USA) and primers 
against TRPM6 (5'-AAAGCCATGCGAGTTATCAGC-3'; 5'-CTTCACAATGAAAACCTGCCC-3'), 
EGFR (5’- CAGAACTGGGCTTAGGGAAC-3’; 5’-GGACGATGTCCCTCCACTG-3’), EGF (5’- 
GAGAATCTACTGGACAGACAGTGG-3’; 5 ’-CTCGAGATTCTCTCCTGGATG-3’) or the 
housekeeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT; 5'- 
TTATCAGACTGAAGAGCTACTGTAATGATC-3'; 5'-
TTACCAGTGTCAATTATATCTTCAACAATC-3’). The mRNA expression levels were quantified 
using a single color real-time PCR detection system (MyiQ™, Biorad, Veenendaal, the Netherlands). 
Data analysis was carried out using the Relative Expression Software Tool (REST©[19]).
Immunohistochemistry- 7 ^m PLP fixed cryosections were prepared and stained with anti- 
TRPM6 (guinea pig antiserum), as described previously [4]. Photographs of TRPM6 staining in 
kidney cortex were taken trough a 25x objective on a Zeiss fluorescence microscope (Sliedrecht, The 
Netherlands) equipped with a digital photo camera (Nikon DMX1200). Semi-quantitative 
determination of TRPM6 protein expression was done using Image J (image processing program, 
NIH, USA), similar to previous publications [20].
Cell culture and transfection- Cells were maintained and transfected using Lipofectamine 2000 
(Invitrogen-Life Technologies, Breda, The Netherlands) as previously described [21]. Briefly, 
HEK293T cells were transiently transfected with a N-terminal HA-tagged TRPM6 in the 
pCINeo/IRES-GFP vector [4] for patch clamp analysis. HEK293 cells were transfected with TRPM6 
N-terminally conjugated to Green Fluorescent Protein (GFP) in the pCINeo vector [5] for FRAP 
analysis. Experiments were performed 48-72 h post-transfection. Cells were preincubated at 37°C in 
the presence or absence Erlotinib (30 ^M or 0.3 ^M) for 60 minutes. Cells were also incubated with 
or without EGF (10 nM) for 30 minutes.
Electrophysiology- Electrophysiological recordings were made as previously described [4, 5]. 
Briefly, whole-cell currents were determined in the tight seal whole-cell configuration using a patch 
clamp amplifier controlled by Patchmaster software (HEKA, Lambrecht, Germany). Cells were kept 
in an extracellular bath solution (150 mM NaCl, 10 mM HEPES/NaOH, 1 mM CaCl2, pH 7.4). 
Electrode resistances were between 2-4 MQ after filling with standard pipette solution (150 mM 
NaCl, 10 mM EDTA and 10 mM HEPES/NaOH, pH 7.2). Capacitance and access resistances were
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continuously monitored using the automatic capacitance compensation of the Patchmaster software. A 
linear voltage ramp protocol from -100 to +100 mV (within 450 ms) was applied every 2 s from a 
holding potential of 0 mV. Extracting the current amplitudes at +80 and -80 mV from individual ramp 
current records assessed the temporal development o f membrane currents. Current densities presented 
were determined by normalizing the current amplitude to the cell membrane capacitance. All 
experiments were performed at room temperature. The analysis and display of patch clamp data were 
performed using Igor Pro software (WaveMetrics, Lake Oswego, USA).
Western blotting and immunoprecipitation- HEK293T cells were incubated with EGF and 
Erlotinib as described above. Immunoprecipitation and western blotting was performed as previously 
described.[22] Briefly, cells were incubated in lysis buffer (150 mM NaCl, 25 mM Tris/HCL pH=7.5, 
1% Brij97 (Polyethylene Glycol Monooleyl Ether), 5 mM EDTA/NaOH pH=8.0, 1 mM Na3VO4, 1 
mM NaF, 1 mm phenylmethylsulfonyl fluoride, 1 ^g/ml leupeptin, 1 ^g/ml aprotinin, 1 ^g/ml 
pepstatin) and spun down at 1000 g for 10 min at 4°C. Lysates were incubated overnight with anti- 
EGFR directed mouse antibodies (sc-120, Santa Cruz Biotechnology, CA, UAS) coupled to protein 
A-Sepharose beads. Immunoprecipitates were run on SDS-PAGE gels and blotted onto membranes 
for detection of tyrosine phosphorylation (4G10, Millipore, MA, USA) and EGFR abundance (sc-03, 
Santa Cruz Biotechnology). Alpha-tubulin was detected in whole cell lysates and used as a 
housekeeping control (T6199, Sigma Aldrich, Zwijndrecht, the Netherlands).
Fluorescence recovery after photobleaching (FRAP)- The experiments were performed 
essentially as described previously [5]. GFP-TRPM6 expressing HEK293 cells were plated onto glass 
Petri dish chambers (0.17 mm thick Wilco Wells, USA) and mounted on a confocal laser-scanning 
microscope (Zeiss LSM 510). Cells were kept in a standard solution (130 mM NaCl, 20 mM 
HEPES/Tris, 5 mM KCl, 5 mM glucose, 1 mM CaCl2 , 1 mM MgCl2 , pH 7.4). After defining two 
regions of interest (ROI) and subsequent recording two base-line fluorescence measurements, 
irreversible photobleaching of one ROI was initiated. Following photobleaching, fluorescence of both 
ROI’s was measured over a 4 min period. Recovery in fluorescence was calculated from baseline 
measurements. The unbleached ROI was used to correct for photobleaching induced by image 
acquisition. The FRAP data was fitted by nonlinear regression analysis using previously published 
equations [23]. Between 14-16 cells were measured in each experimental condition.
Statistical analysis- Values are presented as means ± SEM. Comparisons between two groups 
were made using an unpaired t-test. Statistical significance was determined by ANOVA in the patch 
clamp and FRAP experiments. p<0.05 is considered statistically significant.
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A missense mutation in the Kv1.1 voltage-gated 
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to human autosomal dominant hypomagnesemia
1* 1* 2 2 3Jenny van der Wijst , B o b  G l a u d e m a n s  , R o s a n a  H .  S c o l a  , P a u l o  J .  L o r e n z o n i  , A n g e l i e n  H e i s e r  
A n n e M i e t e  W .  v a n  d e r  K e m p 1, N i n e  V .  K n o e r s 3, J o o s t  G . J .  H o e n d e r o p 1, R e n é  J . M .  B i n d e l s 1
*  c o n t r i b u t e d  e q u a l l y  t o  t h i s  w o r k
d e p a r t m e n t  o f  P h y s i o l o g y ,  R a d b o u d  U n i v e r s i t y  N i j m e g e n  M e d i c a l  C e n t r e ,  N i j m e g e n ,  T h e
N e t h e r l a n d s  
H o s p i t a  
B r a z i l  
n i v e r s i t  
N e t h e r l a n d s
2N e u r o m u s c u l a r  D i s o r d e r s  D i v i s i o n ,  C l i n i c a l  l ,  P a r a n a  F e d e r a l  U n i v e r s i t y ,  C u r i t i b a ,  P a r a n a ,
3
D e p a r t m e n t  o f  H u m a n  G e n e t i c s ,  R a d b o u d  U y  N i j m e g e n  M e d i c a l  C e n t r e ,  N i j m e g e n  , T h e
J  Clin Invest 119:936-942, 2009

Kv1.1 linked to autosomal dominant hypomagnesemia
Primary hypomagnesemia forms a heterogeneous group of disorders characterized by renal or 
intestinal magnesium (Mg2+) wasting, resulting in tetany, cardiac arrhythmias, and seizures. The 
kidney plays an essential role in maintaining blood Mg2+ levels with a prominent function for the 
Mg2+-transporting channel TRPM6 in the distal convoluted tubule (DCT). In DCT, Mg2+ reabsorption 
is an active transport process primarily driven by the negative potential across the luminal membrane. 
Here, by use of a positional cloning approach in a family with isolated autosomal dominant 
hypomagnesemia we identified a N255D mutation in KCNA1, a gene encoding the voltage-gated 
potassium (K+) channel Kv1.1. Patch clamp analysis showed that the mutation results in a non­
functional channel with a dominant negative effect on wild-type Kv1.1 channel functioning. Cell 
surface biotinylation experiments demonstrated that wild-type Kv1.1, Kv1.1 N255D and combinations 
hereof were able to reach the plasma membrane in similar amounts. Furthermore, Kv1.1 is expressed 
in the kidney, where it co-localizes with the Mg2+-permeable channel TRPM6 along the luminal 
membrane of DCT. Thus, Kv1.1 is a renal K+ channel that establishes a favorable luminal membrane 
potential in DCT cells to control the TRPM6-mediated Mg2+ reabsorption.
Introduction
Occurrence of hypomagnesemia (serum Mg2+ levels below 0.70 mM) in the general population 
has been estimated around 2%, while hospitalized patients are more prone to develop 
hypomagnesemia (12%) [1]. Recent studies of intensive care patients have even estimated frequencies 
as high as 60% [2]. The blood Mg2+ concentration depends on the renal Mg2+ excretion in response to 
altered uptake by the intestine. Hence, the kidney is essential for the maintenance of the Mg2+ balance 
[3]. The majority of filtered Mg2+ is reabsorbed along the proximal tubule and the thick ascending 
limb of Henle’s loop via a passive paracellular pathway [4]. However, fine-tuning of Mg2+ excretion 
occurs in the distal convoluted tubule (DCT) in an active transcellular fashion initiated by the Mg2+- 
permeable Transient Receptor Potential Melastatin subtype 6 channel (TRPM6) [5, 6]. Since the 
extra- and intracellular Mg2+ concentration are both in the millimolar range, it has been hypothesized 
that the membrane potential across the luminal membrane acts as the primary driving force for Mg2+ 
entry via TRPM6 [6, 7]. Previously, genetic studies in families with hereditary renal Mg2+ wasting 
syndromes revealed several new genes involved in Mg2+ homeostasis, including tight junction 
proteins claudin 16 and 19 [8, 9], the thiazide-sensitive sodium chloride cotransporter (NCC) [10], the 
y-subunit of the Na+,K+-ATPase (FXYD2) [11], TRPM6 [12, 13] and the recently discovered 
magnesiotropic hormone epidermal growth factor (EGF) [14]. Despite these discoveries, our 
knowledge of renal Mg2+ handling remains far from complete.
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Results
A heterozygous KCNA1 A763G mutation is causative fo r  hypomagnesemia
Here, we identified a large Brazilian family (46 family members of which 21 affected) with 
autosomal dominant hypomagnesemia (Fig. 1A). Affected individuals showed low serum Mg2+ levels 
(< 0.40 mM, normal range 0.70-0.95 mM), while their urinary Mg2+ excretion was normal, suggesting 
impaired tubular Mg2+ reabsorption. The phenotype of the proband (IV-3, Fig. 1A) starting from 
infancy consists of recurrent muscle cramps, tetanic episodes, tremor and muscle weakness, especially 
in distal limbs.
Figure 1. Heterozygous KCNA1 A763G mutation causes isolated hypomagnesemia. A. Pedigree with 5 
generations (I-V) of a Brazilian family with autosomal dominant hypomagnesemia. Affected family members 
are depicted in black, male and female members are shown as squares and circles, respectively. A diagonal line 
indicates that the individual is deceased. The light gray number indicates individuals included in the STS 
mapping. B. A 10K SNP array-based haplotyping approach was performed that showed linkage to a 14,3 cM 
region between SNP rs717596 and rs252028 on the short arm of chromosome 12. This region was confirmed 
and narrowed down with STS markers to a 11,6 cM region between markers D12S1626 and D12S1623 
containing 31 genes, including the KCNA1 gene. C. Mutation analysis of KCNA1 revealed a heterozygous 
A763G missense mutation in affected individual III-1. KCNA1 encodes the voltage-gated potassium channel 
Kv1.1 where the observed mutation results in a N255D amino acid substitution (underlined). D. Multiple 
alignment analysis shows conservation of the N255 amino acid (gray bar) among species and Kv1 family 
members. Mutated amino acids in other families with the Kv1.1 genotype are depicted as dark gray dots [16­
19]. Gray and black colored letters represent conserved and non-conserved amino acids, respectively. E. 
Schematic representation of the Kv1.1 channel that consists of a voltage sensor in transmembrane segment S4 
and a pore forming region (S5 and S6). Localization of the newly identified N255D mutation is denoted by the 
light gray dot, while other nearby mutations are indicated by dark gray dots.
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A single nucleotide polymorphism (SNP)-based linkage analysis identified a 14.3 cM locus on the 
short arm of chromosome 12 (Fig. 1B) which was subsequently narrowed down by fine mapping with 
microsatellite markers to an 11.6 cM region containing 31 genes between the markers D12S1626 and 
D12S1623 (maximum multipoint LOD score 3.0) (Fig. 1B; Fig. 2). Other genes previously associated 
with hypomagnesemia are located outside this critical region and therefore excluded as a candidate 
gene in our family. From the identified locus we sequenced KCNA1 and identified a heterozygous 
mutation A763G (Fig. 1C) in the affected individual III-1 (Fig. 1A) that co-segregates with the 
disorder and was absent in 100 control chromosomes (data not shown). KCNA1 encodes the Shaker- 
related voltage-gated K+ channel Kv1.1 in which the identified mutation causes substitution of the 
highly conserved asparagine at position 255 for an aspartic acid (N255D) (Fig. 1D). The predicted 
amino acid topology of Kv channels shows six transmembrane spanning a-helical segments (S1-6), 
with the S4 segment acting as the voltage-sensor and a hydrophobic pore region between S5 and S6 
(Fig. IE) [15]. The newly identified N255D mutation is positioned in the third transmembrane segment 
(S3) close to the voltage sensor (Fig. IE).
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Figure 2. Haplotype analysis of the autosomal dominant hypomagnesemia locus on the short arm of 
chromosome 12 in the Brazilian family. Affected family members are shown in black; circles and squares refer 
to female and male individuals, respectively. A diagonal line indicates that the individual is deceased. 
Microsatellite markers are depicted on the left. The haplotypes are illustrated by different colors. The brown 
haplotype co-segregates with the disease. Critical recombinations are pinpointed by arrowheads (►) in 
individuals III-7 (telomeric) and IV-16 (centromeric). KCNA1 is located within the critical region between 
markers D12S1725 and D12S99 (black bar).
Localization o f  Kv1.1 in the DCT o f  the kidney
So far, all proteins implied in familial hypomagnesemia, have been shown to be expressed in 
kidney underlining the pivotal role of this organ in body Mg2+ homeostasis. To study the (sub)cellular
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localization of Kv1.1 in kidney, we used a rabbit polyclonal antibody raised against the Kv1.1 
channel. Immunopositive staining was observed along the luminal membrane of distinct tubules 
present in the superficial cortex of the mouse kidney (Fig. 3). Using serial kidney sections, we 
demonstrated that Kv1.1 co-localizes with the epithelial Mg2+ channel TRPM6 in DCT (Fig. 3A). To 
confirm this localization we co-stained kidney sections for Kv1.1 and calbindin-D28K, showing a 
partial overlap in Kv1.1 and calbindin-D28K expression (Fig. 3B). This pattern can be explained by 
earlier observations that calbindin-D28K, besides in DCT, is also expressed in connecting tubule 
(CNT) [20], confirming that Kv1.1 is localized primarily in DCT. Indeed, co-staining between Kv1.1 
and aquaporin-2 (AQP2), a marker for CNT and the collecting duct, was not observed (Fig. 3C). 
These findings support the restricted localization of Kv1.1 in the Mg2+-transporting DCT segment of 
the kidney.
A B C
Figure 3. Immunohistochemical analysis of Kv1.1 in kidney. A. Staining for Kv1.1 and TRPM6 of mouse serial 
kidney sections (right panels, overview of a cortical region; left panels, magnified images of immunopositive 
tubules). The asterisks indicate the same distal tubules on serial sections intensively stained for Kv1.1 and 
TRPM6. B. Mouse kidney sections were co-stained for Kv1.1 and calbindin-D28K (lower panels, 
immunopositive tubules; upper panel, merged DIC (differential interference contrast) image). C. Co-staining of 
Kv1.1 and aquaporin-2 in mouse kidney sections (lower panels, immunopositive tubules; upper panel, merged 
DIC image). Abbreviations used: G, glomerulus; DCT, distal convoluted tubule; CNT, connecting tubule; 28K, 
calbindin-D28K; AQP2, aquaporin-2. Bar denotes the indicated magnification.
K v l.l  N255D results in non-functional channels with dominant negative effect on wild-type channel 
function
To determine the effect of the Kv1.1 N255D mutation on channel activity, Human Embryonic 
Kidney 293 (HEK293) cells were transiently transfected with mock, wild-type Kv1.1 and/or Kv1.1 
N255D. Using the whole-cell patch clamp technique, outward K+ currents were measured by dialyzing 
the cells with a pipette solution containing 140 mM K+. Cells expressing wild-type Kv1.1 channels 
produced typical delayed rectifying currents, while Kv1.1 N255D -expressing HEK293 cells showed 
small currents similar to mock-expressing cells (Fig. 4A,B). Considering the autosomal dominant 
inheritance in our family, a potential dominant negative effect was investigated by co-transfection of
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equal amounts of plasmid DNA encoding wild-type Kv1.1, Kv1.1 N255D or mock in HEK293 cells. 
The K+ current amplitude in HEK293 cells co-expressing wild-type Kv1.1 and Kv1.1 N255D was 
significantly reduced compared to cells expressing wild-type Kv1.1 alone or co-expressing wild-type 
Kv1.1 and mock (P < 0.05) (Fig. 4C). Next, the influence of Kv1.1 N255D expression on the amount 
of Kv1.1 channels at the plasma membrane was examined by cell surface biotinylation experiments. 
As shown in Fig. 4D, co-expression of wild-type Kv1.1 and Kv1.1 N255D in HEK293 cells did not 
affect the plasma membrane localization of Kv1.1 channels. Of note, Kv1.1 was equally expressed in 
all conditions as analyzed in the total cell lysates (Fig. 4D, bottom panel). Kv1.1 channels are 
composed of four subunits and this result suggests that similar amounts of both homotetrameric 
channels wild-type Kv1.1 and Kv1.1 N255D, and heterotetrameric channels composed of wild-type 
Kv1.1 with Kv1.1 N255D are located at the plasma membrane.
Kv1.1 regulates TRPM6 M g2+ influx by setting the membrane potential
Since Kv1.1 and TRPM6 are present in the same nephron segment, we investigated by which 
mechanism Kv1.1 controls Mg2+ influx through TRPM6. We studied the potential direct effect of 
Kv1.1 on TRPM6 activity by patch clamp analysis. To this end, TRPM6 (1.0 ^g) was co-transfected 
with mock (0.1 ^g), wild-type Kv1.1 (0.1 ^g) or Kv1.1 N255D (0.1 ^g) in HEK293 cells. The 
TRPM6-mediated Na+ currents between the three experimental conditions were virtually identical 
(Fig. 4E). Subsequently, the current clamp mode o f the patch clamp technique was used to measure 
the membrane potential of HEK293 cells expressing wild-type Kv1.1 or Kv1.1 N255D. A significant 
hyperpolarization (P < 0.05) was observed in wild-type Kv1.1-expressing HEK293 cells (-39±3 mV, 
n=9) compared to mock or Kv1.1 N255D -expressing cells (-3±1 mV, n=7, and -8±2 mV, n=7, 
respectively). Dendrotoxin K (DTX-K, 10 nM), a specific Kv1.1 channel blocker, significantly 
depolarized the membrane potential in wild-type Kv1.1-expressing cells (from -39±3 mV to -14±2 
mV, n=8, P < 0.05) (Fig. 4F). The membrane potential of mock or Kv1.1 N255D -expressing cells was 
not affected by DTX-K application (Fig. 4F). Furthermore, co-transfection of wild-type Kv1.1 and 
Kv1.1 N255D resulted in an intermediate hyperpolarization compared to the cells expressing only 
wild-type Kv1.1 (-23±1 mV vs. -39±3 mV, respectively, n=15, P < 0.05). These results suggest that 
the Kv1.1 N255D channel diminishes the negative membrane potential compared to the normal 
situation.
Discussion
In this study, we identified a large Brazilian family with autosomal dominant hypomagnesemia. 
Affected individuals showed low serum Mg2+ levels, while serum K+ and Ca2+ levels, and urinary 
Ca2+ excretion were not affected, which is distinct from previously described forms o f inherited 
hypomagnesemia. For example, families bearing a mutation in claudin 16 and 19 (Familial
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Hypomagnesemia with Hypercalciuria and Nephrocalcinosis; OMIM 248250) are hypercalciuric, 
while mutations in FXYD2 (Isolated Dominant Hypomagnesemia (IDH); OMIM 154020) and 
TRPM6 (Hypomagnesemia with Secondary Hypocalcemia; OMIM 602014) result in hypocalciuria 
and hypocalcemia, respectively.
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Figure 4. Electrophysiological analysis of mock, wild-type Kv1.1 (Kv1.1 WT) or Kv1.1 N255D transfected 
HEK293 cells. A. Representative original traces of outward K+ currents of mock (•), Kv1.1 WT (□), Kv1.1 
N255D (A), or Kv1.1 WT and mock (^ )  elicited by voltage steps from -100 to +50 mV in 10 mV increments, 
applied from a holding potential of -80 mV, every 10 s. B. The I-V relationships of mock (• , n=5), Kv1.1 WT 
(□, n=11), Kv1.1 N255D (A, n=10), Kv1.1 WT and mock (^ ,  n=9); C. Histogram presenting averaged current 
densities at +50 mV of mock (n=5), Kv1.1 WT (n=11), Kv1.1 WT and mock (n=9), Kv1.1 WT and Kv1.1 
N255D (n=9), and Kv1.1 N255D (n=10). Asterisk indicates significance (P < 0.05) compared to mock while hash 
indicates significance (P < 0.05) compared to Kv1.1 WT. D. Cell surface biotinylation of mock, Kv1.1 WT, 
Kv1.1 WT and mock, Kv1.1 WT and Kv1.1 N255D, and Kv1.1 N255D transfected HEK293 cells. Kv1.1 
expression was analyzed by immunoblotting for plasma membrane fraction (PM) and input from the total cell 
lysates (IP). Representative immunoblot of four independent experiments is shown. .E. Histogram presenting 
averaged current densities at +80 mV after 200 s of TRPM6 and mock (n=26), TRPM6 and Kv1.1 WT (n=26), 
and TRPM6 and Kv1.1 N255D (n=25). F. Membrane potential of mock, Kv1.1 WT and Kv1.1 N255D upon acute 
application of Dendrotoxin K (DTX-K, 10 nM), measured in current clamp mode of whole-cell patch clamp 
configuration. Representative recordings of eight independent experiments are shown. The error bars denote 
SEM.
Furthermore, patients with Gitelman Syndrome (GS; OMIM 263800), caused by mutations in 
NCC, suffer from hypomagnesemia, hypocalciuria and hypokalemia. The phenotype in the proband 
starting from infancy consists of recurrent muscle cramps, tetanic episodes, tremor and muscle 
weakness, especially in distal limbs. Serum electrolyte levels were measured during severe attacks of 
cramps and tetany in two affected family members (proband V-3; V-2), with serum Mg2+ levels of
0.37 and 0.25 mM, respectively, while Ca2+ and K+ concentrations were normal. As a result, all
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affected family members received a daily dose of magnesium chloride. Importantly, the proband was 
recently hospitalized because of a sudden episode of facial myokymia, tremor, severe muscle spasms, 
muscular pain, cramps, muscular weakness and tetanic contraction episodes, all of which improved 
shortly after intravenous magnesium treatment. This observation further confirmed that the observed 
symptoms are a consequence of the low serum Mg2+ levels.
pro-urine blood
Figure 5. Schematic model of the Mg2+-reabsorbing DCT cell in the kidney. Mg2+ uptake from the pro-urine via 
the epithelial Mg2+ channel TRPM6 is primarily driven by the negative potential across the luminal membrane. 
This luminal membrane potential is maintained by an apical K+ efflux via Kv1.1 energized by the action of the 
Na+,K+-ATPase. At the basolateral membrane, Mg2+ extrusion to the blood side occurs via an unknown 
mechanism. The identified N255D mutation results in a non-functional Kv1.1 channel and thereby decreases the 
driving force for Mg2+ influx, thus resulting in renal Mg2+ wasting.
By use o f a positional cloning approach we revealed a heterozygous mutation in KCNA1, 
encoding the voltage-gate potassium channel Kv1.1, by which the asparagine at amino acid position 
255 was converted into an aspartic acid (N255D). Remarkably, the Kv1.1 N255D genotype causes 
hypomagnesemia, whereas mutations in KCNA1 thus far have been shown to result in episodic ataxia 
type 1 (EA1). Fig. 1D/E shows the previously identified mutations in close proximity to the N255D 
mutation [16-19, 21, 22]. EA1 is a dominant human neurological disorder presumably caused by 
defective Kv1.1 in the cerebellum. Furthermore, abnormal Kv1.1 activity originating in the distal 
motor axons results in muscle hyperactivity, indicative for myokymia [23, 24]. In addition to the 
classical description of this disorder, phenotypic variants include EA1 with partial epilepsy [17, 21], 
EA1 without myokymia [22], and isolated neuromyotonia [17]. We also analyzed the affected 
members o f our Brazilian family for episodic ataxia. On a cerebral MRI of the proband we obtained 
evidence of a slight atrophia of the cerebral vermis (data not shown). Furthermore, electromyographs 
of some affected members showed myokymic discharge in line with the previously observed mixed
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phenotype (data not shown). Now, we present hypomagnesemia as a new phenotypic characteristic 
associated with a mutation in KCNA1. Thus, it would be highly interesting to perform in the near 
future a large-scale phenotypical characterisation of patients with identified mutations in the KCNA1 
gene including neurological description, serum Mg2+ levels and functional analysis of the 
corresponding Kv1.1 mutations.
Previously, genetic studies in familial hypomagnesemia revealed several new proteins with a 
predominant expression in kidney underlining its involvement in Mg2+ homeostasis. Our 
immunohistochemical data clearly demonstrated localization of Kv1.1 along the luminal membrane of 
TRPM6-expressing DCT cells consistent with a potential link between Kv1.1-mediated K+ secretion 
and Mg2+ influx by TRPM6. Therefore, we assessed the role of Kv1.1 in controlling Mg2+ influx 
through TRPM6. Electrophysiological analysis of wild-type Kv1.1 and Kv1.1 N255D revealed that the 
mutation results in a non-functional Kv1.1 channel. Kv1.1 channels consist of four subunits arranged 
symmetrically around an aqueous pore, forming a so-called tetrameric structure [25, 26]. It has been 
shown that Kv1.1 channel subunits can assemble with other Kv channel subunits to form 
heterotetramers [27]. Importantly, hypomagnesemia in the Brazilian family is inherited in an 
autosomal dominant manner and patients with the N255D mutation are heterozygous. Expression of 
both alleles likely results in the formation of heterotetrameric channels composed of wild-type and 
mutated channel subunits leading to a dominant negative effect by the Kv1.1 N255D subunit, as shown 
in this study. The mutation replaces a neutral amino acid (asparagine) by one with an acidic side- 
chain (aspartic acid), which may destabilize the secondary or tertiary channel structure and thereby 
channel formation or trafficking. However, we demonstrated that wild-type Kv1.1 channels, Kv 1. 1 
N255D channels, and the combination hereof are expressed in equal amounts at the plasma membrane.
Considering the striking localization of Kv1.1 in the TRPM6-expressing distal convoluted 
tubules, we investigated a potential direct functional effect of Kv1.1 on TRPM6 activity. However, 
wild-type Kv1.1 nor Kv1.1 N255D altered the TRPM6-mediated Na+ currents and it is, therefore, 
unlikely that Kv1.1 directly regulates the activity of the Mg2+-permeable channel TRPM6. Mg2+ is 
actively reabsorbed in the DCT. Here, Mg2+ influx through TRPM6 is driven by a favorable 
membrane voltage [6, 7]. This membrane potential is maintained by a so far unidentified apical K+ 
efflux pathway, while the K+ gradient is provided by the basolaterally localized Na+,K+-ATPase. 
Previously, a mutation in the Na+,K+-ATPase ysubunit was shown to be the underlying cause for 
autosomal dominant renal Mg2+ wasting and secondary hypocalciuria [11]. Interestingly, K+ efflux 
through K+-permeable channels primarily determines the resting membrane potential. Kv channels are 
widely expressed in excitable and non-excitable cells, where they play an essential role in the 
establishment of the electrical properties of the cell, instrumental for many processes [28]. By use of 
the current clamp mode of the patch clamp technique we demonstrated that Kv1.1 significantly 
hyperpolarizes the plasma membrane compared to mock or Kv1.1 N255D -expressing cells. This effect 
was reversible by DTX-K, a specific Kv1.1 channel blocker, confirming the involvement of Kv1.1 in
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setting the negative membrane potential. We now hypothesize that the voltage-gated Kv1.1 channel is 
responsible for the establishment of the negative membrane potential across the luminal membrane of 
the DCT cell. The N255D mutation leads to depolarization of the luminal membrane, notably 
diminishing the driving force for Mg2+ uptake from the pro-urine (Fig. 5).
In conclusion, a new direct coupling between K+ secretion and active Mg2+ reabsorption is 
disclosed by this study, which is highlighted by our discovery of the N255D mutation in the KCNA1 
gene in autosomal dominant hypomagnesemia. The encoded K+ channel Kv1.1 co-localizes with the 
Mg2+ influx channel TRPM6 along the luminal membrane of DCT, the main site of active renal Mg2+ 
reabsorption. Kv1.1 channels harboring the N255D mutation show close to background currents 
impairing their ability to set a favorable membrane potential facilitating TRPM6-mediated Mg2+ 
influx. These findings will open a new window for other studies on the interrelationship of renal K+ 
and Mg2+ disturbances.
Material and methods
Subjects- We identified a large family (46 family members, 21 affected) with autosomal dominant 
hypomagnesemia (Fig 1A). Phenotype in the proband (IV-3) starting from infancy; recurrent muscle 
cramps, tetanic episodes, tremor and muscle weakness, especially in distal limbs. There were no 
seizures, recurrent urinary tract infections, polyuria, polydipsia and renal stones. At 4 years, a 
significant hypomagnesemia (0.37 mM; normal 0.70-0.95 mM) was determined. Serum K+ (3.9 mM; 
normal 3.5-5.0 mM), Ca2+ (2.35 mM; normal 2.15-2.50 mM), sodium, phosphate, uric acid, 
bicarbonate, urea, creatinine, glucose, bilirubin, aminotransferases, alkaline phosphate, lactate 
dehydrogenase were all normal. Urinary creatinine clearance, urinary Mg2+ excretion (2.8 mmol/24h; 
normal 2.1-6.2 mmol/24h) and Ca2+ excretion were also normal. The patient received a daily dose of 
magnesium chloride, which improved muscular weakness, but slight muscle cramps persisted 
particularly after physical activity. One of her younger brothers (IV-1, Fig. 1A) died in infancy by a 
severe attack of cramps and tetany. At that time the serum Mg2+ level was as low as 0.28 mM. In 
addition to these two patients 18 other family members had shown similar clinical manifestations and 
biochemical features. The proband was tested for signs of cerebellar dysfunction, and admitted to 
have experienced several periods of uncertainty in walking, where she was not able to walk straight. 
Objective clinical signs of cerebellar dysfunction, including nystagmus, multistep or overshoot 
saccades, dysmetria in the finger-nose test, and decomposition of movement of the legs on heel-to- 
shin test, were absent. However, on a cerebral MRI of the proband we found evidence of slight 
atrophia of the cerebral vermis (data not shown). Furthermore, electromyographs of some affected 
members showed myokymic discharge in line with the previously observed mixed phenotype. We 
collected blood samples of the family members (both affected and non-affected; Fig.1A) for linkage 
analysis. Subsequently, DNA was extracted according to standard protocols. Control genomic DNA
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samples (n=100) were kindly provided by Dr. H. van Bokhoven (Department of Human Genetics, 
Radboud University Nijmegen Medical Centre, The Netherlands). The study was approved by the 
Clinical Hospital, Parana Federal University (Curitiba, Parana, Brazil) and written informed consent 
was obtained from the subjects.
Genetic linkage analysis- A genome-wide linkage approach was performed for 12 family 
members selected based on simulations in SLINK using the Affymetrix GeneChip® mapping 10K 2.0 
Array harboring 10,204 SNPs. Sample preparation and hybridization was performed according to the 
manufacturer’s protocol (Affymetrix, Inc., Santa Clara, CA, USA) [29]. Briefly, 250 ng o f genomic 
DNA was digested using 10 units Xbal (Westburg, Leiden, The Netherlands) followed by ligation 
using T4 DNA ligase (Westburg) of universal adaptors to the digested products. Primers 
complementary to the adaptors were used for amplification of the digested products. After 
purification of the products using MinElute™ plates (Qiagen, Venlo, The Netherlands) a 
fragmentation was performed on 20 ^g purified PCR product. Fragmented products were end-labeled 
and hybridized to the Affymetrix 10K GeneChip® overnight. Hybridized arrays were washed and 
stained using the Fluidics Station 400 (Affymetrix). The GeneChip® Scanner 3000 was used to scan 
the hybridized arrays. Automatic SNP calls were generated using GeneChip DNA analysis software 
(GDAS; Affymetrix). SNP calls are AA or BB for homozygous SNPs, AB for heterozygous SNPs. 
When the software was unable to make a call (AA, BB or AB), the SNP was scored as No Call. LOD 
scores were calculated using Merlin software (www.sph.umich.edu/csg/abecasis/Merlin/index.html). 
Eight microsatellite markers (D12S1626, D12S1725, D12S99, D12S374, D12S1623, D12S336, 
D12S77 and D12S89) were selected to fine-map the newly identified hypomagnesemia loci on the 
short arm of chromosome 12 (http://genome.ucsc.edu/cgi-bin/hgGateway). Marker analysis using 
fluorescently labeled primers was performed according to the protocol for the LMS-MD10 version 
2.5 (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Reactions for each marker were 
performed separately, with products being pooled into size and label specific sets before typing. 
Markers were typed on an ABI 3730 DNA analyzer (Applied Biosystems) using GeneMapper 4.0 
software (Applied Biosystems). Allele binning was performed with the Excel 2000 (Microsoft, 
Redmond, USA) macro Linkage-designer developed by van Camp and coworkers[30], and we 
checked Mendelian inheritance of alleles with PedCheck 1.0 software (http://watson.hgen.pitt.edu) 
[31]. Multipoint LOD score and haplotype analysis was performed with GeneHunter, version 2.1 
release 5, in the easyLINKAGE software package[32] and Haplopainter software 
(haplopainter.sourceforge.net/html/index.html).
Mutation analysis- From the critical region, we selected the KCNA1 gene for mutation analysis, 
using the UCSC genome browser database (http://genome.ucsc.edu/). DNA amplification reactions 
were performed in a thermal cycler with heated lid (MJ Research, PTC-200). The KCNA1 exon
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sequence and flanking regions were amplified from genomic DNA of individual III-1 (Fig. 1A) using 
multiple overlapping primer sets based on GenBank accession code BC101733 (Table 1). PCR 
products of correct sizes were selected by DNA agarose gel electrophoresis, following excision and 
subsequent purification with GenElute™ Gel Extraction Kit (Sigma-Aldrich) according to 
manufacturer’s protocol. The fragments were sequenced on both strands by use of the ABI PRISM Big 
Dye Terminator Cycle Sequencing V2.0 Ready Reaction kit and the ABI PRISM 3730 DNA analyzer 
(Applied Biosystems).
Table 1. Overview o f primers sets
Primer sequence 
Forward (5’-3’) Reverse (5’-3’)
KCNA1 set 1 GAGGGGGATTCCAAACTGAG AACTTCTCCATGGCCTCCTC
KCNA1 set 2 GTACTTCTTCGACCGCAACC CCCAGCGTGATGAAATAAGG
KCNA1 set 3 CCCTTCTTCATCGTGGAAAC AGCAACTGAGCCTGCTCTTC
KCNA1 set 4 GACAAT TGGAGG CAAGAT C G CCCAAAATCCTCAATGCAAC
These primer sets, overlapping the human KCNA1 coding region, were used for mutation analysis based on 
GenBank accession code BC101733.
Immunohistochemistry- Immunohistochemistry was performed as previously described [33]. In 
short, either co-immunohistochemical staining or staining of serial sections for Kv1.1 with TRPM6, 
calbindin-D2 8K and AQP2, was performed on 7-^m sections of fixated frozen mouse kidney samples. 
The mouse kidney cryosections were incubated for 16 hr at 4°C with the primary antibodies: rabbit 
anti-Kv1.1 (1:300) (Alamone #APC-009), guinea pig anti-TRPM6 (1:1000) [6], guinea pig anti- 
AQP2 (1:1000) (kindly provided by dr. P.M.T. Deen), and mouse anti-calbindin-D2 8K (1:750) [34]. 
For detection of calbindin-D2 8K and AQP2, sections were incubated with Alexa-conjugated secondary 
antibodies. The tyramide signal amplification kit (NEN Life Science Products, Zaventem, Belgium) 
was used after incubation with biotin-coated goat anti-rabbit and goat anti-guinea pig secondary 
antibodies to visualize Kv1.1 and TRPM6, respectively. Images were taken with a confocal laser 
scanning imaging system (Olympus Fluoroview, FV1000).
DNA constructs- The KCNA1 wild-type and N255D mutant sequences were obtained by 
amplification of genomic DNA from a non-affected and affected family member respectively, using 
primers 5’-GCCGAATTCGGCCACCATGACGGTGATGTC-3’ and 5’-
GCCGTCGACATGCAACAACGCATTGACAG-3’. Both PCR products were cloned into pCMV- 
SPORT6 vectors (Invitrogen, Breda, The Netherlands) using restriction enzymes EcoRI and Sail 
following verification by sequence analysis. Subsequently, both the KCNA1 wild-type and N255D 
sequences were subcloned via the Gateway® pDONR™221 entry vector into a pCIneo IRES-GFP 
destination clone creating human KCNA1 pCIneo IRES GFP (wild-type Kv1.1) and human KCNA1
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N255D pCIneo IRES GFP (Kv1.1 N255D). The pCIneo IRES GFP construct was used as a control 
(mock) in the experiments. The wild-type TRPM6 pCIneo IRES GFP construct has been described 
previously (6).
Electrophysiology- HEK293 cells were cultured and transfected as described previously [35]. 
Whole-cell recordings were performed as described in a previous study [14]. Recorded Kv1.1 currents 
were evoked as described previously, using the same standard pipette and bath solutions[36]. The 
membrane potential of transfected HEK293 cells was measured using the current clamp mode, with 
continuous recording from a holding current of 0 pA. The pipette solution contained (mM): 140 KCl, 
1 Na2 -ATP, 10 HEPES/KOH (pH 7.3). The bath solution contained (mM): 138 NaCl, 5.4 KCl, 1.2 
MgCl2, 1 CaCl2, 10 glucose, and 10 HEPES/KOH (pH 7.3). To measure TRPM6-mediated currents, a 
linear voltage ramp from -100 to +100 mV (within 450 ms) was applied every 2 s from a holding 
potential of 0 mV. The standard pipette solution contained 150 mM NaCl, 10 mM EDTA, and 10 mM 
HEPES/KOH (pH 7.2). The extracellular solutions contained 150 mM NaCl, 10 mM HEPES/KOH 
(pH 7.4). The analysis and display of patch clamp data were performed using Igor Pro software 
(WaveMetrics, Lake Oswego, USA). Current densities were obtained by normalizing the current 
amplitude to the cell membrane capacitance.
Cell surface biotinylation- HEK293 cells were transiently transfected using Lipofectamin 2000 
(Invitrogen-Life Technologies) with 1 ^g DNA of wild-type Kv1.1, 1 ^g Kv1.1 N255D, 1 ^g mock, or 
co-transfected with 0.5 ^g wild-type Kv1.1 and 0.5 ^g Kv1.1 N255D. Cell surface labelling with biotin 
was performed as described previously [37]. At 48 hours after transfection, the biotinylation assay 
was performed. Cells were homogenized in 1 ml lysis buffer as described previously [37], using the 
sulfo-NHS-LC-LC-biotin (Pierce, Etten-Leur, The Netherlands). 1% of the total protein amount was 
collected as an input sample. Subsequently, biotinylated proteins (plasma membrane fraction) were 
precipitated using neutravidin-agarose beads (Pierce). Kv1.1 expression was analyzed by immunoblot 
analysis for the input and the plasma membrane fraction using the monoclonal Kv1.1 antibody 
(1:1000).
Chemicals and statistical analysis- The guinea pig antibody against AQP2 was kindly provided 
by Dr. P.M. Deen (Radboud University Nijmegen Medical Centre). Mouse anti-calbindin-D2 8K was 
purchased from Sigma. Rabbit polyclonal and mouse monoclonal antibodies specific for Kv1.1 were 
purchased from Alamone Labs (Jerusalem, Israel) and Neuromab (Davis, CA, USA), for 
immunohistochemistry and Western Blotting, respectively. Dendrotoxin-K (DTX-K) was purchased 
from Sigma. Data are shown as mean ± SEM. Statistical significance was determined using ANOVA 
Tukey’s test. Differences in means with P < 0.05 were regarded as statistically significant. Statistical 
analysis was performed using Prism (GraphPad, San Diego, USA) software.
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Functional analysis of Kv1.1 N255 mutants
Mutations in the voltage-gated K+ channel Kv1.1 have been linked with a mixed phenotype of 
episodic ataxia (EA) and/or myokymia. Recently, we presented autosomal dominant 
hypomagnesemia as a new phenotypic characteristic associated with a mutation in Kv1.1 (N255D). A 
conserved asparagine at position 255 in the third transmembrane segment was converted into an 
aspartic acid, resulting in a non-functional channel. In this study, we explored the functional 
consequence of this conserved residue by substitution with other hydrophobic, polar or charged amino 
acids (N255E, N255Q, N255A, N255V, N255T, N255H). Upon overexpression in human embryonic kidney 
(HEK293) cells, cell surface biotinylation revealed plasma membrane expression of all mutant 
channels. Next, we used the whole-cell patch clamp technique to demonstrate that the N255E and 
N255Q mutants were non-functional. Substitution of N255 with other amino acids (N255A, N255V, 
N255T, and N255H) did not prevent ion conduction and these mutant channels activated at more 
negative potentials compared to wild-type channels, -41.5±1.6, -45.5±2.0, -50.5±1.9, and -33.8±1.3 
mV to -29.4±1.1 mV, respectively. The time constant of activation was significantly faster for the two 
most hydrophobic mutations, N255A (6.2±0.2 ms) and N255V (5.2±0.3 ms), and the hydrophilic mutant 
N255T (9.8±0.4 ms) in comparison to wild-type (13.0±0.9 ms). Furthermore, the voltage-dependence 
of inactivation was shifted ~13 mV to more negative potentials in all mutant channels except for 
N255H. Taken together, our data showed that an asparagine at position 255 in Kv1.1 is required for 
normal voltage-dependence and kinetics of channel gating.
Introduction
Voltage-gated K+ channels (Kv) are a diverse family of membrane proteins, with the Shaker- 
related group (Kv1) representing a major sub-family [1-3]. Its members play an important role in 
excitable cells by setting the resting membrane potential, shaping the action potentials, and by 
controlling the neuronal excitability [4]. Kv channels comprise of four subunits that encircle a central 
ion conduction pathway [5, 6]. Each subunit consists of six transmembrane-spanning a-helices (S1- 
S6) with both the amino (N) and the carboxyl (C) terminal on the intracellular side. The S1-S4 
segments form the voltage sensing domain, whereas S5 and S6 along with the intervening re-entrant 
P-loop form the pore domain [7, 8]. Kv channels are known to switch between the closed and open 
conformation upon cell depolarization [8, 9]. Several molecular mechanisms on voltage-sensing 
motion have been described, i.e. the canonical or helical screw model, the transporter model, the 
paddle model, and the twisted S4 model [8]. It is generally accepted that the array of positive charges 
on the S4 helix form the principal structural elements responsible for voltage sensing [8].
Kv1.1 was the first mammalian subunit of the Kv family to be cloned and is abundantly expressed 
in excitable and non-excitable cells [10, 11]. Studies with Kv1.1 knock-out (KO) mice showed that 
deletion of Kv1.1 results in a seizure disorder similar to epilepsy [12]. Mutations in Kv1.1 in humans
Summary
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are the cause of periodic episodic ataxia type 1 (EA1) and/or myokymia [13-18]. Electrophysiological 
analyses of these mutant Kv1.1 channels showed either a significant reduction in current amplitude or 
altered kinetic properties compared to wild-type Kv1.1 channels [14, 19, 20].
Recently, a novel mutation, in the third transmembrane segment of Kv 1. 1 was identified in a 
family with isolated autosomal dominant hypomagnesemia. Surprisingly, hypomagnesemia had thus 
far not been reported in patients with mutations in Kv1.1. Furthermore, this study demonstrated Kv1.1 
expression in the apical membranes of the renal distal convoluted tubule (DCT) segment, where 
active Mg2+ reabsorption takes place. The mutation resulted in the single amino-acid substitution of an 
asparagine at position 255 for an aspartic acid (N255D) [21]. The mutant channel was non-functional 
with a dominant negative effect on wild-type channel activity. Aim of the present study is to 
characterize the N255D mutation in Kv1.1. To examine the importance of this position in channel 
function, we systematically substituted six amino acids with different chemical and physical 
properties. The mutant Kv1.1 channels were electrophysiology and biochemically analyzed.
Results
Structure analysis o f  Kv1.1 N255
A few years ago, the crystal structure of the mammalian Kv channel, Kv1.2, has been solved. 
This crystallized structure has been used to construct a paddle-chimera channel where the Kv2.1 
voltage sensor paddle (S3b and S4 helices) has been transferred to Kv1.2 [5, 22]. Based on this latter 
chimaeric Kv1.2-Kv2.1 structure, homology modeling of Kv1.1 was performed (Fig. 1B; 
http://www.cmbi.ru.nl/~hvensela/Kv 1. 1/). The sequence identity between Kv1.2-Kv2.1 and Kv1.1 
was 75%, which is enough to build a good homology model [23]. Kv1.1 subunits consist of six 
transmembrane a-helices with both the N- and the C-terminal tails of the protein at the intracellular 
side (Fig. 1C). Recently, a missense mutation in Kv1.1 was found in patients with isolated autosomal 
dominant hypomagnesemia, converting the highly conserved aspargine at position 255 (Fig. 1A) into 
an aspartic acid [21]. This mutation is positioned in the thirdtransmembrane segment (S3) close to the 
intracellular compartment (Fig. 1B/C). Electrophysiological analysis of the Kv1.1 N255D channel 
expressed in HEK293 cells demonstrated a significantly reduced current amplitude compared to the 
wild-type Kv1.1 expressing cells (72.0±3.2 pA/pF vs. 398±83 pA/pF) [21]. Importantly, both 
channels were expressed at the plasma membrane in equal amounts [21]. To examine the importance 
of N255 in Kv1.1 channel function, we substituted the asparagine by six different amino acids with 
distinct chemical and physical properties (N255E, N255Q, N255A, N255T, N255V, and N255H). We used 
the homology model to study the effect of these mutations on the structure of the channel (Fig. 1D; 
http://www.cmbi.ru.nl/~hvensela/Kv 1. 1/). The asparagine was converted into a glutamic acid or 
histidine to investigate the involvement of charge in channel function. Further, glutamine was used as 
a control to test the possible steric hindrance of the extra CH2 -group in glutamic acid. Next, we
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introduced alanine and valine as non-polar amino acids that are not able to participate in hydrogen 
bonding. Threonine was used as a control for residue size as alanine is a smaller amino acid.
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Figure 1. Structural analysis of mutations in Kv1.1 at position 255. A. Multiple alignment analysis shows 
conservation of the N255 amino acid (black bar) among species, and human family members Kv1.2 and Kv2.1. 
Light gray and dark grey colored letters represent conserved and non-conserved amino acids, respectively. B. 
The predicted 3D-structure model of the tetrameric Kv1.1 channel. C. Schematic representation of the Kv1.1 
channel, which consists of six transmembrane segments (S1-S6) with S1-S4 functioning as a voltage sensing 
domain and a pore-forming region between S5 and S6. Localization of the N255 position is denoted by the light 
gray dot. D. Enlarged view of the predicted 3D-structure model showing the side chains of the polar residues 
surrounding N255 and the mutated amino acids at this position.
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Figure 2. Expression of wild-type and mutant Kv1.1 channels. A. Cell surface biotinylation of mock, Kv1.1, 
Kv1.1 N255D, Kv1.1 N255E, Kv1.1, N255Q, Kv1.1 N255A, Kv1.1 N255V, Kv1.1 N255T, and Kv1.1 N255H 
expressing HEK293 cells. Kv1.1 expression was analyzed by immunoblotting for plasma membrane fraction 
and input from the total cell lysates. Representative immunoblot of four independent experiments is shown. B. 
The I—V relationships of the outward K+ currents in HEK293 cells expressing mock (O ), wild-type Kv1.1 (■ ), 
Kv1.1 N255D (O ), Kv1.1 N255E (A ), Kv1.1 N255Q (□ )  (right panel). The I-V relationships of the outward K+ 
currents in HEK293 cells expressing Kv1.1 N255A (▲), Kv1.1 N255V ( • ) ,  Kv1.1 N255T ( ♦ ) ,  and Kv1.1 N255H 
(▼) (left panel). Mean ± SEM values are shown. C. Histogram presenting averaged current densities at +50 mV 
of mock (n=4), wild-type Kv1.1 (WT, n=11), Kv1.1 N255D (D, n=6), Kv1.1 N255E (E, n=4), Kv1.1 N255Q (Q, 
n=4), Kv1.1 N255A (A, n=10), Kv1.1 N255V (V, n=7), Kv1.1 N255T (T, n=9), and Kv1.1 N255H (H, n=9) 
expressing HEK293 cells. Asterisk indicates significance (P < 0.05) in comparison to Kv1.1 wild-type 
expressing cells. Mean ± SEM values are shown.
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Surface expression o f  the K v1.1 m utants
The effect o f the substituted amino acids on the amount o f Kv1.1 channels at the plasma 
membrane was examined by cell surface biotinylation experiments. As shown in Fig. 2A, the 
substitution o f N 255 by other amino acids did not affect the expression o f Kv1.1 channels at the plasma 
membrane.
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Figure 3. Channel activation of wild-type and mutant Kv1.1 channels. A. Representative tail currents of wild­
type Kv1.1 at -80 mV, recorded in response to a set of 150 ms voltage steps from -100 to +50 mV in 10 mV 
increments every 10 s. B. The activation curve of the wild-type Kv1.1 (n=5) and Kv1.1 N255A currents (n=4), 
wild-type Kv1.1 (n=5) and Kv1.1 N255T currents (n=5), wild-type Kv1.1 (n=5) and Kv1.1 N255V currents (n=5), 
and wild-type Kv1.1 (n=5) and Kv1.1 N255H currents (n=4), respectively. Normalized tail currents are plotted 
as a function of the pre-pulse potential. The lines reflect the best fits to the averaged current-voltage data points, 
according to the Boltzmann equation: I  = Imax / (1 + exp (( V-V1/2 ) / k)), where I  is the current measured at each 
test potential, V; Imax is the maximal current; V1 /2 is the voltage of half-maximal activation; and k  is the slope 
factor.
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E lectrophysio logica l characteriza tion  o f  K v l . l  m utants
Whole-cell patch clamp recordings from HEK293 cells transiently expressing the wild-type 
Kvl.1 gave typical delayed rectifying currents, in response to a depolarization step from -100 mV to 
+50 mV (Fig. 2B). We observed in the K v l.l mutants a clear difference in current amplitude 
corresponding to the amino acid substituted. The K v l.l N255E and N255Q mutants showed small 
current amplitudes, similar to mock and the described K v l.l N255D mutation [2l]. Further, K v l.l
255  255  255N A, N T, and N H displayed slightly increased current amplitudes compared to wild-type 
K v l.l. The other substituted amino acid (N255V) did not affect the current amplitude of K v l.l (Fig. 
2B/C).
Figure 4. Time dependence of activation from wild-type and mutant K vl.l channels. A. Representative current 
traces of wild-type K vl.l elicited in response to a set of l50-ms voltage steps from -l00 to +40 mV in l0 mV 
increments every l0  s. These activating traces were fitted with a mono-exponential function. B. The time 
constants of activation for wild-type K v l.l, K vl.l N255A, K vl.l N255T, K vl.l N255V, and K vl.l N255H 
channels were plotted as a function of pre-pulse potentials and fitted with the equation: r  = TV1 /2 exp ( V-V1/2 ) / k, 
where TVl/2 is the time constant at the half-maximal activation voltage (V1/2 ) of the channels, and k  is the slope 
factor for the voltage-dependence of the time constants.
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In order to characterize the activation from the functional mutant and wild-type K v l.l channels, 
tail currents were elicited by 150 ms depolarizing pulses from -100 mV to +50 mV in 10 mV 
increments every 10 s, from a holding potential of -80 mV (Fig. 3A). The voltage dependence of 
activation was determined by recording tail currents after pre-pulse voltage steps. The amplitude of 
the tail currents was normalized to the maximum current and plotted as a function of the conditioning 
potential. Data points were fitted with a Boltzmann equation to determine the potential of half- 
maximal activation (V1/2) and the slope factor or steepness of voltage dependence (k). This revealed 
that V1/2 for all mutant channels was shifted to more negative potentials compared to wild-type, with 
extreme shifts of 15 to 20 mV for Kv1.1 N255V and N255T (Fig. 3B; Table 1). The slope factor was not 
significantly changed for the Kv1.1 mutants compared to wild-type Kv1.1 (Table 1). Mono­
exponential functions were used for fitting K+ current rise to quantify the time dependence of 
activation (Fig. 4A). Means of the calculated activation time constants were plotted against the test 
potentials (Fig. 4B), demonstrating that the mutant channels activated ~2-3 times faster, except for 
Kv1.1 N225H that was not different from wild-type Kv1.1 (14.6±0.7 ms vs. 13.0±0.9 ms) (Fig. 4B; 
Table 1).
The inactivation of the total outward currents was determined using a standard double-pulse 
protocol (Fig. 5 A). With the holding potential of -80  mV, 10 s conditioning potentials were given 
from -90  to +30 mV in 10 mV increments, every 10 s. Then, the membrane was depolarized to +30 
mV for 300 ms (Fig. 5A). The rate of inactivation was quantified by measuring the peak current (Ipeak) 
and the current at the end of the conditioning pulse (Ifinal). The ratio, Ifinal/Ipeak, showed that 
inactivation kinetics were not altered in the mutant channels compared to wild-type channels (Fig. 
5B). Voltage-dependence of inactivation was investigated by plotting the relative amplitudes of the 
elicited outward currents at +30 mV as function of the potentials. The derived steady-state 
inactivation curve was fitted to the Boltzmann function, demonstrating the voltage-dependence of 
inactivation (Fig. 5C). The N255A, N255T, N255V, N255H mutant channels showed 50% inactivation at - 
46.7±1.8, -46.9±1.8, -46.8±1.5, and -39.6± 1.7 mV, respectively, compared to -33.5± 1.0 mV for wild­
type Kv1.1 (Fig. 5C; Table 1).
Discussion
Voltage-gated potassium (Kv) channels are gated in response to changes in transmembrane 
voltage [24]. Kv1.1 is abundantly expressed in excitable and non-excitable cells [3, 10, 11]. Recently, 
a mutation in Kv1.1 (N255D) was found in a large Brazilian family with isolated autosomal dominant 
hypomagnesemia [21]. In the present study, we investigated the nature of the Kv1.1 N255D mutation 
and demonstrated that the asparagine at position 255 is essential for normal voltage-dependence and 
kinetics of channel gating. First, homology modeling of Kv1.1 was performed, based on 75% 
sequence identity with the crystallized Kv1.2-Kv2.1 chimaera. Subsequently, the N255 was substituted
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into different amino acids (N255E, N 255Q, N 255A, N 255V, N 255T, N 255H), which did not affect the 
expression o f  the channels at the plasma membrane. Second, the N 255E and N 255Q mutant channels 
displayed current amplitude close to the control situation (mock) and N 255D, and were considered as 
non-functional.
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Figure 5. The steady state inactivation of wild-type and mutant Kvl.1 channels. A. The representative wild-type 
K vl.l currents recorded with the double-pulse protocol. Outward currents were evoked on membrane 
depolarizations to +30 mV after (10 s) conditioning pre-pulses to potentials between -90 and +30 mV from a 
holding potential of -80 mV. B. Histogram of current amplitudes at the end of the conditioning voltage step 
(Ifinal) at +30 mV relative to the peak current amplitude at the beginning of the step (Ipeak). C. The steady-state 
inactivation curve of the wild-type K vl.l (n=5) and K vl.l N255A currents (n=5), wild-type K vl.l (n=5) and 
K vl.l N255T currents (n=5), wild-type K vl.l (n=5) and K vl.l N255V currents (n=5), and wild-type K vl.l 
(n=5) and K vl.l N255H currents (n=2), respectively. The peak amplitudes of currents at +30 mV evoked from 
each conditioning potential were measured in individual cells and normalized to the amplitude of the current 
evoked after the conditioning pulse at -80 mV. Normalized currents are plotted as a function of the conditioning 
potential. The lines represent the best Boltzman fits to the data points I  = Imax / (l + exp (( V-V1/2 ) / k  )), where I  
is the current measured at each test potential, V; Imax is the maximal current; V1 /2 is the voltage of half-maximal 
inactivation; and k  is the slope factor.
Third, the other mutants (N 255A, N 255V, N 255T) showed a negative shift in Vl/2 compared to w ild-
255type K v l . l  and had a faster time constant o f  activation except for N  H. Fourth, the half-maximal 
inactivation voltage was shifted to more negative potentials for all mutants, with N 255H as the
l44
Functional analysis of Kv1.1 N255 mutants
exception. Affected family members from the Brazilian family with inherited hypomagnesemia 
showed low plasma Mg2+ levels (0.40 mM; normal range, 0.70-0.95 mM) and suffered from muscle 
cramps, tetanic episodes, tremor, and muscle weakness. Remarkably, mutations in Kv1.1 thus far 
were known to result in a mixed phenotype of episodic ataxia (EA1) and myokymia [13-16, 18, 21], a 
neurological phenotype in which hypomagnesemia has not been reported. Kv1.1 was shown to 
localize to the apical membrane of DCT cells and postulated to be involved in the generation of a 
favorable apical membrane voltage as a driving force for Mg2+ entry [21]. It is puzzling that distinct 
mutations in nearby amino acid residues in Kv1.1 can result in phenotypes with dysfunction in two 
different organs (brain and kidney). A possible reason is that the composition of Kv1.1 channels in 
brain and kidney is different, due to tissue-specific expression of auxiliary p-subunits or co-assembly 
with other Kv1 subunits that define the functional characteristics of these channels [25-27]. As a 
result, mutations at close locations within the protein may have tissue-specific effects, giving rise to 
diverse phenotypic characteristics. Electrophysiological analyses of the EA1/myokymia-related 
mutant Kv1.1 channels showed either a significant reduction in current amplitude or altered kinetic 
properties compared to wild-type Kv1.1 channels [14, 19, 20]. The mutation identified in the 
Brazilian family caused substitution of the asparagine at amino acid position 255 into an aspartic acid 
(N255D). The asparagine at position 255 is highly conserved among species and Kv1 family members, 
which suggests its importance in channel function. Indeed, we demonstrated that the change of the 
neutral asparagine into a negatively charged aspartic acid results in a non-functional channel [21]. In 
the present study, we investigated the amino acid substitution at position 255 in relation to channel 
function more extensively.
The tertiary structure of Kv1.1 was modeled by the WHAT-IF server, based on 75% sequence 
identity with the crystallized Kv1.2-Kv2.1 chimearic channel [5, 22]. The asparagine residue (N255) is 
located in the third transmembrane segment (S3) close to the S4 voltage-sensor element. S4 contains a 
long array of positive charges that are shown to sense differences in voltage and start the transition 
from the closed to open conformation by forming stabilizing hydrogen bonds with the external and 
internal negative clusters in the voltage-sensing domain [28, 29]. In general, mutations can affect 
channel activity via loss-of-function at the plasma membrane, protein instability or lack of plasma 
membrane targeting. Importantly, cell surface biotinylation studies showed that all mutants were 
expressed at the plasma membrane. Thus, the change in amino acid at position 255 had no effect on 
channel trafficking. However, the amino acid substitution has a clear effect on channel activity, as we 
demonstrated that N255E and N255Q channel were non-functional. This indicates that next to the 
addition of a negative charge at position 255 also an additional CH2 -group in the side-chain influences 
channel function, likely via affecting conformational rearrangements. Subsequently, the voltage- 
dependence and kinetics of channel gating of the wild-type functional mutant channels were 
examined. All mutations stabilized the open state o f Kv1.1, measured as negative shifts in the voltage 
dependence of channel activation. There was no obvious correlation between charge and the
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magnitude of the shift in V 1/2 and k  as the effect was not significantly changed for N255H. Depending 
on the polarity of the side chain, amino acids vary in their hydrophilic or hydrophobic character [30]. 
These properties are important determinants of the protein structure and the physical properties of the 
side chains influence the amino acid residues' interactions with other structures, both within a single 
protein and between proteins. Therefore, the hydrophilic asparagine could be important for structural 
rearrangements within the channel in response to voltage changes, which can be affected by 
conversion into hydrophobic amino acids as alanine and valine. Interestingly, the change in activation 
kinetics was most evident with these two residues as N 255A and N255V activated 2 to 3-fold faster than 
wild-type channels. Furthermore, these mutants significantly shifted the voltage-dependence of 
activation. However, the magnitude of shift in V1/2 was highest for N255T, which suggests that channel 
gating is independent of hydrogen bonding with the residue at position 255.
Table 1. Electrophysiological characteristics of kvl.1 wild-type and mutant channels.
W T A T V H
V oltage -dependence (n=5) (n=4) (n=5) (n=5) (n=4)
< fo 3 < -29.4±1.1 -41.5±1.6a -50.5±1.9a -45.5±2.0a -33.8±1.3
k (m V) 12.1 ±1.0 13.7±1.4 11.2±1.7 13.9±1.8 12.3±1.2
A ctiva tion (n=8) (n=5) (n=4) (n=5) (n=5)
\U2 (mS) 13.0±0.9 6.2±0.2a 9.8±0.4b 5.2±0.3a 14.6 ±0.7
Inactivation (n=4) (n=5) (n=4) (n=6) (n=3)
L a i ' 'peak 0.44±0.07 0.49±0.01 0.50±0.04 0.41±0.04 0.40±0.08
S teady-s ta te
inactiva tion
(n=5) (n=5) (n=5) (n=5) (n=2)
V 1/2(m V) -33.5±1.0 -46.7±1.8a -46.9±1.8a -46.8±1.5a -39.6±1.7
The voltage-dependent parameters of activation and inactivation (V1/2 and k) were obtained from the Boltzmann 
equation as described in Fig. 3 and Fig. 5, respectively. Activation time constants at V1/2 (Tvi/2) were derived 
from Fig. 4. Inactivation was measured at 30 mV and is presented as the ratio Ifmal/Ipeak. Data are presented as 
mean±SEM, with the number of investigated cells in parenthesis. 
aP < 0.01 (compared to WT) 
bP < 0.05 (compared to WT)
Inactivation, besides activation, is another important property with respect to channel function. 
Interestingly, the voltage-dependence o f inactivation was significantly affected in all mutant Kv1.1
255channels compared to wild-type Kv1.1 except for N H. Substitution of the asparagine with other 
amino acids shifted the half-point for inactivation to more negative potentials. The acceleration of the 
inactivation process is also of interest, as it is explained by a constriction mechanism of the outer
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mouth of the channel vestibule [31, 32]. It has been demonstrated that negatively charged clusters in 
the S2 and S3 segments, together with the positive charges in S4, are involved in the opening and 
closing of Kv1 channels [22]. In line with this, an earlier study showed that mutation of conserved 
negatively charged residues in the S2 and S3 segments selectively modulate channel gating. Mutation 
of the aspartic acid at position 258 in Kv1.1 abolished channel activity [33]. Therefore, we suggest 
that an additional negative charge nearby this cluster in S3 could keep the channel in the inactivated 
state, which may explain the non-functionality of the mutation found in patients with 
hypomagnesemia (N255D). However, there were no significant changes in inactivation kinetics 
between wild-type and mutant channels.
Taken together, we have previously described hypomagnesemia as a new phenotypic variability 
associated with a mutation in Kv1.1 (N255D) [21] In this study, we provided more information about 
the structural arrangement of N255 and its involvement in channel activity. We have demonstrated that 
N255 is essential for normal channel function, since substitution by other amino acids significantly 
altered channel activity, voltage-dependence and kinetics of Kv1.1 channels.
Material and methods
DNA constructs- Full-length wild-type KCNA1 and N255D mutant were constructed in the 
pCIneo-IRES-GFP expression vector as previously described [21]. Other KCNA1 mutants (N255A, 
N255E, N255Q, N255H, N255T, N255V) were created using the QuickChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s protocol. All constructs were 
verified by sequence analysis.
Electrophysiology- HEK293 cells were grown in DMEM (Bio Whittaker Europe, Vervier, 
Belgium) containing 10% (v/v) fetal calf serum, 2 mM l-glutamine and 10 ^g/ml Ciproxin at 37 °C in 
a humidity-controlled incubator with 5% (v/v) CO2. Cells were transiently transfected with the 
respective constructs using Lipofectamine 2000 (Invitrogen-Life Technologies, Breda, The 
Netherlands), as described previously [34], and electrophysiological recordings were performed 48 
hours after transfection. Transfected cells were identified by their green fluorescence when 
illuminated at 488 nm. Non-transfected (GFP-negative) cells from the same batch were used as 
controls. Patch clamp experiments were performed in the tight seal whole cell configuration at room 
temperature (20-25°C). An EPC-10 patch clamp amplifier computer was used and controlled by 
PatchMaster Classic 1.20 software (HEKA Elektronik). Currents were digitized at 20 kHz and 
digitally filtered at 2.9 kHz. Patch pipettes were pulled from thin-walled borosilicate capillaries (1.5 
mm OD, 1.17 mm ID); pipette resistance was typically between 2 and 4 MQ. The liquid junction 
potential was not corrected. The pipette solution contained (mM): 140 KCl, 1 MgCl2, 0.1 CaCl2, 2 
EGTA, 10 HEPES/KOH (pH 7.3), and 1 Na2-ATP. The bath solution contained (mM): 138 NaCl, 5.4
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KCl, 1.2 MgCl2 , 1 CaCl2 , 10 EGTA, 10 HEPES/NaOH (pH 7.3), and 10 glucose. Recordings of 
Kv1.1 were obtained by voltage steps, applied every 10 sec, consisting of 150 ms steps from -100 mV 
to +50 mV (10 mV increments). The holding potential was -80 mV. Equimolar pipette and bath 
solutions of K+ (140 mM) were used to determine the voltage dependence of activation. For steady- 
state inactivation, cells were held at -80 mV, and then subjected to steps from -90 mV to +30 mV (10 
mV increments) for 10 s, followed by a depolarizing step to +30 mV. Linear leak and capacitance 
currents were corrected with a P/5 leak subtraction procedure [35]. The analysis of patch clamp data 
was performed using Igor Pro software (WaveMetrics, Lake Oswego, USA). Current densities were 
obtained by normalizing the current amplitude to the cell membrane capacitance.
C ell surface bio tinyla tion- Cell surface labelling with biotin was performed as described 
previously [36]. HEK293 cells were transiently transfected with 1 ^g wild type or mutants Kv1.1 
constructs using Lipofectamin 2000 (Invitrogen-Life Technologies), in 6-well plates (1,5 million cells 
per plate). At 48 hours after transfection, the biotinylation assay was performed using the sulfo-NHS- 
LC-LC-biotin (Pierce, Etten-Leur, The Netherlands). Cells from each 6 well were homogenized in 1 
ml lysis buffer as described previously [37]. Next, 5% of the total protein amount was collected as an 
input sample. Subsequently, biotinylated proteins (plasma membrane fraction) were precipitated using 
neutravidin-agarose beads (Pierce). Kv1.1 expression was analyzed by immunoblot analysis for the 
input and the plasma membrane fraction using the monoclonal Kv1.1 antibody (Neuromab, Davis, 
CA, USA).
Sequence analysis a n d  structure m odelling- The structural model of Kv1.1 was built based on the 
3D structure of a chimeric Kv1.2-Kv2.1 channel [22] (PDB-file 2R9R). In order to obtain optimal 
modeling results, we used a re-refined version of this template from the PDB_REDO data bank [38]. 
The sequences of the template and Kv1.1 share 75% sequence identity. The WHAT IF server 
(http://swift.cmbi.ru.nl) was used for model building, Yasara [39] was used for loop building, energy 
minimization and subsequent mutation analysis. The tetrameric model was obtained by superposing 
four models on the biological subunit of PDB file 2R9R, followed by an energy minimization in 
Yasara. Visit http://www.cmbi.ru.nl/~hvensela/Kv1.1/ for more details.
Sta tistica l analysis- Data are shown as mean ± SEM values. Statistical significance was 
determined using ANOVA followed by Tukey’s test. Differences in means with P < 0.05 were 
regarded as statistically significant. Statistical analysis was performed using Prism (GraphPad, San 
Diego, USA) software.
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General discussion and summary
A key molecule involved in Mg2+ handling is the Transient Receptor Potential Melastatin subtype 
6 (TRPM6). Mutations of this gene have been associated with the rare monogenetic disorder 
hypomagnesemia with secondary hypocalcemia (HSH) [1, 2]. The TRPM6 gene contains 39 exons 
encoding a protein of 2,022 amino acids [1-3]. TRPM6 shares approximately 50% sequence 
homology with TRPM7. These channels are composed of six membrane-spanning domains with a 
pore region between the fifth and sixth segment, and large intracellular amino (N) and carboxyl (C) 
termini. Furthermore, they are thought to form functional homotetramers or heterotetramers, which 
influences their channel characteristics [4, 5]. TRPM6 functions as a divalent cation channel and it 
has a higher affinity for Mg2+ than for Ca2+ [3]. Its channel activity is tightly regulated by intracellular 
Mg2+ levels ([Mg2+]i) and inhibited by ruthenium red in a voltage-dependent manner [3]. Furthermore, 
micromolar levels of 2-aminoethoxydeiphenyl borate (2-APB) can increase TRPM6 currents [5]. In 
addition, Li et al. [5, 6] demonstrated that TRPM6 inward currents significantly enhanced upon 
extracellular acidification, which is linked to specific residues in the TRPM6 pore region. In addition 
to its Mg2+ selectivity and sensitivity, TRPM6 has a restricted localization pattern along the luminal 
membranes of the colon and distal convoluted tubules (DCT) of the kidney, supporting a central role 
in active Mg2+ (re)absorption [3].
TRPM6 regulation by its a-kinase domain
TRPM6, together with its closest homologue TRPM7, is unique by combining an ion channel 
with a fused a-kinase domain [7, 8]. While it has previously been shown that this catalytic domain is 
not essential for channel activity, recent studies have revealed an indirect regulatory role in the 
modulation of channel functioning [9, 10] (Chapters 2-4).
Background of the a-k inase  domain
In 1999, Ryazanov et al. discovered the alpha-kinases as a new class of protein kinases with a 
catalytic domain. Alpha-kinases were named according to their substrate recognition, as they were 
shown to phosphorylate amino acids within alpha-helices [11]. They have no detectable sequence 
homology to the conventional protein kinases (CPKs). To date, six mammalian alpha-kinases have 
been identified, including elongation factor-2 (eEF-2) kinase, lymphocyte alpha-kinase, heart alpha­
kinase, muscle alpha-kinase and TRPM6 and TRPM7 [11-13]. The crystal structure of the TRPM7 
kinase has been elucidated, demonstrating structural similarities with CPKs [14]. In particular, the N- 
terminal lobe shows high homology to the structure in CPKs and is important for anchoring and 
orientation. The C-terminal tail is mainly important for substrate binding and phosphotransfer. 
Primary structural differences can be found in this site of catalysis, which leads to diverse substrate 
specificity and kinase regulation. Another clear distinction between the two kinases is the zinc
Introduction
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binding module in the C-terminus of TRPM7 a-kinase, which is important for structural integrity as 
cysteine mutations leads to loss of kinase activity [8, 15]. Recently, some studies have revealed 
phosphorylation targets of the a-kinase domain. TRPM6 and TRPM7 have been shown to share 
exogenous phosphorylation substrates as myosin IIA, IIB, and IIC [16]. Furthermore, Clark et al. [17] 
showed that the C-terminus of TRPM7 undergoes massive autophosphorylation, thereby increasing 
the rate of substrate phosphorylation [18"] The TRPM7 autophosphorylation has been mapped to a 
serine/threonine-rich region close to the a-kinase domain and the TRPM6 a-kinase activity was 
suggested to be regulated in a comparable fashion [17]. Despite these findings, little is known about 
the interrelationship between the TRPM6 channel and alpha-kinase. Therefore, we screened for 
interacting proteins of the TRPM6 a-kinase domain and identified three new modulators of TRPM6, 
namely the receptor for activated C-kinase 1 (RACK1), repressor of estrogen receptor activity (REA), 
and methionine sulfoxide reductase B1 (MsrB1) as discussed below.
A utophosphorylation activity of the a-k inase  domain -  RACK1
RACK1 has been identified as the first TRPM6-associated partner (C hapter 2). RACK1 is a 36- 
kDa scaffold protein containing seven internal Trp-Asp 40 (WD40) repeats and is originally 
discovered as an adaptor for protein kinase C (PKC) [19, 20]. It is ubiquitously expressed and 
involved in diverse biological functions (reviewed by McCahill et al. [21]). Our study demonstrated 
that RACK1 co-expresses with TRPM6 in the DCT where active Mg2+ reabsorption occurs (C hapter 
2). RACK1 interacts with the a-kinase domain thereby inhibiting TRPM6 channel activity (Fig. 1). 
The inhibitory effect of RACK1 was shown to be dependent on autophosphorylation of a threonine 
residue (T1851) in the a-kinase domain (C hapter 2). Our data suggest that the inhibitory action of 
RACK1 requires functional phosphotransferase activity. This notion is supported by the fact that the 
current of the phosphorylation-impaired mutants (K1804R and T1851A) is insensitive to RACK1, while 
the constitutive phosphorylated mutant t 1851D was still inhibited by RACK1. Based on these 
observations, an increased channel activity for the phosphorylation-impaired mutants (K1804R and 
T1851A) and the TRPM6 A-kinase mutant was expected. However, functional analysis of these 
mutated channel proteins did not indicate elevated channel activity. It has been demonstrated that the 
TRPM7 a-kinase domain can regulate channel activity via other signaling pathways. For instance, 
previous studies indicated that the TRPM7 activity controlled by intracellular Mg2+, nucleotides, and 
the cAMP/protein kinase A pathway requires the a-kinase domain or kinase activity [10, 22, 23]. It is, 
therefore, conceivable that removing the a-kinase domain or suppressing its phosphotransferase 
activity may abolish associated regulation(s) of TRPM6 channel activity. This could compensate for a 
potential upregulation of TRPM6 activity caused by removal of the inhibitory RACK1 action.
Our findings support the conclusion that TRPM6 a-kinase autophosphorylation events are not 
vital for TRPM6 channel activation since the phosphotransferase-deficient K1804R mutant displayed
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currents indistinguishable from wild-type TRPM6. The mutants T1851A and t 1851D displayed currents 
similar to the wild-type channel but exhibited a significant albeit reduced autophosphorylation, while 
the autophosphorylation of mutant K1804R was fully abolished. This suggests that, besides T1851, 
additional autophosphorylation sites are present in TRPM6. However, we hypothesize that T1851 plays 
a key role in controlling channel activity as its phosphorylation state influences the Mg2+-dependent 
inhibition of TRPM6 activity (C hapter 2). Channel inactivation by elevated [Mg2+]i may function as 
negative-feedback machinery to balance the Mg2+ homeostasis. Matsushita and coworkers postulated 
that regulation of TRPM7 channel activity by [Mg2+]i is disassociated from its a-kinase activity [13], 
whereas other studies suggested the involvement of the a-kinase domain [11, 14]. In our study, the 
T1851A mutant is less sensitive to [Mg2+]i, which is in agreement with previous studies showing that 
TRPM7 phosphotransferase activity influences the Mg2+-dependent inhibition of channel activity [11, 
14]. This shift in Mg2+ sensitivity could have significant impact on TRPM6 activity during 
transepithelial Mg2+ transport because the channel is tightly controlled by [Mg2+]i [2]. The T1851A 
mutant is still inhibited by high [Mg2+]i suggesting that additional Mg2+-sensing site(s) are present 
within TRPM6. Our data indicated that wild-type TRPM6 autophosphorylation activity is gradually 
enhanced by increasing the Mg2+ concentration [0.1-1.0 mM Mg2+]i, in contrast to 
autophosphorylation of the T1851A mutant for which the Mg2+ sensitivity is abolished. Thus, residue 
T1851 seems crucial in the Mg2+ sensitivity of TRPM6 autophosphorylation. In line with our study, 
Minagawa and coworkers demonstrated that the Mg2+ sensitivity of PhoQ phosphorylation, vital for 
Escherichia coli Mg2+ homeostasis, relies on a single residue, D179 [29]. Over the last decade, the idea 
was that the free [Mg2+]i is more or less constant. However, more recent studies provided evidence 
that the free [Mg2+]i varies significantly [30, 31]. Enzymes like adenylate kinases and the TRPM7 
kinase are shown to be dependent on [Mg2+]i [11, 32, 33]. Moreover, it was shown that siRNA- 
mediated downregulation of endogenous RACK1 significantly reduces the inhibition of the TRPM6 
current by Mg2+. These findings suggest that RACK1 determines in part the Mg2+ sensitivity of 
TRPM6 channel activity. Together, it is proposed that TRPM6-mediated Mg2+ influx induces 
phosphorylation of T1851 located in the a-kinase domain. Subsequently, the phosphorylation of T1851 
will activate the inhibitory effect of RACK1. This latter step may act as an intracellular feedback 
regulation to control TRPM6-mediated Mg2+ influx and avoid Mg2+ overload during renal epithelial 
Mg2+ transport. Experiments with RACK1-knockout mice, which have yet to be generated, could be 
of interest to further investigate the role o f RACK1 in Mg2+ handling.
Phosphorylation activity of the a-k inase  dom ain -  REA
By using similar screening assays, a new TRPM6-interacting protein, REA, was identified 
(C hapter 3). REA is a 37 kD protein that was first identified as an interacting protein of the estrogen 
receptor (ER), where it functions as a selective co-regulator repressing the transcriptional activity of
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ERs [24]. REA binds to the 6th, 7th, and 8th ^-sheets in the a-kinase domain, which is the same region 
as for RACK1 (C hapter 2/3). Most amino acids in this area are located on the peripheral region of 
the tertiary structure, which facilitates the interaction with regulatory proteins. REA inhibits TRPM6 
channel activity in an a-kinase activity-dependent manner, since REA has no functional effect on the 
TRPM6 phosphotransferase-deficient mutant (K1804R) (C hapter 3). However, we demonstrated that 
REA is not a phosphorylation target of TRPM6, nor was TRPM6 autophosphorylation affected by 
REA (C hapter 3). These data suggest another indirect regulation of TRPM6 activity, independent of 
autophosphorylation, but reliant on TRPM6 a-kinase activity. REA is also abundantly present in the 
TRPM6-expressing DCT segment. Taken together, REA acts as another negative modulator involved 
in renal Mg2+ handling via regulating TRPM6-mediated Mg2+ influx (Fig. 1).
So far, REA has only been described as co-repressor of the nuclear ERs. In this study, we also 
demonstrated for the first time a rapid non-genomic estrogen signaling that activates TRPM6 (also see 
section Hormonal control o f  TRPM6). Further investigation is, therefore, needed to demonstrate a link 
between REA and the rapid estrogen signals on TRPM6.
Oxidative stress and channel regulation -  M srB l
MsrBl was identified as an interaction partner of the TRPM6 a-kinase domain, but does not 
affect the channel activity in normoxic conditions (C hapter 4). M srBl is an oxidoreductase which 
catalyzes the thiol-dependent reduction of methionine sulfoxide [25]. It belongs to the Msr family 
composed of MsrA and MsrB. Mammals contain one MsrA and three MsrBs that are highly abundant 
in kidney, liver, heart and nervous tissue [26-30]. These enzymes protect cells from oxidative stress 
via the repair of oxidative damage to proteins and thereby restore biological activity. They can be 
involved in reactive oxygen species (ROS)-mediated signal transduction through modulation of the 
function of target proteins [25, 31-33]. Accumulating evidence suggests that ROS are not only 
harmful side products of cellular metabolism, but also central players in cell signaling and regulation 
[34-37]. Free and protein-bound methionine residues are among the most susceptible to oxidation by 
ROS [38]. Surface exposed methionine residues in a protein are proposed to constitute an antioxidant 
defense mechanism since various oxidants can easily react with these residues to form methionine 
sulfoxide. Reduction to methionine by methionine sulfoxide reductases could catalytically drive this 
antioxidant system as has been suggested by several studies [39-41]. So, the reversible methionine 
oxidation and reduction plays a dynamic role in cellular signaling pathways [42, 43]. Importantly, 
there should be a cellular balance between ROS production and its removal through antioxidant 
mechanisms, as overproduction of ROS results in a condition of oxidative stress. Oxidative stress is 
an important component in several pathophysiological conditions, such as ischemia/reperfusion and 
diabetes, potentially contributing to cardiac arrhythmia. Over the last years, several studies have 
implicated TRPM channels in ischemia [44, 45]. Sun et al. showed that decreased TRPM7 channel
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expression significantly reduced neuronal cell death after global ischemia [46]. Furthermore, TRPM4 
channel activation in vascular smooth muscle has been shown to contribute to cell death of vascular 
cells during ischemic injury and TRPM2 has been well studied in relation to oxidative stress [47-50]. 
Interestingly, we have demonstrated that H2O2 significantly decreases the TRPM6-mediated current in 
HEK293 cells. As H2O2 did not change the surface expression of TRPM6, it possibly regulates 
TRPM6 channel activity directly through modulation of the channel conductance. Importantly, the 
decreased TRPM6 channel activity can be partly recovered by co-expression with M srBl (C hapter 
4). Furthermore, we identified four methionine residues located on the peripheral of the TRPM6 a- 
kinase domain 3D structure (see http://www.cmbi.ru.nl/~hvensela/trpm6/), M1755, M1775, M1904, and 
Ml947. Mutation of Ml755 to A significantly attenuates the effect of H2O2 on TRPM6 channel activity, 
mimicking the M srBl effect (C hapter 4). These data suggest that M1755 is a crucial target of H2O2. 
Notably, renal DCT cells contain the largest number of mitochondria, the major source of endogenous 
H2 O2 , per unit length of any cell along the nephron, underlying a vast source of intracellular H2 O2
[51]. TRPM6 is predominantly expressed in DCT and is inhibited by H2O2. Therefore, it is 
conceivable that the metabolic state of DCT cells, which influences the abundance of ROS generated 
from mitochondria, modulates the Mg2+ reabsorption via TRPM6.
Regulation by ATP
Next to the associated proteins, ATP was found as a regulatory factor of the a-kinase domain
[52]. The functional role of ATP and the a-kinase domain in regulating TRPM6/TRPM7 channel 
activity is controversial [22, 52-55]. It has been suggested that Mg2+-ATP acts as a source of Mg2+ to 
decrease channel activity rather than inhibition by ATP itself [53]. On the other hand, it was 
concluded that ATP-dependent regulation of TRPM7 is mediated via a nucleotide-binding site in the 
a-kinase domain that acts synergistically with a Mg2+-binding site outside this domain [10, 22]. 
Interestingly, a recent study demonstrated that intracellular ATP can regulate TRPM6 channel activity 
via its a-kinase domain [52]. By binding to a conserved ATP-binding pocket in this domain, TRPM6- 
mediated currents are inhibited in a dose-dependent manner by Na+-ATP and Mg2+-ATP [52]. 
Mutation of a conserved residue (G1955D) in the putative motif eradicated the inhibitory ATP action, 
whereas this effect remained preserved in the TRPM6 K1804R mutant. The inhibition was specific for 
ATP as the effect could not be mimicked by GTP or CTP. Furthermore, strong Mg2+ chelators like 
EDTA were used to demonstrate that the inhibitory effect is not due to release of Mg2+ from Mg2+- 
ATP [52]. These results indicate another regulatory mechanism of the a-kinase domain via the effect 
of intracellular ATP on TRPM6 channel activity independent of a-kinase activity [52].
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Figure 1. Schematic representation of TRPM6 regulation. TRPM6 channels, located in the luminal membrane, facilitate transport of Mg~+ from the pro-urine into 
the cell, which is primarily driven by the luminal membrane potential established by the voltage-gated K+ channel, K vl.l. The intracellular factors RACK1, REA, 
and MsrBl were identified as modulators of TRPM6 channel activity, through their binding to the fused alpha-kinase domain. MsrBl recovers the EEOo 
inhibitory effect on TRPM6. EGF and estrogen function as magnesiotropic hormones stimulating TRPM6 activity. EGF binds its EGF receptor, thereby 
activating Racl-mediated signaling that leads to increased TRPM6 trafficking to the plasma membrane. Estrogen affects TRPM6 via both a genomic and non- 
senomic Dathwav. Cetuximab and Erlotinib affect TRPM6 function through inhibition of the EGF receDtor.
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Conclusion
Taken together, these studies led to new fundamental understanding of the molecular mechanism 
of transepithelial Mg2+ transport and regulation hereof by the TRPM6 alpha-kinase. However, the 
unique role of alpha-kinase activity on TRPM6 function and vice versa is still unresolved. So, future 
experiments, using state of the art mass spectrometry and signal transduction technology, should: i) 
identify renal downstream targets of the TRPM6 alpha-kinase domain; ii) examine the 
phosphorylation-control of TRPM6; iii) unravel signaling pathways involved in TRPM6 regulation.
Hormonal control of TRPM6
Over the last 10 years several hormones have been suggested to be essential for the maintenance 
of the Mg2+ balance. Previous studies in immortalized mouse DCT cells suggest that parathyroid 
hormone (PTH), glucagon, and arginine vasopressin (AVP) stimulate Mg2+ uptake [56, 57]. However, 
molecular mechanisms how these hormones affect transepithelial Mg2+ transport in the DCT are 
lacking. In addition, other studies were not able to confirm the stimulatory action of these hormones 
on Mg2+ influx. Recently, two novel regulatory mechanisms involving hormonal control of TRPM6 
have been elucidated.
EGF as the first magnesiotropic hormone
Recently, genetic screening of two Dutch sisters with isolated autosomal recessive 
hypomagnesmia (IRH) led to the discovery of the first magnesiotropic hormone [58]. IRH is due to a 
mutation in the gene encoding EGF precursor protein pro-EGF (P1070L), which is expressed in DCT 
together with TRPM6. Physiologically, pro-EGF is sorted to both apical and basolateral membranes 
where it is cleaved by extracellular proteases into the active molecule EGF [58, 59]. It is suggested 
that the P1070L mutation, in the cytoplasmic domain, predominantly impairs the release of the 
hormone to the basolateral site. This disturbs the stimulatory effect of EGF on TRPM6 channel 
activity and leads to renal Mg2+ wasting [58].
Normally, EGF will activate the basolateral EGF receptor (EGFR) following an intracellular 
signaling cascade to increase TRPM6 surface expression (Fig. 1) [60]. This signaling involves both 
the Src family of tyrosine kinases and the downstream effector Racl. Using fluorescence recovery 
after photo bleaching (FRAP), it was demonstrated that activation of Rac1 increased the mobility of 
TRPM6 and a constitutively active mutant of Racl mimicked the stimulatory action of EGF on 
TRPM6 mobility and activity [60]. Another study reported that EGF increased the phosphorylation of 
ERK1/2, leading to upregulation of TRPM6 expression and Mg2+ influx, which results in an increase 
in cell proliferation [61]. Supportive for these studies was the observation that patients treated with 
the anticancer agent Cetuximab, an EGFR-specific monoclonal antibody, develop hypomagnesemia
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[58]. Indeed, pre-incubation with Cetuximab abolished the stimulatory effect of EGF on TRPM6 
channel activity.
Erlotinib: A small molecule inhibitor of EGFR
The EGFR is overexpressed in many types of cancer, presumably leading to uncontrolled cell 
division. Blocking the receptor either using monoclonal antibodies or tyrosine kinase inhibitors 
would, therefore, slow cancer progression. Instead of Cetuximab, which hinders binding of EGF to its 
receptor, numerous cancer patients receive tyrosine kinase inhibitors, such as Erlotinib. These 
compounds bind to the ATP pocket of EGFR and thereby block the downstream signaling. So far, 
there were no published clinical reports detailing the potential effect of tyrosine kinase inhibitors on 
systemic and renal Mg2+ handling. Chapter 5 shows that Erlotinib is capable of altering Mg2+ 
handling by affecting TRPM6 regulation. We observed that mice, receiving supraphysiological doses 
of Erlotinib for 23 days, developed a decrease in their serum Mg2+ concentration. In addition, these 
Erlotinib-injected mice failed to reduce the fractional renal excretion of Mg2+ in response to the 
decreased serum Mg2+ concentration. Whole-cell patch clamp analysis revealed that Erlotinib 
significantly inhibited EGF-stimulated TRPM6 channel activity, through dosages in the same range as 
the expected plasma concentration in mice (30 ^M of Erlotinib). Although moderate effects of 
Erlotinib were observed in vivo, application of the compound could still inhibit EGF-stimulated 
TRPM6 channel activity and transport to the plasma membrane. Given that the free circulating 
concentration of Erlotinib is likely to be around 0.3 ^M in human patients, we tested whether this 
concentration would be able to block the effect of EGF on TRPM6 channel activity. Here we could 
not detect any significant differences from EGF-stimulation. Evaluating EGF-induced tyrosine 
phosphorylation of its receptor substantiated these data. In addition, the inhibitory effect o f Erlotinib 
on Mg2+ transport is likely to occur via inhibition of TRPM6 routing, by preventing EGF-mediated 
changes in the mobile fraction of TRPM6 proteins.
Around 97% of colorectal cancer patients treated with the monoclonal antibody EGFR inhibitors 
such as Cetuximab develop hypomagnesemia to varying degree [62]. These compounds are currently 
being considered as first-line treatment for metastatic colorectal cancer. It is now becoming 
increasingly clear that hypomagnesemia is one of the most commonly reported side effects of these 
treatments. Chapter 5 is the first to delineate the effects of Erlotinib on Mg2+ handling in vivo. The 
effect on the systemic Mg2+ concentration seems less potent than that observed with antibody-based 
EGFR inhibitors. Still, clinical data concerning the effect of Erlotinib on Mg2+ handling is missing. 
Based on the doses given to cancer patients it is not likely that Erlotinib severely affects serum Mg2+ 
concentrations in these individuals. Furthermore, one could envision that Erlotinib only blocks the 
overexpressed EGFR often found in tumors, due to its lower affinity for the receptor than EGF and its 
overall circulating levels in the body. It is, therefore, unlikely to interfere with the normal functions of 
the EGFR, such as the Mg2+ reabsorption in the DCT. However, it should be noted that Erlotinib has
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the potential to modulate renal and systemic M g2+ handling in vivo. Therefore, caution should be 
given when treating individuals prone to developing hypomagnesemia, such as patients receiving
combinational treatment with Mg2+ lowering compounds like cisplatin-based chemotherapy [63].
Table 1. Overview o f  factors affecting TRPM6
Effect on TRPM6: mRNA channel 
expression activity
Remarks: Reference:
Intracellular factor:
[Mg2+]i
pH
H 2 ° 2
ATP
76 (Chapter 1) 
Chapter 4 
52
Associated protein: 
RACK1 
REA 
M srBl
j  Autophosphorylation-dependent Chapter 2
j  Kinase activity-dependent Chapter 3
Recovery o f oxidative stress Chapter 4
Hormone:
EGF t t Increases TRPM6 trafficking 60,61
erlotinib j Blocks EGF-dependent stimulation Chapter 5
cetuximab - Blocks EGF-dependent stimulation 58
Estrogen { t - 66 (Chapter 3)
Insulin | - - 92 (Chapter 1)
Drugs:
Tacrolimus | - - 98 (Chapter 1)
Cisplatin { - - Unpublished results
Cyclosporin A { - - Ikari et al., 2008
Other:
Chronic metabolic:
alkalosis j - - 93 (Chapter 1)
acidosis f - - 93 (Chapter 1)
M g2+ diet:
enriched { - - 66
restricted f - - 66
Two estrogen signaling pathways affecting TRPM6
G enom ic p a th w a y
Estrogen has also been suggested as magnesiotropic hormone since clinical studies have shown 
that the hypermagnesiuria in postmenopausal women significantly reduced after estrogen therapy [64, 
65]. In addition, Groenestege et al. [66] demonstrated that the renal TRPM6 m RNA level is decreased 
in ovariectomized rats, which could be restored by supplementation with 17p-estradiol. This effect
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can be explained by enhanced transcriptional activity or mRNA stabilization of TRPM6. Thus far, 
detailed analysis did not result in estrogen-responsive elements in the putative promoter site of 
TRPM6.
Non-genomic pathway
Next to the classical transcriptional pathway, accumulating evidence suggests also rapid estrogen 
effects that occur within minutes via a non-transcriptional route [67-69]. Interestingly, our study 
revealed a rapid stimulatory effect of 17^-estradiol on TRPM6 (C hapter 3). Treatment with 17^- 
estradiol disassociated the binding between REA and TRPM6 a-kinase domain, thereby attenuating 
its inhibitory effect on TRPM6 channel activity (Fig. 1). In agreement with this, 17^-estradiol 
significantly stimulated TRPM6 activity, without affecting the plasma membrane trafficking 
(C hapter 3). Estrogen has the ability to facilitate rapid membrane-initiated signaling cascades 
through activation of plasma membrane-associated receptors, such as the recently discovered G 
protein-coupled receptor 30 (GPCR30) [70]. In addition, it was demonstrated that the classical 
estrogen receptor alpha (ERa) is localized to the plasma membrane in response to estrogen or by 
interaction with adaptor proteins like Shc and p130Cas [71, 72]. Thus, the signaling pathway of 
estrogen receptor activation leading to increased TRPM6 activity needs to be further investigated.
Link between estrogen signaling and EG FR
Both estrogen and EGF are required for growth and survival, particularly of estrogen-responsive 
tissues. However, the receptors that mediate the effects of estrogen and EGF utilize apparent different 
signaling mechanisms. The proliferative effects of estrogen are primarily mediated by nuclear ERs 
that induce gene transcription in these tissues [73]. In contrast, EGF activates EGFRs, that signal 
through transmembrane receptor tyrosine kinases (RTKs), which in turn recruit intracellular signaling 
cascades. However, more evidence is appearing that these divergent signaling mechanisms may cross- 
communicate. Interestingly, in vivo administration of estrogen was shown to upregulate EGFR 
expression [74, 75]. While this was first shown to be the consequence of ER-mediated gene 
transcription, other studies reported that estrogen could promote rapid EGF-like effects. This link 
between estrogen and EGF signaling was highlighted shortly after the discovery of GPR30. GPR30, 
also referred to as GPER1 (G protein-coupled estrogen receptor1), was identified based on the 
difference in gene expression in response to estrogen in breast cancer cells [76]. Subsequently, it was 
shown by several groups that GPR30 is activated by estrogen [70, 77-79].
It has been demonstrated that GPR30 stimulation leads to the activation of the trimeric G protein 
(aPy). The a  subunit induces activation of adenylate cyclase, which results in the production of 
cAMP. The P and y subunits of the G protein activate Src tyrosine kinase that, via several signaling 
molecules, can activate matrix metalloproteinase (MMP). It should be noted that inactive membrane-
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anchored precursors of EGF (pro-EGF) must be cleaved and released by metalloproteinases to 
generate the active, mature form of the growth factor [80]. So, the activated MMP degrades pro-EGF, 
which releases EGF that can then activate the EGFR via an autocrine/paracrine mechanism, leading to 
the activation of PI-3K. The activated EGFR also induces ERK activation [81, 82]. In the past years, 
transactivation of EGFRs by GPCRs is a recurrent theme in cell signaling [83] and it would be 
interesting to take this mechanism into account when studying hormonal regulation of TRPM6.
Conclusion
Altogether, these recent studies highlight an important role for EGF and estrogen signaling in the 
maintenance of Mg2+ homeostasis with TRPM6 as a critical player. It would be interesting to 
investigate the effect of other blocking antibodies and antagonists of the EGFR on Mg2+ balance in 
general and in particular on TRPM6 activity. Furthermore, it would be highly significant to elucidate 
the estrogen signaling pathway leading to TRPM6 stimulation.
2+Kv1.1 as new player in TRPM6-mediated Mg transport
Voltage-gated K+ channels (Kv) are a diverse family of membrane proteins, with the Shaker- 
related group (Kv1) representing a major sub-family [84-86]. Its members play an important role in 
excitable cells by setting the resting membrane potential, shaping the action potentials, and by 
controlling the neuronal excitability [87]. Kv channels comprise of four subunits that encircle a 
central ion conduction pathway [88, 89]. Each subunit consists of six transmembrane-spanning a- 
helices (S1-S6) with both the amino (N) and the carboxyl (C) terminal on the intracellular side. The 
S1-S4 segments form the voltage sensing domain, whereas S5 and S6 along with the intervening re­
entrant P-loop form the pore domain [90, 91]. Kv channels are known to switch between the closed 
and open conformation upon cell depolarization [91, 92]. Kv1.1 was the first mammalian subunit of 
the Kv family to be cloned and is abundantly expressed in excitable and non-excitable cells [93, 94]. 
Studies with Kv1.1 knock-out (KO) mice showed that deletion of Kv1.1 results in a seizure disorder 
similar to epilepsy [95].
Genotype -  Phenotype
C hapter 6 describes the identification of a novel mutation in the KCNA gene, encoding the 
voltage-gated Kv1.1, in a family with isolated autosomal dominant hypomagnesemia. Affected 
individuals showed low serum Mg2+ levels (< 0.40 mM, normal range 0.70-0.95 mM), while their 
urinary Mg2+ excretion was normal, suggesting impaired tubular Mg2+ reabsorption. The phenotype of 
the proband starting from infancy consists of recurrent muscle cramps, tetanic episodes, tremor and 
muscle weakness, especially in distal limbs (C hapter 6). Previously identified mutations in Kv1.1 are 
characterized by episodic ataxia 1 (EA1; OMIM 160120), which manifests during the first or second
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decade of life [96-110]. Attacks of ataxia are in some cases accompanied by myokymia [96-107, 
109], neuromyotonia [99-105, 107] and epilepsy [99, 100, 106]. The diverse phenotype is nicely 
illustrated by the mutation of the Kv1.1 residue Thr226, which dependent on the mutation causes 
isolated EA1 (T226A), isolated myokymia (T226K) or a mixture of EA1, myokymia and epilepsy that 
can vary between families and even among family members affected by the same mutation (T226R). 
The affected members of our Brazilian family were also analyzed for episodic ataxia. On a cerebral 
MRI of the proband we obtained evidence of a slight atrophia of the cerebral vermis (data not shown). 
Furthermore, electromyographs of some affected members showed myokymic discharge in line with 
the previously observed mixed phenotype (Chapter 6). Now, hypomagnesemia is presented as a new 
phenotypic characteristic associated with a mutation in KCNA1. As it was unknown whether renal 
Mg2+ handling is also affected in patients with other KCNA1 mutations, serum Mg2+ levels were 
evaluated. Three EA1 patients have been analyzed [103, 104, 109] and their serum Mg2+ levels (I262T:
0.76 mM; L305P: 0.80 mM; V404I: 0.73 mM) were within the normal range (0.7-1.1 mM) (unpublished 
data). Possibly, as observed for EA1, the hypomagnesemia differs in time and should, therefore, be 
measured at different time points. It would be interesting to perform in the near future a large-scale 
phenotypical characterisation of patients with identified mutations in the KCNA1 gene including 
neurological description, serum Mg2+ levels and functional analysis of the corresponding Kv1.1 
mutations.
Functional characterization
So far, electrophysiological analyses of these mutant Kv1.1 channels showed either a significant 
reduction in current amplitude or altered kinetic properties compared to wild-type Kv1.1 channels 
[98, 100, 111]. The mutation identified in the Brazilian family caused substitution of the asparagine at 
amino acid position 255 into an aspartic acid (N255D). The asparagine at position 255 is highly 
conserved among species and Kv1 family members, which suggests its importance in channel 
function. Indeed, we demonstrated that the change of the neutral asparagine into a negatively charged 
aspartic acid results in a non-functional channel (Chapter 6). It has been shown that Kv1.1 channel 
subunits can assemble with other Kv channel subunits to form heterotetramers [112]. Importantly, 
hypomagnesemia in the Brazilian family is inherited in an autosomal dominant manner and patients 
with the N255D mutation are heterozygous. Expression of both alleles likely results in the formation of 
heterotetrameric channels composed of wild-type and mutated channel subunits leading to a dominant 
negative effect by the Kv1.1 N255D subunit (Chapter 6). The mutation replaces a neutral amino acid 
(asparagine) by one with an acidic side-chain (aspartic acid), which may destabilize the secondary or 
tertiary channel structure and thereby channel formation or trafficking. However, we demonstrated 
that wild-type Kv1.1 channels, Kv1.1 N255D channels, and the combination hereof are expressed in 
equal amounts at the plasma membrane (Chapter 6).
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Interestingly, the newly identified heterozygous Asn255Asp mutation is positioned close to the 
voltage sensor element (S4). S4 contains a long array of positive charges that are believed to sense 
differences in voltage and start the transition from the closed to open conformation by forming 
stabilizing hydrogen bonds with the external and internal negative clusters in the voltage-sensing 
domain [113, 114]. The evidence of a closely located, complicated hydrogen network together with 
introduction of an additional charge, led to the hypothesis that the N255D mutation interferes with the 
voltage sensor characteristics of Kv1.1. Therefore, the tertiary structure of Kv1.1 was modeled by the 
WHAT-IF server, based on 75% sequence identity with the crystallized Kv1.2-Kv2.1 chimearic 
channel [88, 115]. Additionally, six mutations were introduced at position 255 to study amino acid 
substitution at position 255 in relation to channel function more extensively (Chapter 7). Depending 
on the polarity of the side chain, amino acids vary in their hydrophilic or hydrophobic character [116]. 
These properties are important determinants of the protein structure and the physical properties of the 
side chains influence the amino acid residues' interactions with other structures, both within a single 
protein and between proteins. Importantly, the change in amino acid at position 255 had no effect on 
channel trafficking as all mutant were expressed at the plasma membrane (Chapter 7). The 
hydrophilic asparagine residue could be important for structural rearrangements within the channel in 
response to voltage changes, which are possibly hampered by the introduction of a negative residue
255 255 255(N255D). To investigate this, another negative glutamic acid (N255E) or positive histidine (N255H) 
residue were introduced. Compared to asparagine, the glutamic acid contains an extra CH2-group. As 
a control for steric hindrance, the non-charged glutamine was introduced (N255Q), which is the same 
size as Glu. Whole-cell patch clamp analysis demonstrated that N255E and N255Q channels were non­
functional, while N255H functions as a normal channel. This indicates that next to the addition of a 
negative charge at position 255 also an additional CH2-group in the side-chain influences channel 
function, likely by conformational rearrangements. Alternatively, introduction of the N255D mutation 
may block the formation of hydrogen bonds, which reduces the stability of the Kv1.1 channel
255 255 255structure. Therefore, alanine (N A), valine (N V), and threonine (N T) were introduced. Alanine 
and valine contain both non-polar side chains such that participation in hydrogen bounds is precluded, 
whereas threonine has an alcoholic group in its side-chain and is, therefore, able to contribute to 
hydrogen binding. These amino acid substitutions had no effect on Kv1.1 channel activity as shown 
by patch clamp analysis. Furthermore, the voltage-dependence and kinetics of channel gating of these 
functional mutants (N255A, N255V, N255T, N255H) was examined (Chapter 7). There was no 
correlation between the size, loss of hydrogen bond or charge and the magnitude of the shift in V1/2 
for activation or inactivation. Though, the acceleration of the inactivation process is also of interest, 
as it is explained by a constriction mechanism of the outer mouth of the channel vestibule [117, 118]. 
The N255H mutation enables the channel to undergo a slightly faster inactivation (Chapter 7), which 
might indicate that the residue at this position takes part in the conformational change during 
inactivation. So, charged residues at position 255 could be important for conformational changes
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since this effect was specific for N255H. It has already been demonstrated that negatively charged 
clusters in the S2 and S3 segments, together with the positive charges in S4, are involved in the 
opening and closing of Kv1 channels [115]. In line with this, an earlier study showed that mutation of 
conserved negatively charged residues in the S2 and S3 segments selectively modulated channel 
gating. Mutation of the aspartic acid at position 258 in Kv1.1 even abolished channel activity [119]. 
Therefore, we suggest that an additional negative charge nearby this cluster in S3 could keep the 
channel in the inactivated state, which may explain the non-functionality of the mutation found in 
patients with hypomagnesemia (N255D). Altogether, Asn255 is essential for normal channel function, 
since substitution by other amino acids significantly altered channel activity, voltage-dependence and 
kinetics of Kv1.1 channels, but more detailed structural information is necessary to specify the 
involvement of this residue in voltage-sensing and channel opening.
Expression and physiological role of Kv1.1
Kv1.1 was shown to localize to the apical membrane of DCT cells and postulated to be involved 
in the generation of a favorable apical membrane voltage as a driving force for Mg2+ entry. The Mg2+ 
influx via TRPM6 is energized by the local electrochemical gradient. Importantly, the DCT cell lacks 
a substantial chemical gradient for Mg2+. The Mg2+ concentration in the pro-urine is likely around 1.1 
mM, while the free intracellular Mg2+ concentration has been estimated to be 0.5-1.0 mM [120]. The 
luminal membrane potential in the DCT is approximately -70 mV [121], favouring luminal Mg2+ 
influx. Thus, the movement of Mg2+ into the DCT cell seems mainly driven by the electrical gradient. 
The renal outer medullary potassium channel (ROMK) was proposed to generate the luminal 
membrane potential via K+ efflux. Nevertheless, immunolocalization studies showed specific ROMK 
staining in the TAL and connecting tubule (CNT), but not the DCT [122]. Alternatively, Kv1.1 has 
been identified as luminal K+ channel in DCT that is believed to establishe a favourable luminal 
membrane potential to control TRPM6-mediated Mg2+ reabsorption. Consequently, mutation of 
Kv1.1 residue Asn255 leads to impairment of renal Mg2+ handling [125] (Chapter 6). Interestingly, the 
fact that Kv1.1 channels expressed in DCT cells are not easily activated at the existing membrane 
potential suggest that their activities are relatively transient, making it difficult to ascribe a functional 
role. However, there are many examples of Kv channels expressed in epithelial tissue with diverse 
functions including transepithelial electrolyte transport, cell volume regulation, K+ secretion, and 
apoptosis [94, 123, 124]. Future studies should confirm the exact role of Kv1.1 channels in the DCT 
cell.
It is, however, still unknown how distinct mutations in nearby amino acid residues in Kv1.1 can 
result in phenotypes with dysfunction in two different organs (brain and kidney). There are several 
mechanisms to explain the kidney-associated phenotype, which so far has only been observed for the 
Kv1.1 N255D mutation: i) the composition of Kv1.1 channels in brain and kidney is different, due to 
tissue-specific expression of auxiliary P-subunits or co-assembly with other Kv1 subunits that define
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the functional characteristics of these channels [126-128]; ii) the Kv1.1 N255D mutation may have a 
dominant effect on the function of an unidentified kidney-specific interaction partner, but not on the 
interaction partners expressed in brain; iii) the expression of an alternative tissue-specific Kv1.1 
coding sequence. So far, most studies have focused on the neurological phenotype and other kidney- 
specific transcripts may have been missed. For that reason, it is interesting to investigate whether 
other Kv1.1 transcripts exist within the kidney; iv) post-translational modification processes differ 
between tissues such as the brain and kidney. In combination with the mutation, this may give rise to 
a tissue-specific phenotype. Importantly, further experiments are necessary to identify the mechanism 
that underlies the kidney-specific phenotype.
Kir4.1 as new K+ channel in the DCT
Recently, mutations in the KCNJ10 gene, encoding the K+ channel Kir4.1, were identified as the 
cause for a unique autosomal recessive form of Gitelman-like renal salt wasting disorder [129, 130]. 
Patients have a complex combination of features that is called EAST syndrome: epilepsy, ataxia, 
sensorineural deafness, and (a salt-wasting) renal tubulopathy (or seizures, sensorineural deafness, 
ataxia, mental retardation, and electrolyte imbalance (SeSAME)). Kir4.1 immunostaining has been 
found at the basolateral membrane of the DCT in human, rat and mice [131, 132]. Here, the Na+,K+- 
ATPase facilitates transport of Na+ to the interstitium and K+ to the intracellular compartment against 
their respective chemical gradients, generating a driving force for luminal NaCl influx via NCC and 
basolateral Cl- transport via ClC-Kb. Kir4.1 is suggested to recycle K+ into the interstitium to allow a 
sufficient supply of K+ for optimal Na+,K-ATPase activity. Another functional adaptation of DCT 
cells is that they are rich in mitochondria and have deep basolateral infoldings, leading to increased 
membrane surface. These characteristics were shown to be greatly diminished under conditions with 
lowered transport activity, as shown in a mouse model for GS [133]. The transport processes in the 
DCT are similarly affected in patients with EAST syndrome [129].
Conclusion
Taken together, the emerging role for particularly K+ channels in controlling the reabsorption of 
Mg2+ and their localization to the same tubule segments is remarkable. Combined disturbances in the 
K+ and Mg2+ balance are frequently observed in common pathological conditions. An extensively 
studied case is Gitelman syndrome, where patients endure hypokalemic metabolic alkalosis with 
hypomagnesemia and hypocalciuria [134, 135]. Additionally, individuals suffering from hypokalemia 
often require co-administration of Mg2+ and K+ in order to correct the hypokalemia successfully [136]. 
Furthermore, several K+ channels, including Kv1.1, are shown to be sensitive to intracellular Mg2+ 
[137]. Future studies should reveal the interrelationship between K+ and Mg2+ homeostasis.
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Intracellular Mg detection
As discussed in this thesis, Mg2+ is an essential electrolyte for all living organisms. Though, 
studying the correlation between the biochemical characteristics of Mg2+ and its involvement in a 
plethora of biological functions has been obstructed by missing appropriate techniques to monitor 
changes in free [Mg2+]i in the cell. The following paragraphs compose a summary of various methods 
that are presently used to measure [Mg2+]i or Mg2+ transport in cells.
Atomic absorbance spectrophotometry11381
This is the most commonly used method for measuring Mg2+ in biological samples, because it has 
advantages in terms of selectivity, sensitivity, and reproducibility. The determinations are usually 
carried out in the presence of other cations to minimize complexes with interfering anions. In view of 
the relatively high cellular Mg2+ content, the sensitivity is also a drawback because it requires dilution 
of samples or determination after culturing under artificially low concentrations of extracellular Mg2+. 
Other major limitations are that it measures total, rather than free, Mg2+ content and that the technique 
requires lysis of the sample, which limits any kinetic analysis.
Radioactive 28Mg2+
Radioactive Mg2+ can be used in uptake assays, which allow the calculation of the kinetic 
parameters, like the Michaelis constant (Km), dissociation constant (Ki) and maximum rate of uptake 
(Vmax), to ultimately determine changes in Mg2+ content of cells. However, the radioactive half-life of 
28Mg, the most stable of the radioactive Mg2+ isotopes, is only 21 hours. This fast decay severely 
restricts the number of possible experiments. In addition to these limitations intrinsic to any isotopic 
trace determination, 28Mg is not routinely produced and is only available at an exorbitant cost.
31P nuclear magnetic resonance spectroscopy
Nuclear magnetic resonance (NMR) spectrometry was first used to estimate free [Mg2+]i in 1977 
[139]. This method was proven to be useful for estimating free Mg2+ content non-invasively in 
biological samples. It is based on differences in NMR spectral signal of the two major ATP forms in 
the cell, namely free ATP and Mg-ATP complex. A major drawback is the lack of sensitivity, as the 
shift observed under normal conditions is only a fraction of the possible spectral shift. This is due to 
the fact that most cytosolic ATP is in the ATP-Mg form. So, even large changes in intracellular Mg2+ 
content will have only a small effect on the concentrations of ATP-Mg and therefore on the apparent 
shift. This means that the technique will be relatively insensitive to physiological changes in cytosolic 
free Mg2+ for most mammalian cells. Furthermore, the accuracy of free [Mg2+]i determination depends 
on the dissociation constant (Kd) used and on factors that influence this equilibrium, such as pH, 
temperature and osmolarity in the cell [140].
Chapter 8
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Mg2+-selective electrodes
The first Mg2+-selective microelectrode was developed about 30 years ago (ETH1117, [141]). 
Unfortunately, the cytosolic Mg2+ values obtained with this electrode were quite variable, most likely 
due to lack of selectivity for Mg2+ over K+. In 1989, a significantly improved Mg2+-selective 
ionophore was developed (ETH 5214, [142]), based on which several new ionophores have been 
developed in the past years (reviewed by Gunzel [143]). These electrodes have been widely used as 
they have some advantages over other techniques. First, the membrane potential is measured 
simultaneously, so that the condition of the cell is constantly monitored. Second, these 
microelectrodes, with very few exceptions, cannot penetrate intracellular organelles, so that their 
response exclusively reflects concentration changes within the cytoplasm. Once successfully impaled, 
microelectrodes allow continuous recording as long as the impalement holds, even for up to several 
hours. However, a major disadvantage is that their use is limited to relatively large, strong cells, like 
oocytes, in which changes can only be monitored at the specific location of impalement. Furthermore, 
there is mostly interference from other cellular cations as Na+ and K+, which requires the 
simultaneous measurements of many ions via multibarrel microelectrodes [144] followed by 
appropriate corrections.
Fluorescent indicators
Commercial Mg2+ indicators
Fluorescent indicators provide a tool to measure [Mg2+]i levels and transients in individual cells 
with both spatial and temporal resolution. The first report of a fluorescent indicator that was able to 
measure Mg2+ levels in serum and urine appeared in 1959 [145]. It took thirty years for the 
development of a new fluorescent Mg2+ indicator, named mag-fura-2 (or furaptra by Raju et al. [146]. 
This compound is based on the Ca2+ indicator fura-2 (Grynkiewicz et al.). In general, the usefulness 
of fluorescent indicators in measuring [Mg2+]i depends on the ability to load cells with the compound 
and on the affinity for Mg2+. Cell loading with mag-fura-2 and other indicators is generally realized 
with an acetoxymethylester derivative (mag-fura-2-AM), which diffuses into the cell where cytosolic 
esterases cleave the acetoxymethyl group such that the indicator gets trapped. Importantly, mag-fura- 
2 has a higher affinity for Ca2+ than for Mg2+ (Kd ~ 50 ^M vs. 1.5 mM, respectively [147]). Thus, 
only the fact that the [Ca2+]i in most cells is in the nanomolar range permits mag-fura-2 to be used as 
Mg2+ indicator. In addition, polyamines, such as putrescine and spermine, have been reported to 
reduce the response of mag-fura-2 to Mg2+ [148]. Similarly, alterations in cell volume during an 
experiment may produce viscosity changes that can alter mag-fura-2 responses [149]. Based on the 
discovery of mag-fura-2 , several other fluorescent indicators have synthesized with slightly different 
dissociation constants and characteristics, which are listed in the Molecular Probes catalog [150]. 
However, they still have a relatively high affinity for Ca2+, thereby requiring appropriate corrections 
that limit their use.
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KMG-104
In 2004, Komatsu et al. synthesized three novel Mg2+ fluorescent indicators KMG-101, -103, and 
-104 [151]. The compounds of this series feature a charged P-diketone as a binding site specific for 
Mg2+ and a fluorescein residue as the fluorophore that can be excited with an Ar+ laser such as is 
widely used in confocal scanning microscopy. Among the KMG series, the KMG-104 showed the 
best properties. It has a suitable dissociation constant (Kd ~ 2.1 mM) and had significantly lower 
affinity for Ca2+ (Kd ~ 7.5 mM). Furthermore, it appears to be unaffected by pH shifts between 6.0 
and 7.6 [151]. This led to the development of the membrane-permeable KMG-104-AM, which can be 
employed for sensitive and selective Mg2+ determination. In the past years, this probe has been used 
use to measure [Mg2+]i in several mammalian cell types [152-154]. However, the major disadvantage 
of the KMG series is that their measurement is based on a single wavelength, termed non-ratiometric, 
which may lead to artificial alterations in the fluorescence signal that could be misinterpreted as 
changes in Mg2+ level. These alterations are most likely due to changes in cell volume in response to 
osmolarity differences in the intracellular and extracelluar milieu. Interestingly, our group has also 
used KMG-104-AM to measure [Mg2+]i and demonstrated increase in fluorescence signal in response 
to increasing Mg2+-containing extracellular solutions. Unfortunately, we were not able to detect any 
KMG-104 signal when Mg2+-containing solutions were corrected for osmoloratiy changes, indicating 
that this putative Mg2+ probe is not specifically Mg2+-sensitive but rather too responsive to other 
cellular responses as cell swelling/shrinking. (unpublished data).
Other possibilities
On one hand, the ideal Mg2+ indicator is still not available, while on the other hand, other imaging 
techniques could also be essential to better exploit the existing indicators. For example, Fluorescence 
Lifetime Imaging Microscopy (FLIM) can produce an image based on the differences in decay rate of 
fluorescence. So, the lifetime of the signal, rather than its intensity, is used to create the image in 
FLIM. As most of the fluorescent indicators undergo a change in fluorescence lifetime upon Mg2+ 
binding, this method could be used for imaging. Furthermore, FLIM can create an image contrast at 
each point in a two-dimensional image, thereby taking information on cellular changes due to the 
chemical environment (pH, viscosity) into account during the measurement. A different approach 
would be the development of FRET-based sensors by inserting a natural Mg2+ binding site in the 
cyan-yellow fluorescent proteins (CFP-YFP), which are commonly used in FRET-based methods. 
The protein will undergo a conformational change upon Mg2+ binding, leading to a FRET change. 
Importantly, these proteins could also be employed for targeting to specific subcellular locations, 
allowing detailed Mg2+ measurement at the plasma membrane or in certain organelles as 
mitochondria.
The ultimate challenge is not only to design the probe with ideal characteristics, but also to 
develop appropriate tools to study Mg2+ levels in vivo. A combinational approach including chemical,
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physical and biological methods will be necessary for the synthesis of new probes and imaging 
techniques to allow this scenario to come true.
Summary
It can be concluded that none of the above-described techniques is without serious drawbacks, 
which stresses the need to develop alternative approaches. The possibility to measure [Mg2+]i in a 
living organism would highly advance the Mg2+-related research.
Conclusion and future directions
The overall aim of this thesis was to provide more insight in the physiological and molecular 
regulation of transepithelial Mg2+ transport processes. The studies presented in this thesis illustrated 
the identification of regulators of TRPM6 and the discovery of Kv1.1 as new renal ion channel 
essential in controlling the body’s Mg2+ balance. This research has greatly increased our knowledge 
on the mechanisms that regulate the active Mg2+ reabsorption through effects on TRPM6 function. 
However, the processes of cytosolic Mg2+ diffusion and basolateral extrusion are not well studied. In 
the past years, much of the understanding of mechanisms regulating Mg2+ homeostasis has come from 
studies of inherited forms of Mg2+ wasting. So, discovery of new genes by genetic screening studies 
might help to elucidate these processes further. In addition, several Mg2+ transport proteins have been 
discovered through homology searches with prokaryotic counterparts and screening for genes that 
were upregulated in cells that were subjected to low [Mg2+]e. Further investigation could unravel a 
possible physiological role of the protein products of these genes in renal Mg2+ handling and 
improved Mg2+ detection methods will certainly help in the classification and validation of these 
proteins. Moreover, a future challenge would be to further understand the role of the fused a-kinase 
domain in TRPM6 function. So far, the investigations described in this thesis demonstrated an 
indirect regulatory role of the a-kinase domain via interaction with proteins that modulate TRPM6 
channel activity. New projects should aim to investigate the mechanism of a direct interrelationship 
between TRPM6 channel function and a-kinase activity by identification of renal downstream target 
protein of this domain and by unraveling the phosphorylation-dependent control of TRPM6. 
Altogether, future studies should increase our understanding of the molecular mechanism of 
transepithelial Mg2+ transport and regulation hereof by the TRPM6 channel and its fused alpha­
kinase. Subsequently, this can be exploited to develop novel therapies for hypomagnesemia and 
associated pathologies.
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Het menselijk lichaam bestaat uit miljoenen cellen, die elk verschillen in grootte en functie. De 
cel kan gezien worden als kleinst georganiseerde eenheid in een organisme. Alle cellen worden 
omgeven door een plasmamembraan, die een afscheiding vormt tussen het interne en externe milieu. 
De plasmamembraan is opgebouwd uit hydrofobe (waterafstotende) vetten en hydrofiele 
(wateraantrekkende) moleculen. De hydrofobe vetten vormen een barrière voor het 
membraantransport van hydrofiele en elektrisch geladen moleculen (ionen). In de jaren ’50 en ’60 zijn 
er speciale transporteiwitten ontdekt, die ionen door de plasmamembraan kunnen vervoeren. Deze 
eiwitten worden ionkanalen genoemd. Het transport van ionen door ionkanalen in de 
plasmamembraan kan gemeten worden als elektrische activiteit. De ontwikkeling van een techniek 
genaamd patch clamp maakt het mogelijk om de elektrische activiteit van een enkel ionkanaal in een 
levende cel te meten. Op deze manier kan de ionenstroom door het ionkanaal bepaald worden.
In de laatste decennia heeft onderzoek op dit gebied geleid tot de ontdekking van vele verschillende 
ionkanalen. De Transient Receptor Potential (TRP) transporteiwitten vormen een familie van 
ionkanalen. Er bestaan 28 TRP kanalen, die kunnen worden onderverdeeld in zes subfamilies: 
canonical (TRPC), vanilloid (TRPV), polycystin (TRPP), mucolipin (TRPML), ankyrin (TRPA) en 
melastatin (TRPM). De TRPM6 en TRPM7 kanalen zijn essentieel voor het behoud van een gezonde 
Mg2+ balans in het lichaam. TRPM6 is voornamelijk gelokaliseerd in een speciaal segment van de 
nier, het distaal convoluut, waar het zorgt voor Mg2+ opname vanuit de voorurine. Deze opname, ook 
wel Mg2+ resorptie genoemd, bepaalt de uiteindelijke Mg2+ concentratie in het bloed. Genetisch 
onderzoek heeft uitgewezen dat TRMP6 frequent aangetast is in erfelijke aandoeningen met verlaagde 
bloed Mg2+ spiegels (hypomagnesiëmie). Een defect in het TRPM6 gen leidt tot een disfunctionerend 
TRPM6 kanaal, waardoor de patiënten onvoldoende Mg2+ resorberen vanuit de voorurine naar het 
bloed. Dit leidt tot de aandoening hypomagnesiëmie met secundaire hypocalcemie (HSH). In 
tegenstelling tot TRPM6 komt TRPM7 in de meeste weefsels in het lichaam voor en speelt een 
belangrijke rol bij de algemene cellulaire Mg2+ huishouding.
De TRPM6 en TRPM7 eiwitten bestaan uit de unieke combinatie van een porievormend domein 
voor iontransport en een a-kinase domein. De a-kinases moduleren andere eiwitten door een 
fosfaatgroep toe te voegen (fosforylatie), waarmee deze eiwitten geactiveerd worden. Er is echter nog 
weinig bekend over de functionele rol van dit a-kinase domein in de regulatie van de TRPM6 
kanaalfunctie. Daarnaast is er nog verder onderzoek vereist naar de regulatie van TRPM6 door 
bindingseiwitten, hormonen en andere factoren. Het onderzoek beschreven in dit proefschrift heeft 
als doel meer inzicht te bieden in de moleculaire regulatie van het epitheliale Mg2+ kanaal TRPM6 om 
zodoende de kennis over het proces van actieve Mg2+ resorptie in de nier te vergroten.
Introductie
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RACK1 als eerste bindingspartner van het TRPM6 a-kinase domein
Receptor for Activated C Kinase 1 (RACK1), ontdekt als bindingseiwit van Protein Kinase C 
(PKC), komt samen met TRPM6 voor in de Mg2+-transporterende distaal convoluut cellen in de nier. 
Door binding aan het a-kinase domein van TRPM6 is RACK1 in staat de TRPM6 kanaalactiviteit te 
remmen (Hoofdstuk 2). Verlaging van endogeen RACK1 in de cel leidde tot stimulatie van de 
TRPM6 activiteit, hetgeen de directe remming van TRPM6 door RACK1 aantoonde. De inhibitie 
door RACK1 was afhankelijk van fosforylatie van een TRPM6 threonine residu (Thr1851) door het 
TRPM6 a-kinase domein (autofosforylatie). Deze autofosforylatie van Thr1851 beïnvloedde tevens de 
Mg2+ gevoeligheid van de TRPM6 kanaalactiviteit en de a-kinase autofosforylatie activiteit. De 
binding tussen RACK1 en het TRPM6 a-kinase domein werd sterk verminderd door activering van 
PKC, dat vervolgens het remmend RACK1-effect op de TRPM6 kanaalactiviteit kon opheffen. In 
deze studie is een nieuw model beschreven waarbij RACK1 de TRPM6-gedreven Mg2+ influx 
reguleert via interactie met het a-kinase domein, met een belangrijke rol voor de fosforylatie status 
van het Thr1851 residu.
TRPM6 regulatie door REA en oestrogeen
De naam ‘Repressor of Estrogen receptor Activity’ (REA) duidt de oorspronkelijk beschreven 
functie van het eiwit aan. REA onderdrukt namelijk de transcriptionele activiteit van 
oestrogeenreceptoren door binding aan de receptor. In het onderzoek beschreven in Hoofdstuk 3 van 
dit proefschrift is REA als bindingspartner van het TRPM6 a-kinase domein geïdentificeerd, waarbij 
het aan dezelfde regio bindt als het eerder beschreven RACK1. Daarnaast bevindt REA zich in 
hetzelfde niersegment als TRPM6, wat de fysiologische rol van het eiwit benadrukt. REA was in staat 
om de TRPM6 kanaalactiviteit te remmen, maar had geen effect heeft op een kinase-inactieve 
TRPM6 mutant (K1804R), die wel in staat was om REA te binden. De functie van REA werd 
bovendien niet aangetast door het wegvallen van de TRPM6 kinase activiteit, want REA werd niet 
gefosforyleerd door TRPM6 . Daarnaast had REA geen effect op de autofosforylatie activiteit van 
TRPM6, dus de remmende werking van REA op de kanaalactiviteit kan niet het gevolg zijn van een 
eventueel remmend effect op autofosforylatie. Deze gegevens wijzen op een nog onbekende indirecte 
regulatie van TRPM6 door REA. Een mogelijke schakel in dit geheel zou het eiwit PKC kunnen zijn, 
aangezien activering van dit kinase zorgde voor extra remming van REA op TRPM6 . Een interessante 
bevinding was de rol die oestrogeen in dit proces speelde. Toevoeging van de synthetische variant van 
oestrogeen, 17^-estradiol, verstoorde de interactie tussen REA en TRPM6. Door verstoring van deze 
interactie was 17^-estradiol in staat de TRPM6 kanaalactiviteit te stimuleren. In een eerdere studie is 
al aangetoond dat muizen die langdurig behandeld werden met 17^-estradiol een toegenomen 
hoeveelheid TRPM6 kanalen in de nier aanmaakten. Hoofdstuk 3 van dit proefschrift beschrijft een 
geheel nieuw kort tijdspad waarop oestrogeen TRPM6 kan stimuleren. Tevens is REA ontdekt als
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negatieve factor in de regulatie van de TRPM6-gedreven Mg2+ resorptie, met oestrogeen als 
belangrijke schakel in dit proces.
TRPM6, MsrB1 en oxidatieve stress
Methionine sulfoxide reductase B1 (MsrBl) behoort tot de Msr familie van eiwitten die bestaat 
uit MsrA en drie MsrB leden. Deze eiwitten komen met name voor in de nier, de lever, het hart en in 
het zenuwstelsel. Ze beschermen cellen tegen oxidatieve stress, doordat ze beschadigde eiwitten in de 
cel kunnen reparen. Deze schade ontstaat door de vorming van zogenaamde ’reactive oxygen species’ 
(ROS), ofwel zuurstofradicalen die ontstaan uit normale metabole reacties. Er is echter steeds meer 
bewijs dat ROS niet alleen schadelijke producten zijn van deze reacties, maar ook een essentiële rol 
vervullen voor signalen in de cel. MsrBl, dat methioninesulfoxide reduceert tot methionine, zou een 
dynamische rol kunnen spelen in deze signaalpaden. MsrBl is geïdentificeerd als derde 
bindingspartner van het TRPM6 a-kinase domein (Hoofdstuk 4). Onder normale metabole condities 
had MsrB 1 geen effect op de TRPM6 kanaalactiviteit. Inductie van oxidatieve stress door toediening 
van waterstofperoxide (H2O2) veroorzaakte echter een drastisch remmend effect op de TRPM6 
kanaalactiviteit. Het methionine residu (Met1755) in TRPM6 was van belang voor het H2O2 effect. 
Verandering van deze methionine in alanine (Met1755Ala, een residue dat niet geoxideerd kan worden) 
was in staat de remming op de TRPM6 kanaalactiviteit grotendeels op te heffen. Bovendien kon het 
remmend effect gedeeltelijk worden hersteld door MsrBl. Deze data geven aan dat MsrBl een rol 
speelt bij de regulatie van TRPM6 gedurende oxidatieve stress. Het grote aantal mitochondria in de 
distaal convoluutcellen, een belangrijke bron voor H2O2, zou een fysiologische verklaring kunnen zijn 
voor de link tussen TRPM6 en MsrB l .
Het effect van Erlotinib op TRPM6-gedreven Mg2+ transport
Het is bekend dat receptoren van de epidermale groei factor (EGFR) bij verschillende typen 
kanker overvloedig aanwezig zijn in de cel en voor ongecontroleerde celgroei zorgen. Deze 
ongecontroleerde groei kan geblokkeerd worden door het gebruik van monoklonale antilichamen 
tegen EGFR of specifieke remmers van de zogenaamde tyrosine kinase functie van de EGFR. 
Cetuximab, een bekende blokker van de EGFR, wordt regelmatig gebruikt tegen darmkanker en het 
uit recente studies blijkt dat deze behandeling tot hypomagnesiëmie kan leiden. Naast de EGFR 
antilichamen, zoals Cetuximab, zijn er ook patiënten die behandeld worden met tyrosine kinase- 
remmers, waaronder Erlotinib. Er is tot dusver niks bekend over het potentiële effect van Erlotinib op 
de Mg2+ huishouding. In Hoofdstuk 5 van dit proefschrift is het effect van Erlotinib op de regulatie 
van de Mg2+ balans bestudeerd. Gedurende 23 dagen hebben muizen een supra-fysiologische doses 
Erlotinib toegediend gekregen. Vervolgens werden de Mg2+ waarden in bloed en urine gemeten en de 
hoeveelheid TRPM6 eiwit in de nier bepaald. De muizen vertoonden een verlaagde bloed Mg2+
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waarde, terwijl er geen verandering in Mg2+ concentratie in de urine zichtbaar was. Dit suggereert een 
defect in de nieren. Er was bovendien geen verandering waarneembaar in de hoeveelheid TRPM6 
eiwit in de nier. Om het effect van Erlotinib op TRPM6 verder te onderzoeken is de kanaalactiviteit 
gemeten. Er is al eerder aangetoond dat EGF in staat is de TRPM6 kanaalactiviteit te vergroten door 
transport van TRPM6 eiwitten vanuit het cytoplasma naar de plasmamembraan te stimuleren. Onze 
studie toonde aan dat Erlotinib deze EGF-gedreven stimulatie van TRPM6 kanaalactiviteit ophief. De 
remmende werking van Erlotinib is te wijten aan het blokkeren van de EGF-gedreven beweging van 
TRPM6 kanalen naar de plasmamembraan. De effecten van Erlotinib zijn concentratieafhankelijk, 
aangezien lagere Erlotinib concentraties (zoals ze worden toegediend aan patiënten) geen effect 
hebben op de EGF stimulatie. Dit verklaart het feit dat patiënten die Erlotinib voorgeschreven krijgen 
geen hypomagnesiëmie ontwikkelen. Er zou desondanks extra oplettendheid geboden moeten worden 
bij patiënten die meer gevoelig zijn om hypomagnesiëmie te ontwikkelen, door combinatie-gebruik 
van Mg2+-verlagende medicijnen.
Kv1.1 als nieuw ionkanaal in de regulatie van de Mg2+ balans
Voltage-afhankelijke kalium (K+) kanalen behoren tot een veelzijdige familie van ionkanalen, Kv 
genaamd, die een belangrijke rol spelen bij de elektrische signalen in de cel. Ze gaan open en dicht als 
gevolg van veranderingen in de elektrische lading over de plasmamembraan van de cel 
(membraanpotentiaal). In Hoofdstuk 6 van dit proefschrift wordt een familie beschreven, die aan een 
erfelijke aandoening van renaal Mg2+ verlies lijdt, als gevolg van een mutatie in het gen dat codeert 
voor Kv1.1,. De aangedane familieleden hebben zeer lage bloed Mg2+ spiegels (< 0.40 mM, normaal 
0.70-0.95 mM) en hebben al vanaf jonge leeftijd last van spierkrampen, tetanie, spierzwakte en 
myokymie. Tot dusver zijn er enkel mutaties beschreven in Kv1.1 die leiden tot de ziekte episodische 
ataxie (EA1) en onze studie toont voor het eerst een link aan tussen Kv1.1 en hypomagnesiëmie. Er 
is aangetoond dat Kv1.1 evenals TRPM6 voorkomt op de plasmamembraan aan de voorurine zijde 
van de distaal convoluutcellen. De mutatie die gevonden is in de patiënten van bovenstaande familie 
resulteert in de aminozuurverandering Asn255Asp. Het gemuteerde kanaal bevindt zich nog wel op de 
plasmamembraan, maar kan niet meer normaal functioneren. Hierdoor is het defecte Kv1.1 kanaal 
niet meer in staat om de membraanpotentiaal van de cel te handhaven. Aangezien er geen verschil is 
tussen Mg2+ concentraties aan beide zijden van de plasmamembraan (chemische gradiënt), is een 
negatieve membraanpotentiaal essentieel om een elektrische gradiënt te creëren voor Mg2+ opname 
via TRPM6 vanuit de urine. De hypothese in deze studie is dat Kv1.1 de membraanpotentiaal van de 
distaal convoluutcellen verzorgt en dat de mutatie in Kv1.1 dit proces verstoort, zodat er een 
verminderde Mg2+ resorptie plaatsvindt die de hypomagnesiëmie in deze familie verklaart.
Chapter 9
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255Functionele gevolgen van de Kv1.1 N D mutatie
Zoals hierboven beschreven, leidt de mutatie in Kv1.1 tot een ‘dood’ kanaal, terwijl de 
hoeveelheid kanalen op de plasmamembraan niet verminderd was. Daarom is het onderzoek 
beschreven in Hoofdstuk 7 gericht op het belang van het bovengenoemde asparagine residu (N255) 
voor de Kv1.1 kanaalfunctie. Hiervoor werden er diverse aminozuurveranderingen aangebracht op de 
positie van het N255 residu om het effect van verandering van lading, verlies van 
waterstofbrugvorming en sterische hindering te bestuderen. Geen van de aminozuurveranderingen had 
een effect op het vervoer van Kv1.1 kanalen naar het plasmamembraan. De hypothese dat een 
negatieve lading op het 255  residu de kanaalfunctie zou veranderen, is onderzocht door vervanging 
van de neutrale asparagine door een negatief geladen glutaminezuur (N255E) of een positief geladen 
histidine (N255H). Daarbij werd tevens als controle voor structurele hindering van het grotere
255 255 255glutaminezuur het effect van een ongeladen glutamine (N Q) onderzocht. De N E en N Q 
kanalen konden geen K+ meer konden transporteren, terwijl het N255H kanaal normaal functioneerde. 
Dit laat zien dat er geen specifieke link is tussen lading op het 255 residu en kanaalfunctie. Een 
andere optie die werd onderzocht, is dat een aminozuurverandering op het 255  residu de vorming van 
waterstofbruggen met ander residuen opheft, wat gevolgen heeft voor de kanaalfunctie. Daarom 
werden de gemuteerde Kv1.1 kanalen N255A (asparagine naar alanine), N255V (asparagine naar valine) 
en N255T (asparagine naar threonine) getest. De aminozuurveranderingen bleken geen effect te hebben 
op de activiteit van het kanaal, maar tasten zowel de kinetiek van het openen en sluiten van de 
kanalen aan, als ook de gevoeligheid voor veranderingen in de membraanpotentiaal. Er kan echter 
geen duidelijke correlatie worden gelegd tussen enerzijds de aminozuurverandering die leidt tot 
verschillen in grootte van het aminozuur, verlies van waterstofbrugvorming of introductie van lading, 
en anderzijds de verandering van de kinetiek en voltage-gevoeligheid voor het openen en sluiten van 
het Kv1.1 kanaal. Er kan geconcludeerd worden het N255 residu essentieel is voor een normale Kv1.1 
kanaalfunctie, aangezien de aminozuurveranderingen significante verschillen vertoonden in 
bovenstaande karakteristieken van het kanaal. Een meer gedetailleerde analyse van de structuur en de 
betrokkenheid van andere aminozuren is echter noodzakelijk om de link tussen het N255 residu en 
Kv1.1 kanaalfunctie te ontrafelen.
Conclusie en toekomstperspectieven
Het doel van het onderzoek, beschreven in dit proefschrift, is het vergroten van de kennis en 
inzicht in de (patho)fysiologische aspecten en moleculaire regulatie van actieve Mg2+ resorptie in de 
nier. Tijdens de diverse studies zijn verschillende regulatoren van TRPM6 gevonden, waaronder 
bindende eiwitten, hormonen en specifieke medicijnen. Bovendien is Kv1.1 ontdekt als cruciaal 
ionkanaal in de nier voor het behoud van de Mg2+ balans. Dit draagt bij aan de opheldering van de 
regulatiemechanismen die betrokken zijn bij het proces van Mg2+ resorptie. Desondanks zijn
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verscheidene aspecten in dit proces nog onbekend, zoals het eiwit dat Mg2+ vanuit de distaal 
convoluutcel naar het bloed vervoert en een eiwit dat betrokken is bij de Mg2+ diffusie en/of buffer in 
de cel. Nieuwe genen, coderend voor Mg2+-transporterende eiwitten, kunnen worden ontdekt middels 
genetische studies naar aandoeningen met erfelijk verlaagde bloed Mg2+ spiegels, zoals in dit 
proefschrift is gedaan. Daarnaast zijn er in de afgelopen jaren al enkele Mg2+-transporterende eiwitten 
ontdekt en nader onderzoek naar deze eiwitten kan de mogelijke fysiologische rol in de Mg2+ 
huishouding ontrafelen. Er ligt ook een interessante uitdaging om de rol van de TRPM6 a-kinase 
verder op te helderen. Nieuwe projecten kunnen gericht zijn op de bestudering van een directe link 
tussen TRPM6 kanaalfunctie en de functie van het a-kinase domein. Gezamenlijk zullen de 
toekomstige studies de kennis vergroten rondom het moleculaire mechanisme van actieve Mg2+ 
resorptie en regulatie hiervan door het TRPM6 kanaal en a-kinase domein. Dit kan uiteindelijk 
worden gebruikt om nieuwe therapieën te ontwikkelen voor hypomagnesiëmie en andere Mg2+- 
gerelateerde aandoeningen.
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[Mg2+]i intracellular Mg2+ concentration
2-ABP 2 -amino-ethoxydiphenyl borate
ANOVA analysis of variance
ATP adenosine 5’-triphosphate
ATPase adenosine 5’-triphosphatase
bp base pairs
Ca2+ calcium ion
cAPM cyclic adenosine monophosphate
CD collecting duct
cDNA complementary deoxyribonucleic acid
Cl- chloride ion
CLC-Kb Cl- channel Kb
CLDN16 gene encoding claudin 16
CLDN19 gene encoding claudin 19
CNT connecting tubule
cM centi-Morgan
DCT distal convoluted tubule
DMEM dulbecco’s modified eagle medium
EDTA ethylenediaminetetraacetate
EGF epidermal growth factor
EGFR epidermal growth factor receptor
FTMS fourier transform ion cyclotron resonance mass spectrometry
GFP green fluorescent protein
GST glutathione S-transferase
HEK293 human embryonic kidney cells
HEPES 4-(2-hydroxy ethyl)-1 -piperazineethanesulfonic acid
HSH hypomagnesemia with secondary hypocalcemia
IC50 half maximal inhibitory concentration
IRH isolated recessive renal hypomagnesemia
I/V current-voltage relationship
K+ potassium ion
KCl potassium chloride
KCNA1 gene encoding Kv1.1
kDa kilo dalton
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List of abbreviations
Kv 1.1 voltage-gated K+ channel 1.1, shaker, member 1
MDCK cells madin darby canine kidney cells
Mg2+ magnesium ion
Mg2+-ATP Mg2+ bound to ATP
mRNA messenger ribonucleic acid
MsrB 1 methionine sulfoxide reductase B 1
mTAL medullary thick ascending limb of Henle’s loop
Na+ sodium ion
NaCl sodium chloride
NCC Na+,Cl--cotransporter
PBS phosphate-buffered saline
PCR polymerase chain reaction
PIP2 phosphatidylinositol 4,5-bisphosphate
PKA protein kinase A
PKC protein kinase C
PLC phospholipase C
PMA phorbol 12-myristate 13-acetate
PT proximal tubule
RACK1 receptor for activated c-kinase 1
REA repressor of estrogen receptor activity
RRS ras recruitment system
RT-PCR reverse-transcriptase polymerase chain reaction
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM standard error of the mean
TAL thick ascending limb of Henle’s loop
TIRF total internal reflection fluorescence
TM transmembrane segment
Tris tris(hydroxymethyl)aminomethane
TRP transient receptor potential channel
TRPA transient receptor potential channel, subfamily ankyrin
TRPC transient receptor potential channel, subfamily canonical
TRPM transient receptor potential channel, subfamily melastatin
TRPML transient receptor potential channel, subfamily mucolipin
TRPP transient receptor potential channel, subfamily polycystin
TRPV transient receptor potential channel, subfamily vanilloid
YFP yellow fluorescent protein
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Wat zijn de jaren voorbij gevlogen als ik terugkijk, zoveel geleerd en zoveel gegroeid, op 
wetenschappelijk én op persoonlijk vlak. Het is fijn om op deze laatste pagina’s van m’n proefschrift 
alle mensen (collega’s, vrienden en familie) te bedanken die daaraan hebben bijgedragen.
Allereerst wil ik mijn promotores Prof. dr. René Bindels en Prof. dr. Joost Hoenderop bedanken. Ik 
heb ’n goede tijd gehad op de afdeling Fysiologie.
Beste René, ik wil je bedanken voor de mogelijkheid om mijn promotieonderzoek hier te doen. Jouw 
inzicht in de fysiologie, slagvaardigheid, en organisatietalent zijn bewonderenswaardig en een 
fundament voor het succes van de afdeling. Ik heb veel geleerd van je kritische blik en daarnaast heeft 
je vertrouwen in mijn werk me gesteund. De EMBO fellowship voelt als ‘n kroon op dit alles en laat 
het maar een goede start zijn van ‘n mooie nieuwe periode.
Beste Joost, jouw inzet en enthousiasme voor onderzoek zijn onnavolgbaar. Het is enorm fijn 
geweest om het gevoel te hebben altijd bij je binnen te kunnen stappen. Daarnaast wil ik je bedanken 
voor alles wat je me geleerd hebt op het gebied van presentatie- en schrijfvaardigheden.
Ook gaat mijn dank uit naar Prof. dr. Nine Knoers. Door samenwerking met de afdeling 
Antropogenetica zijn er mooie publicaties tot stand gekomen. Ik wil je verder heel veel succes wensen 
met je nieuwe baan in Utrecht.
Een andere prettige samenwerking is die met het CMBI. Ik wil graag Prof. dr. Gert Vriend en 
Hanka Venselaar bedanken voor alle behulpzaamheid en de verhelderende blik op de structuur van 
het TRPM6 kinase domein, maar vooral voor de modeling van Kv1.1.
Hierbij wil ik ook mijn student Anna-Lena Forst betrekken. Anna-Lena, bedankt voor je enorme 
inzet tijdens je stage en alle uitleg over de structuursveranderingen van Kv1.1, het heeft tot ’n mooie 
publicatie geleid.
I would like to thank all my colleagues of the department of Physiology for support, nice talks, good 
drinks, fruitful discussions and for creating an ‘gezellige’ atmosphere. I would especially like to thank 
a couple of people that were closer related to my daily lab activities over the past four years.
Gang, your enthusiasm for science is great! It was great having you as my supervisor for the student 
internship. This is where our collaborative studies started on your TRPM6 kinase babies. I enjoyed 
working with you, thanks a lot!
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Wouter, wat was ’t goed om bij jou in de unit te belanden als student. Eerst voornamelijk met m’n 
mond vol tanden staan, maar ik heb flink wat opgestoken van jou directe en adremme opmerkingen, 
bedankt! Je heldere blik en humor doen ’t trouwens nog steeds goed, tegenwoordig onder genot van 
’n biertje en veel gezelligheid.
Kirsten, het was fijn dat jij ook in Zürich zat toen ik daar als naïeve student stage kwam lopen. Ik heb 
je leren kennen als ’n lieve, warme persoon en wil je alle succes wensen met je nieuwe uitdaging in 
Utrecht komend jaar!
Rob (J.), ik ben blij dat we contact zijn blijven houden. Het is altijd erg fijn en gezellig om je weer te 
zien en spreken. En wat was New York tof!! Ik hoop over vier jaar ook jouw boekje te mogen 
ontvangen, succes met je promotietraject in Amsterdam!
Todd, I have fond memories of the time you spend in Nijmegen, I cherish your goodbye email and I 
hope to see you this year, either in Nijmegen or in Alberta, Canada.
AnneMiete en Irene, jullie draaien al ’n aantal jaren mee op de afdeling. AnneMiete, jouw bijdrage 
in het onderzoek is in nagenoeg ieder hoofdstuk van dit proefschrift terug te vinden, bedankt hiervoor. 
Irene, ik wil je bedanken voor je bijdrage in de vorm van het altijd tijd vrij maken voor alle 
bestellingen en vragen. Daarnaast wil ik jullie vooral bedanken voor de interesse die altijd getoond 
werd tijdens de koffiepauzes.
Femke en Mark, jullie zijn ’n belangrijke spil op de afdeling en ik bewonder de manier hoe jullie 
flexibel tussen verschillende projecten switchen. Ook wil ik jullie beide bedanken voor de extra 
experimenten die vaak nodig waren voor alle rebuttals van de artikelen in dit proefschrift.
Silvia en Anke, I really enjoyed our dinner nights/afternoons (together with Leonie)! I wish you all 
the best with finishing your PhD thesis at the department, you will do great!
Mannen uit ’t hetzelfde startjaar: Anne, Theun, Henrik, wat was ’t fijn om gezamenlijk deze 
promotietijd te doorlopen. Anne, jouw positiviteit is geweldig! Een hoop gezelligheid met jou op ’t 
lab en daarbuiten. Ik herinner me genoeg mooie bieravondjes en toffe feestjes op de Molenweg. 
Theun, ik vond ’t altijd fijn om met je praten en voel veel herkenning. Jij bent er ook bijna met je 
boekje en ik wens je veel succes met de vervolgstap. Henrik, “my Unit-partner”, I cannot think of a 
better one:-) Thanks for your support and good laughs!
Patch team: Stephanie, thanks for helping me out in the starting period as patcher. Catalin, jij was de 
eerste met wie ik dagenlang in de patchruimte heb doorgebracht, erg fijn en leerzaam! Kyu pil, I got 
to know you as very clever and technically skilled patcher, thanks for all the things you have learned
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me in this field. Anil, I admire your bright vision on both daily lab work and daily life. I appreciate 
your warm and caring personality. It’s fantastic that you’ll be standing next to me as paranimf. 
Sjoerd, jouw positieve instelling is super! Ik vond ‘t enorm fijn om met je samen te werken en om 
daarnaast portjes en biertjes met je te drinken, top! Sergio, you are the newest member of the patch­
team and your quick way of mingling, both inside and outside of the lab, is wonderful.
Onmisbaar voor een succesvolle OIO periode is de tijd die je nog spendeert buiten het lab met ’n 
aantal zeer mooie en lieve vrienden:
Bobby, jij hebt deze periode van zeer dichtbij meegemaakt en wat hebben we de afgelopen 
tweeënhalf jaar veel beleefd in ons paleisje in hartje Nijmegen; gediscussieerd, steun gezocht en 
gevonden, gelachen, gehuild (ik dan), geleerd met en van elkaar, onvergetelijk! ‘Een bonte tijd’ als ik 
erop terugkijk....Bij jou zal ’t leven nooit kleurloos worden, je bent ’n bijzonder en mooi persoon, 
Bob! Ik heb er alle vertrouwen in dat je ‘t helemaal gaat maken in Zürich (en kijk al uit naar onze 
bezoekjes).
Minja, sweety, I will always remember our coffee breaks during working hours, which could be 
either helpful for serious stuff or just fun for juicy details;-) I cherish our lazy dinner/movie nights, as 
well as the ones we went out for dancing that mostly started off with great photos at your place. Let’s 
keep on visiting each other, anywhere in the world!
Goric, wat is het goed dat er PhD retraites bestaan, vooral die van 2009! Erg fijn dat we elkaar 
hebben leren kennen. Je bent een lieve vriendin en een topper in je werk, ik heb alle vertrouwen in je! 
En Ad, wat was New York ’n toffe ervaring, ik ben blij je daar te hebben leren kennen en laten we ‘t 
zien als ’n mooie start voor de toekomst. We gaan gedrieën vast nog veel mooie dingen beleven onder 
het genot van lekkere wijntjes.
An, ik ben zo enorm blij dat we elkaar zijn tegengekomen! Jouw enthousiasme, stralende lach en 
open blik naar de wereld doen ’t altijd goed. Leven staat met ’n hele grote L in ons woordenboek!! 
Leo, ik wil je bedanken voor alle momenten dat je voor me hebt klaargestaan. En daarbij voor al je 
gezelligheid natuurlijk! Je moet weten dat je ook altijd bij mij terecht zal kunnen.
En voor jullie samen An en Leo, ik ga nog vaak terugdenken aan onze enorm gezellige ‘eet-klets-of- 
sauna-avondjes’, die blijven we doen hoor!
Marie, jij maakte ’t extra fijn om thuis te komen in Uden. Ondanks onze drukke schema’s van de 
afgelopen jaren, heb ik onze ‘dates’ altijd heel erg gewaardeerd, supergezellig en verhelderd. Je ben 
’n schat!
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Frouk, wat zijn onze levens toch veranderd vergeleken met zo’n 10 jaar geleden. We zien elkaar niet 
zo vaak meer als vroeger, maar je moet weten dat ik ’t altijd heel leuk vind om samen te komen. 
Grote hoeveelheden vlees eten bij Marc’s BBQ of de Griek moeten we er gewoon in houden;-)!
Rob (P.), ik heb jou leren kennen in m ’n studietijd en het voelt daarom als ‘n cirkel rondmaken met 
jou als paranimf. Het is fijn om te weten dat er iemand is die minstens zo perfectionistisch is als ik;-) 
Ik zou eigenlijk alleen willen zeggen: “maak je niet te druk, Erwin en jij zijn samen top!”
Job, jij bent een belangrijke pilaar geweest tijdens m’n studie en start van m’n promotie. Ik heb heel 
goede herinneringen aan onze tijd samen. Je hebt een mooi plekje in m’n hart!
Freek en Lisa, ik had me geen betere afsluiting van m’n promotietijd voor kunnen stellen dan met 
jullie door Laos en Cambodja te reizen. Ik heb er enorm van genoten en het heeft me veel nieuwe 
energie gegeven om verder te gaan. Het is zeker jammer dat jullie niet bij de verdediging zullen zijn, 
maar zoals afgesproken zien we elkaar weer in Schotland!
En natuurlijk, paps en mams, wil ik jullie enorm bedanken! Ik ben misschien niet even gemakkelijk 
voor jullie geweest in de afgelopen hectische periode, maar het geeft ’n enorm goed gevoel om te 
weten dat jullie altijd onvoorwaardelijk achter me staan en trots zijn op wat ik doe. Dit maakt mede 
tot wie ik ben en waar ik sta. Jullie steun is ontzettend belangrijk voor me, dank jullie wel!!
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